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Be it the conscription of cofactors for replication, perturbation of cellular processes to create an 
advantageous microenvironment, or the necessary subversion of immune defenses for the 
purpose of effective propagation, the intricate interaction between the virus and its host is 
fundamental to the determination of virulence. An improved understanding of these events will 
not only allows us to gain new insights into the complicated field of coronavirus biology, but 
may also provide new directions for therapeutic interventions.  
 
Using primarily the prototypic IBV as our model coronavirus, we explored two key aspects of 
virus-host interactions in this dissertation. Firstly, through a genome-wide RNA interference 
screen, we identified critical cellular cofactors that have roles in modulating coronavirus 
replication. While some of these factors are already known to be implicated in coronavirus 
replication, many others are novel cofactors that have yet to be characterized. Among the cellular 
host factors identified, the role of valosin containing protein (VCP) in the modulation of 
coronavirus replication was examined in greater detail. From our study, it was found that VCP is 
required for the efficient transfer of viral particles from early endosomal compartments to the 
host cytosol where viral replication occur. 
 
 In the second part of the thesis, we focused on understanding the interplay between coronavirus 
infection and host cell innate immune response. Through examining the status of interferon 
(IFN) activation in different cell lines susceptible to IBV infection, it was observed that IBV 
counteracts the effective activation of the host anti-viral mechanisms via distinct strategies that 
 xiii 
include passive evasion of immune detection, as well as active inhibition of events leading to the 
establishment of an anti-viral state. Lastly, through a screen for interaction between IRF3, a key 
transcription factor regulating IFN activation in host cells and SARS-Coronavirus encoded 
ORFs, we identified SARS ORF8 to be novel antagonist of IFN signaling. As SARS ORF8 binds 
to the self-association domain in IRF3, we hypothesized that by disrupting IRF3 
homodimerization that is required for its nuclear translocation, SARS ORF8 prevents the 
transcriptional activation of IFN mediated by IRF3. (344 words) 
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Be it the conscription of cofactors for replication, perturbation of cellular processes to create an 
advantageous microenvironment, or the necessary subversion of immune defenses for the 
purpose of effective propagation, the intricate interaction between the virus and its host is 
fundamental to the determination of virulence. An improved understanding of these events will 
not only allows us to gain new insights into the complicated field of coronavirus biology, but 
may also provide new directions for therapeutic interventions. Therefore, using primarily the 
prototypic IBV as our model coronavirus, we aspire to explore two aspects of virus host 
interactions in this dissertation. Firstly, through a genome wide RNA interference screen, we 
identified critical cellular cofactors that have roles in modulating coronavirus replication. In the 
second part of the thesis, we focused on understanding the interplay between coronavirus 
infection and host cell innate immune response. Coronaviral strategies of immune evasion were 








CHAPTER ONE: LITERATURE REVIEW OF BIOLOGY OF 
CORONAVIRUS  
 2 
1.1: CORONAVIRUS: AN OVERVIEW 
1.1.1 Taxonomy 
Coronaviruses are species of enveloped RNA virus belonging to the subfamily of 
Coronavirinae in the family of Coronaviridae. Together with the Arteviridae and 
Roniviridae family of viruses, they are classified in the order of Nidovirales [1]. The 
word ‘nidus’, meaning ‘nest’ in Latin is in reference to the production of 3’ nested 
set of subgenomic mRNAs by these families of viruses during transcription. 
Depending on their antigenic properties, gene sequences/organization and conserved 
domains in their replicase gene, this subfamily can be further classified into three 
genera: alpha-, beta-, and gamma- coronavirus [2]. 
 
 
                
Figure 1.1: Taxonomical classification of coronaviruses 
 
Alphacoronaviruses and betacoronaviruses comprise of diverse coronavirus species 
infecting a wide range of mammalian hosts (pigs, cattle, cats, dogs, bats) including 









Genus Sub-family Family Order 
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HCoV-OC43 and severe respiratory syndrome coronavirus (SARS-CoV) belongs to 
the latter. In contrast, the gammacoronaviruses group is made up of mainly avian 
coronaviruses and includes species like infectious bronchitis virus of fowls and other 
coronaviruses of birds. Selected representative species of each genus are presented in 
the table below. 
 
Table 1.1: Representative species of Alpha- Beta- and Gamma- coronaviruses 
Genus Representative species Host 
Alphacoronavirus Transmissible gastroenteritis virus 
Porcine Epidemic Diarrhea Coronavirus 
Pigs 
Feline Coronavirus (serotype 2) Cats 
Bovine Coronavirus Cattle 
Human coronavirus 229E, Human coronavirus 
NL63 
Human 
Betacoronavirus Mouse Hepatitis Virus Mouse 
Severe Acute Respiratory syndrome Coronavirus 
Human coronavirus O43 
Human 
Bat Coronavirus HKU9 Bats 
Gammacoronavirus Avian Infectious Bronchitis Virus Chickens 




1.1.2 Diseases of Coronavirus 
Coronavirus is the etiologic agent for the Severe Respiratory Syndrome (SARS) 
outbreak in 2002-2003 which caused approximately 10% mortality in the 8000 
people infected worldwide [3]. Apart from causing acute respiratory disease, they 
also infect many systemic organs such as gastrointestinal tract, liver, kidney and 
brain [4], leading to symptoms such as fever, dyspnae, lympopenia, diarrhea and 
lower respiratory tract infection [5]. 
 
In contrast, other human coronaviruses such as HCoV-229E, HCoV-OC43, NL63 
and HKU1 cause only mild symptoms and are collectively responsible for about 10-
30% of common colds. Despite speculations of them associating with more severe 
clinical outcomes such as multiple sclerosis, hepatitis and gastritis in immuno-
compromised individuals, infants and the elderly [6,7,8], they are generally perceived 
as harmless and left limiting. 
 
Murine coronaviruses are the most extensively studied coronavirus prior to the SARS 
outbreak in 2003. There are multiple strains of murine coronaviruses, which differ in 
both tropism and virulence. Highly epidemic, they spread quickly among population 
causing respiratory, enteric, neurologic and nephritic diseases in rodents and in 
particular laboratory mice that are kept in closed colonies.  As neurotrophic strains 
such as JHM and A59 cause acute encephalitis and chronic demyelination, these are 
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routinely used in animal models for the study of demyelinating diseases such as 
multiple sclerosis (reviewed in [9,10]) 
 
Transmitted via aerosol, infectious bronchitis viruses (IBV) cause highly contagious 
respiratory diseases found in chickens. While IBV replicates mainly in the upper 
respiratory tract, there are some strains that are known to cause infection in other 
epithelial tissues such as kidney, reproductive organs and gut. While IBV affects 
chickens of all ages, more severe clinical symptoms are manifested in young chicks, 
leading to higher mortality. The loss of young, weight loss, decrease in overall 
fitness, and decrease in egg production associated with IBV infection can therefore 
cause significant economic losses to the broiler industries (reviewed in [11]). Both 
live and attenuated vaccines have been developed to confer protection against IBV 
but the prevalence of multiple serotypes has undermined the efficacy of many 
vaccination programmes. 
 
Coronaviruses are also of considerable concern to other livestock industries as they 
also infect farmed animals such as cattle [12] and pigs [13], causing both respiratory 
and enteric diseases. Mortality in the young, weight loss and decrease yield of animal 
produce (e.g. milk) resulting from these infections can cause significant losses to the 
industry. Coronaviruses also infect domesticated such as cats and dogs. In particular, 
feline infectious peritonitis virus (FIPV) causes unusually high mortality in cats, with 
the onset of viremia leading to multiple systemic failures [14].  
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In addition to the diverse range of species they can infect, coronavirus are notorious 
for their propensity for host switching. For instance, HCoV-OC43 bears strong 
resemblance to bovine coronavirus and is believed to have originated in one species 
before crossing over to the other [15]. The transmission of SARS-CoV from bats to 
palm civets and finally humans [16] illustrates how the “interspecies jumping” 
potential of coronavirus presents a real threat of the re-emergence of a novel CoV 
epidemic. 
 
1.1.3 Morphology and Structure of coronavirus 
Coronaviruses are spherical and moderately pleiomorphic, averaging around 100-
120nm in size. The name ‘coronavirus’ is derived from the Latin word ‘corona’ that 
means crown or halo. As befits its name, the viron particles adopt distinctive crown-
like appearance under electron microscopy. The crown-like projections at the fringes 
of the viron particles are contributed by trimers of the spike protein (S) spanning 
across in the double membrane envelope of the virus. A second type of surface 
projection comprising of haemagglutinin-estarase (HE) homodimers can be found in 
some betacoronaviruses. Apart from the S and HE, the membrane (M) and envelope 
(E) protein are also integral components of the viral envelope architecture. At the 
core of the virion particle is a helical ribonucleocapsid core that comprises of the 
RNA genome in close association with the nucleocapsid (N protein).  
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               (A)      (B) 








Figure 1.2: Structure of coronavirus morphology. (A) Electron micrograph of infectious 
bronchitis virus isolated from chickens (Cook, 1983) [17] (B) Schematic representation of 
the coronavirus.  
 
 
1.1.4 Genome Organization of Coronavirus 
Coronaviruses have exceptionally large single stranded positive sense RNA genomes 
that range from 27 to 32 kb. The 5’ capped single stranded positive sense genomic 
mRNA is typically flanked by two untranslated regions (UTR). The 5’ UTR contains 
a leader sequence that ranges from 65 to 98 nucleotides in length while the 3’ end 
comprises of an octameric sequence of GGAAGAGC upstream of its poly (A) tail. 
 
Occupying approximately the first two-thirds of the genome are two large open 
reading frames, designated ORF1a and ORF1b which codes the virus replicase. 
ORF1a encodes the polyprotein pp1a while polyprotein pp1b is translated from both 
ORF1a and ORF1b via a (-1) ribosomal frameshift at the ORF1a/1b junction. The 
rest of the genome at the 3’ distal end encodes structural proteins in the order of S, E, 
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M, N. For some betacoronavirus, the HE gene is typically found between ORF1 and 
S. Interspersed between the structural genes are ORFs encoding for various virus-
specific accessory proteins. The genome serves multiple purposes during infection. 
With the exception of the replicase polyprotein that is translated directly from the 
genome, all the coronavirus encoded proteins stem from the subgenomic mRNA 
species that are derived from the genomic strand via a negative strand intermediate. 
Apart from translation and transcription, the coronavirus RNA genome also serves as 




Figure 1.3: Genome organisation of Coronaviruses. ORF1 encoding the replicase gene is 




1.1.5 Proteins encoded by Coronavirus 
Proteins encoded by coronaviruses can be broadly classified into three categories: 
structural, replicase and accessory proteins. The known biological functions of these 
proteins are reviewed briefly. 
 
1.1.5.1 Structural proteins 
S protein 
The S protein is a large glycosylated protein of approximately 150-180kDa. S protein 
contains a large N terminal ectodomain, followed by a transmembrane domain and 
finally a short C terminal endodomain. Post-translational cleavage of the ectodomain 
by cellular proteases [18,19,20] yields two fragments: the amino (S1) and carboxy 
(S2) domains, which correspond to the receptor binding and transmembrane domain 
respectively. By harbouring the receptor-binding site, divergence in the S1 region is a 
major determinant of host specificity and cell tropism [21]. The S2 domain on the 
other hand is more conserved across species and mediates viral and cellular 
membrane fusion via an internal peptide fusion sequence. For some coronaviruses, 
the S1/S2 cleavage appears to also promote cell fusion between infected and 






The expression of the HE protein is exclusive to a subgroup of betacoronaviruses. 
Although they also extend across the virion envelope, they form much shorter 
‘spikes’ than the S protein. HE binds O acetylated sialic acid and display receptor 
destroying enzymatic activity [24]. The significance of HE binding to sialic acid in 
viral attachment is, however, minimal because as discussed above, this is a role 
undertaken by S protein. The importance of HE in coronavirus infection is 
controversial. For some coronaviruses, viral titers decrease in the presence of esterase 
inhibitors [25] and HE-specific antibodies [26] whereas HEs are dispensable for the 
replication of other coronaviruses in cultured cells [27].  
 
N protein 
Typically averaging around 400 amino acids (43-50kDa), N protein is a 
phosphoprotein whose principle role is the encapsidation of virus RNA to form the 
helical nucleocapsid core. N protein also functions as RNA chaperone [28] and can 
bind specifically or nonspecifically to various regions of the viral RNA such as the 5’ 
leader, 3’ UTR and the packaging signal [29,30,31]. The RNA binding domain of 
different coronaviruses N protein has been mapped but the domain involved appear 
to vary across strains [32,33,34]. N protein has a proposed three-domain structure, 
separated by two highly variable linker regions. While the first two domains are rich 
in basic residues such as arginine and lysine, the ratio of basic to acidic residues are 
reversed in the third domain, resulting in a net negative charge at its carboxy 
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terminus [35,36] that appears to be important for virion assembly by facilitating 
interaction with M protein [37]. This model is derived from early comparative 
studies involving MHV strains, but was found to be also applicable to coronaviruses 
of other types. N protein is a multifunctional protein, that is also involved in RNA 
synthesis [38,39,40] and possibly translation [41]. Moreover, N protein is a known 
interferon antagonist [42,43] as well.  
 
M protein 
A major component of the virion envelope, M protein is the most abundantly 
expressed protein in coronaviruses. A triple membrane spanning protein 
accompanied by a short amino ectodomain and a large carboxy cytosolic domain, M 
protein is pivotal to virion morphogenesis and assembly by virtue of the extensive 
interactions made between itself and other structural components: Homotypic 
oligomerisation of M protein results in a protein lattice that constitute the scaffold for 
viral envelope morphogenesis while heterotypic interactions made between S, N and 
E orchestrate the appropriate recruitment of these structural components to the 
budding site (reviewed in [35]). Coronavirus M protein appears to also interact with 
cellular proteins. For example, interaction between IBV M and β-actin was found to 
be important for assembly and budding but not release [44]. Apart from virion 
morphogenesis and assembly, M protein appears to have a role in viral pathogenesis 




The E protein is a small integral membrane protein that is only around 8-10kDa in 
size. Despite its small size and low abundance in the virion, E protein has been 
ascribed with multiple functions [46,47] and of all, its role in virion assembly is best 
established. The role of E protein in virion assembly is dependent on its interaction 
with M protein during budding and may be linked to its membrane-curving 
properties. E proteins of a number of coronaviruses also possess ion channel 
activities [48,49] that may alter membrane permeability to the advantage of virus 
release. Recent studies have further implicated E in viral pathogenesis as the 
suppression of cell stress response associated with its expression may aid in 
downplaying the host immune response [50]. 
 
1.1.5.2 Replicase and non-structural proteins 
As discussed previously, the translation of ORF1 yields two poly proteins pp1a and 
pp1ab. With the exception of some gammacoronavirus such as IBV that lack the first 
non-structural protein (nsp1), pp1a and pp1ab are cleaved into 16 non-structural 
proteins by their internal proteases. The first 11 nsps (or 10 for IBV) are derived 
from ORF1a while nsp12-16 are encoded in ORF1b Three main protease domains 
are involved in this auto-proteolytic processing of the replicase. Two papain-like 
proteases (PLpro), PLP1 and PLP2 of nsp3 are primarily involved in the cleavage of 
the first three (on in the case of IBV, two) at the N terminus, while the 3C-like (or 
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Mpro) protease at nsp5 is the major protease responsible for processing the rest of the 
nsps. [35,51].  
 
 
Figure 1.4: The domain organization of the replicase protein. Cleavage sites processed 
by papain-like protease (PLP1 and PLP2) and 3C-like protease (3CL) are denoted by red and 
yellow triangles respectively. The enzymatic activities associated with each domain are also 
highlighted: ADP-ribose-1’-monophosphate, RNA dependent RNA polymerase (RdRp), 
RNA helicase (HEL), exonuclease (ExoN), uridylate-specific endoribonuclease (NeU) and 
methyltransferase (MT). Note: nsp1 and its corresponding cleavage site is absent in IBV. 
 
Apart from proteolytic activity, several other enzymatic functions are encompassed 
within the replicase polyprotein: Nsp12 is a RNA-dependent RNA polymerase and 
nsp13 contains the superfamily I RNA helicase that possess accompanying NTPase, 
dNTPase and triphosphatase activities. Nsp14 has dual functions: The 3’ to 5’ 
exonuclease in nsp14 ensures fidelity of RNA transcription while a (guanine-N7)-
methyl transferase (N7-MTase) mediates RNA capping. Nsp16, an S-adenosyl-L-
methionine-dependent RNA (nucleoside-2’-O)-methyl transferase (2’O-MT), plays a 
role in RNA capping, similar to that of nsp14. The uridylate-specific 
endoribonuclease activity in Nsp15 is critical for virus replication but its exact 
function is unknown. [21,52].  
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1.1.5.3 Accessory proteins 
Coronaviruses encode a variable number of group specific accessory proteins that 
share little sequence similarity with other proteins of coronaviruses. Accessory 
proteins can be derived from additional ORF interspersed between the canonical 
replicase and structural genes, or arise from the internal ORF of existing genes. The 
origins of these additional gene sequences are debatable. Sequence analysis studies 
suggest that recombination events involving both cellular and viral sources led to the 
acquisition of 2a and HE protein in MHV [53,54]. Majority of the accessory proteins 
however bear no homology to other cellular and viral sequence. There is also 
evidence to suggest that accessory proteins result from the duplication of the virus’ 
own genome [55], or they may be the consequence of high frequency mutations in 
hypervariable regions [56]. Accessory proteins are dispensable for viral replication in 
culture [57,58,59] but recent studies have demonstrated that deletion of some of these 
genes were shown to be attenuating in natural hosts [58,60].  
 
1.1.5.4 SARS Accessory proteins 
At a tally of eight, the SARS-CoV genome encodes an exceptionally high number of 
accessory proteins. When expressed, many of them modulate various cellular 
functions such as DNA and protein synthesis, cell cycle progression and apoptosis 
(reviewed in [61,62]). How these cellular perturbations affect viral 
replication/pathogenesis, however, is not fully understood. A more direct effect on 
viral pathogenesis can be linked to their effect on the host innate immune pathway. 
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In a screen for interferon antagonists, Kopecky et al observed that the expression of 
ORF3 and ORF6 suppress both interferon synthesis and signaling [63]. Incorporation 
of accessory proteins such as 3a, 6, 7a, 7b, 9b in virus particles suggest that they may 
be important for virus assembly, release, stability and/or infectivity [64,65,66,67]. 
Interestingly, SARS-CoV ORF8 is further implicated in host adaption of the virus. 
Epidemiological studies revealed that while only one intact ORF8 exist in early and 
animal SARS-CoV isolates, most of the SARS-CoV isolated from patients in the 
later period of the outbreak has two distinct ORFs – 8a and 8b as a result of a 
naturally occurring 29 nucleotide deletion [68]. Although these observations hinted 
of a correlation with the adaption of the virus from animal carriers to human, reverse 
genetics studies showed that there is little consequence of this deletion on virus 
replication in cell culture [57]. 
 
Table 1.2 A summary of the known functions of accessory proteins encoded by SARS-
CoV. 
Protein No. of amino 
acids 
Effects on Cellular/Viral Function(s) 
3a 274 Induce apoptosis 
3b 154 Apoptosis, cell cycle arrest at G0/G1, interferon 
antagonist 
6 63 Enhance DNA synthesis, interferon antagonist 
7a 122 Induce apoptosis, Inhibits cellular protein synthesis, 
cell cycle arrest at G0/G1 
7b 44 Not determined 
8a/8b* 39  
8ab** 84  
9b 98 Viral structural protein 
        *expressed from ORF8a and ORF8 found in late human SARS-CoV isolates.  
        **expressed from one continuous ORF8 found in animal and early human CoV isolates. 
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1.1.6 The Coronavirus Life Cycle 
 
1.1.6.1 Attachment and entry 
The infectious life cycle of coronavirus is initiated with the binding of S protein to 
the host cell surface receptors. The receptor specificity of S protein is therefore the 
key determinant for the virus’ host specificity and tropism. Alphacoronaviruses 
appear to have a preference for membrane bound metallopeptidase named 
aminopeptidase N (APN) (reviewed in [35]). HCoV-NL63 is an exception through its 
usage of angiotensin-converting enzyme 2 (ACE2), a receptor that is shared with the 
SARS-CoV [69,70]. Members of the betacoronaviruses group utilize a more diverse 
range of receptors: The BCoV and HCoV-OC43 share the strategy of  influenza C 
virus’ in employing N-acety-9-O-acetyl neuraminic acid (9-O-Ac-NeuAc) for their 
cell surface receptor [71,72]. MHV on the other hand utilizes the cacinoembryonic 
antigen-cell adhesion molecules (CEACAMs), a group glycoproteins belonging to 







Table 1.3: Known cellular receptors utilized by coronaviruses 
Group Host Virus Receptor 
Alpha- Cat Feline coronavirus  
Feline infectious peritonitis virus  
APN 
APN 
Dog Canine coronavirus  APN 
Pig Transmissible gastroenteritis virus  APN 
Human Human coronavirus-229E APN 
Beta- Cattle Bovine coronavirus 9-O-acetylated sialic acid 
Human Human coronavirus-OC43 
SARS coronavirus 
HCoV-NL63 
9-O-acetylated sialic acid 
Angiotensin converting enzyme 2 
Angiotensin converting enzyme 2 
Mouse Mouse hepatitis virus  Carcinoembryonic antigen 
adhesion molecule 1 
 
Upon receptor binding pH activation and/or proteolytic activation, S protein 
undergoes extensive conformational changes to prime the virion for fusion with the 
host membranes. The first conformation change dissociates S2 domain from S1 to 
expose an internal fusion event peptide sequence (heptad repeat regions) that is 
inserted into the host membrane. Further rearrangements in the S2 domain lead to the 
formation of a six-helix bundle (6-HB) that helps draw the viral and cellular 
membrane into close proximity and henceforth facilitating fusion (reviewed in [18]). 
 
While there are studies to suggest that direct membrane fusion occurs for a subset of 
coronaviruses, the general consensus is that the host’s endocytic pathway is the 
preferred route of entry for majority of the coronaviruses (reviewed in [74]). Release 
of nucleocapsid into the cytosol following membrane fusion then allows the genomic 
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RNA to be made available for translation. The process of release and dissociation of 
N from the genomic RNA is poorly understood but may involve cellular factors [75] 
and dephosphorylation of N [76]. 
 
 
1.1.6.2 Translation and assembly of replicase complex 
By virtue of its 5’-methylated cap and poly(A) tail, the virion genomic RNA closely 
resembles that of the host. This allows the virus to exploit the host translational 
machinery to directly synthesize the replicase polyprotein (from ORF1) from its 
positive stranded mRNA. As mentioned earlier, the replicase polyprotein undergoes 
auto-proteolytic cleavage to generate 15-16 non structural proteins which perform 
varying function (see section 1.1.4). 
 
The non-structural proteins are localized to intracellular membranes near the 
perinuclear region of infected cells where they coalesce to form the replicase 
complex [77]. The replicase complex is anchored to double membrane vesicles 
(DMV) of purportedly ER origins [78,79]. The multiple transmembrane domains in 





1.1.6.3 Replication and Transcription 
RNA synthesis dominates the next stage of the virus life cycle with two objectives: 
genome replication and production of subgenomic mRNA that encode for structural 
(S, E, M, N) and other accessory genes. This is initiated by the production of minus-
strand RNAs to serve as templates for both genomic and subgenomic mRNA 
synthesis. While genome replication is achieved via continuous duplication of its full 
length minus strand templates, transcription of sub-genomic mRNA deploys a vastly 
different strategy of discontinuous transcription.  
 
The number of subgenomic species differs among coronaviruses but they embody 
similar features. All subgenomic RNAs share common 3’ ends but possess 5’ ends of 
varying lengths. In addition, they contain an identical leader sequence at the 5’ end 
that is also present on the genomic RNA [35]. Situated immediately downstream of 
the leader sequence (TRS-L) and before the body of each open reading frame is a 
region of intergenic sequences known as the ‘transcription-regulating sequences’ 
(TRS-B). Encompassed within the TRS, is a stretch of highly conserved core 
sequences (CS). To illustrate, the organization of subgenomic mRNA produced by 
gammacoronavirus IBV is presented in Figure 1.5.  
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Figure 1.5: Subgenomic mRNAs of IBV. The nested set of 6 positive-sense mRNAs 
contain identical 5’ leader sequence and are 3’ co-terminal. The positive-sense genomic 
mRNA (gRNA) correspond to mRNA1. 
 
Although the mechanism is not completely understood, a three-step model for 
discontinuous transcription in negative-strand synthesis has been proposed (Figure 
1.5) [81]. Briefly, the initiation of discontinuous transcription begins with the 
circulation of genomic RNA resulting from complementary base pairing between 
CS-L and CS-B at 5’ TRS-L and 3’- TRS-B respectively. Stabilized by RNA binding 
proteins, they form complexes along the template. Transcription by the replicase 
complex commences and continues from the 3’ distal end of the template strand until 
it reaches a CS-B where it stalls. Next base-pairing complementarity occurs between 
the TRS-L hairpin and TRS-B in the nascent minus-stranded RNA and finally 
template switching occurs when the replicase dissociates from TRS-B in the nascent 
minus strand and exchanges it for the TRS-L in close proximity to resume 
transcription with the inclusion of the leader sequence. 
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Figure 1.6: A three-step model for discontinuous transcription. Adapted from (dufour). 
The leader sequence and TRS-L are represented in gray, and the CS sequences are 
represented as light rectangles. (I) Sequence similarities foster complementary base pairing 
between the TRS-L and the TRSs-B, forming complexes along the coronavirus genome. 
These complexes stall the replicase complex. (II) Assessment of base-pairing 
complementarity between the TRS-L hairpin and TRS-B in the nascent minus-stranded RNA 
is followed by (III) Template switch to the TRS-L resumes the minus strand synthesis.  
 
1.1.6.4 Translation 
The structural proteins (and accessory proteins) are translated from the subgenomic 
RNAs, each from a different transcript. Translation is primarily driven by a cap-
dependent mechanism. Therefore, even as the subgenomic mRNAs contain more 
than one ORF, only the most 5’ ORF is translated. Exceptions occur when additional 
ORFs are translated from an internal ribosome entry site [82]. N protein is 
synthesized by free polysomes in the cytoplasm, where it coalesces with the newly 
synthesized genomic RNA to form the nucleocapsid. Other membrane bound 
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structural proteins (M, S and E) are synthesized in the ER and co-translationally 
inserted into the ER membrane prior to their transport to the ERGIC for virion 
release.  
 
1.1.6.5 Virion assembly and release 
The process of virion assembly is driven by cooperative interactions among the 
structural proteins, with M as the nucleating factor. Lateral homotypic interactions of 
M form an M-M lattice that is thought to be important for assembly of the viral 
envelope. Expression of M alone however, is not sufficient for this process [83] and 
requires the interaction with E protein via its cytoplasmic domain [84,85]. How E 
protein contributes to the assembly process is not entirely clear but it is prostulated to 
have a role in membrane curvature and scission [86]. Genetic studies have identified 
multiple residues in the carboxy tail to be important for interactions with S [87] and 
N protein [88,89,90]. Coronaviruses produces multiple transcripts, all in association 
with N, and yet only those associated with the genomic RNA are recruited by M 
protein [91]. The selective encapsidation of viral genomic RNA is conferred by a 
packaging signal that is located in gene 1b of the genomic RNA [92]. Finally, virions 
co-opt the host secretory pathway en route to the plasma membrane to release their 




Table 1.4: Cooperative interactions between structural proteins drives virion assembly 
Interactions Domain (In M) Function 
M-M TM Scaffold for viral envelope formation 
M-E CD Curvature and scission of membrane? 
M-S CD  Incorporation of nucleocapsid into virion 
M-N CD  Incorporation of nucleocapsid into virion 
M-N-gRNA ? Encapsidation of genomic RNA into virion 
                  TM: transmembrane  CD: cytoplasmic domain 
 
1.1.7 Reverse Genetics and other genetic manipulation of coronaviruses 
Reverse genetics refers to the transcription of infectious RNA from a full-length 
cDNA duplicate of the virus genome. Although the unusually large size of the 
genome coupled with toxicity of the replicase genes in bacteria systems had 
encumbered the initial efforts of applying it to coronaviruses, these difficulties were 
finally bypassed with strategies of using 1) low copy bacterial artificial 
chromosomes, 2) in vitro ligation of smaller, more stable sub-cloned cDNAs and 3) 
long-range RT-PCR vaccinia virus vectors (reviewed in [35]). The success of 
infectious clone systems, by making the whole genome amenable to mutagenesis 
studies, has greatly advanced our understanding of coronavirus biology.  Reverse 
genetics also offer a promising platform for the development of vaccines and 
coronavirus-based gene delivery vectors. 
 
One such full-length clone was used extensively in this dissertation. By replacing the 
accessory ORF3a/3b with the firefly luciferase gene, the full-length infectious clone 
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assembled using the in vitro ligation method generates a recombinant (IBV-Luc) that 
expresses the firefly luciferase during infection. [93]. Expression of luciferase gene 




1.2 VIRUS-HOST INTERACTIONS 
Coronavirus interacts with its host in many ways. Be it through modulation of the 
host cell responses or direct recruitment of cellular proteins for its replication, 
appropriate viral-host interactions are vital for optimal replication. This section 
provides a review on what is currently known about these interactions, with special 
emphasis on the interplay between coronavirus infection and host innate response. 
 
1.2.1 Host factors in coronavirus replication 
The regulation of viral transcription/replication requires cross talk between distal 
regulatory domains such as the 5’- and 3’ UTR, and TRS of leader (TRS-L) and each 
ORF (TRS-B), and this is mediated by protein-RNA and protein-protein interactions 
comprising of both viral and cellular proteins. Many of the cellular proteins involved 
in coronavirus replication are therefore initially identified through their ability to 
bind viral RNA or replicase subunits.   
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1.2.1.1 Heterogenous nuclear ribonucleoprotein A1 (hnRNP A1) 
Heterogenous nuclear ribonucleoprotein A1 (hnRNP A1) is a RNA-binding protein 
belonging to the heterogenous nuclear ribonucleoprotein family. Residing 
predominantly in the nucleus, hnRNP A1 functions primarily in the regulation of pre-
RNA splicing and RNA export [94]. However, a subset of hnRNP A1 is also known 
to shuttle between the nucleus and cytoplasm. The cytoplasmic function of hnRNP 
A1 appears to be distinct from its nuclear counterparts by being associated with 
instead mRNA turnover and translation [95,96]. 
 
 hnRNP A1 was first discovered to be a cofactor for coronavirus replication by virtue 
of its affinity for the negative strand of the MHV leader (TRS-L) and intergenic (IG) 
sequences [97,98]. Later, it was found to also interact with other regulatory elements 
such as positive stranded 3’-UTR of the MHV RNA [99,100]. hnRNP A1 is 
redirected to the cytoplasm during MHV infection [97] where it appears to function 
in both coronavirus transcription [97,101] and replication [102]. In view of its 
multiple interactions with the viral RNA and the ability to form ribonucleoprotein 
complex with negative strand leader sequence and TRS in vitro [103], hnRNP A1 is 
proposed to be an integral component of the virus replication-transcription complex 
(RTC), by serving as a protein mediator to bridge distant RNA elements. This model 
is further supported by observations that hnRNP also binds the MHV [104] and 
SARS-CoV [105] nucleocapsid protein, another  integral component of the RTC.  
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Despite its conclusive role in coronavirus RNA synthesis, it was found later that the 
function of hnRNP A1 can be complemented by other closely related members of the 
hnRNP family that share hnRNP A1’s specificity and binding affinity towards MHV 
RNA [106]. Therefore, it is conceivable that multiple hnRNP A1 related proteins 
with similar biochemical properties and functions might perform similar functions in 
coronavirus replication. 
 
1.2.1.2 Polypyrimidine-tract binding (PTB) protein 
Polypyrimidine-tract binding (PTB) protein binds to the UCUAA pentanucleotide 
repeats encompassed within the leader TRS on the positive strand. As these repeats 
are required for transcription [107], a role for PTB in the regulation of coronavirus 
transcription is proposed. PTB also interacts with the 3’-UTR of the negative strand 
at two sites: A strong binding site at nt53-149 and a weaker one at nt 270-307. 
Mutation of these sites that reduces their affinity for PTB led to a corresponding 
decrease in subgenomic mRNA synthesis [108]. Furthermore, the binding of PTB to 
the strong binding site induces a conformational change in neighboring RNA regions. 
A reduction in PTB binding and the subsequent loss of conformation change 
rendered by partial deletions within this site were accompanied by loss of mRNA 
transcription [108]. 
 
Like hnRNP A1, PTB, (also known as hnRNP I), is a multifunctional RNA binding 
protein that shuttles between the nucleus and cytoplasm. Its diverse cellular functions 
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ranges from originally RNA splicing, polyadenylation, mRNA stability and 
translation initiation (reviewed in [109]). Notably, apart from the initiation of cellular 
translation, PTB is also involved in internal ribosome entry site (IRES) mediated 
translation of several viruses [110,111,112]. Direct evidence of PTB similarly 
regulating translation in coronavirus however, has yet to be reported.  
 
1.2.1.3 Poly (A) binding protein (PABP) 
Poly (A) binding protein (PABP) which binds 3’ poly (A) on eukaryotic mRNA also 
interacts specifically with the poly(A) tail located within the 3’UTR of coronavirus 
positive sense RNA [113]. The poly(A) tail in coronavirus mRNA is a crucial 
regulatory signal for the synthesis of minus strand RNA [114]. Disruption to PABP 
binding by shortening the poly(A) tail is accompanied by a diminished capacity for 
RNA synthesis [113], suggesting a role for PABP in the modulation of coronavirus 
replication. This however, may also be attributed indirectly to the effect of PABP on 
viral translation upon virus entry. PABP interacts with both the 3’ poly (A) and 5’ 
cap of eukaryotic mRNA. Association with the 5’ cap is achieved via its interaction 
with eukaryotic initiation factor (eIF) 4G [115] which is an important subunit of the 
eIF4F cap binding complex formed at the 5’ cap structure of mRNA that is primed 
for translation. The interaction PABP with eIF4F via eIF4G therefore mediates cross 
talk between the two extreme ends during translation initiation [116]. The 
coronavirus genome is similarly capped and polyadenylated. Its resemblance to host 
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mRNA has raised possibilities that PABP may regulate coronavirus translation in a 
similar fashion. 
 
1.2.1.4 Mitochondrial aconitase 
Despite the lack of a consensus RNA-binding domain, mitochondrial aconitase (m-
aconitase) was one of four cellular proteins reported to form RNA-protein complexes 
with the 3’ extreme of MHV genomic RNA [117]. In the same study, the authors 
showed that m-aconitase also partially colocalizes with MHV N protein in MHV 
infected cells. Although the exact mechanims by which m-acontiase functions in 
coronavirus replication is not known, elevated levels of m-aconitase were associated 
with an increase in viral translation and virus progeny production at early time point. 
It is postulated that the binding of m-aconitase to 3’-UTR increases virus translation 
through the stabilization of viral sRNAs, a role analogous to that carried out by its 
cytoplasmic homolog – c-aconitase. C-aconitiase, also known as iron regulatory 
protein 1, is a RNA binding protein that coordinates the expression of ferritin and 
transferrin receptor during iron metabolism by binding to iron-responsive elements in 
the 5’ and 3’ UTRs respectively [118,119]. 
 
The identity of the three other cellular proteins that form RNA-protein complexes 
with the 3’ extreme of MHV genomic RNA was resolved to be mitochondria proteins 
HSP40, HSP60 and HSP70 [120]. These proteins associate even in the absence of 
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viral RNA, suggesting they are likely to interact collectively with MHV RNA in 
cooperation with m-aconitase. 
 
1.2.1.5 DEAD box helicases 
The RdRp (nsp 12), helicase (nsp 13) and N protein are recognized as essential 
components of the coronavirus replication-transcription complex (RTC). As such, the 
search for cellular binding partners of these viral proteins represents an alternative 
approach to the identification of cellular cofactors that participate in coronavirus 
replication. Two members of the DEAD box family of helicases were identified with 
this approach. Members of the DEAD box family protein are typically involved in 
various aspects of RNA processing  (transcriptional regulation, pre-mRNA 
processing, degradation, export), ribosome assembly and translation [121].  
 
DDX5 was first identified from a yeast two-hybrid screen using SARS-CoV nsp13 as 
bait protein [122]. The affinity for DDX5 was further established using mammalian 
cell hybrid systems and co-immunoprecipitation. DDX5 role in viral replication was 
demonstrated when depletion of DDX5 by small interfering RNA (siRNA) 
significantly suppressed SARS-CoV replication and viral titers in infected cells. 
DDX1, on the other hand, was identified via its interaction with IBV nsp14 
(exonuclease)[123]. Although nsp14 is not one of the major subunits of the RTC, its 
exonuclease activity has been shown to be vital for the efficient and accurate 
synthesis of viral RNA [124,125,126]. DDX1 is a predominant nuclear protein at 
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steady state. In IBV infected cells, DDX1 relocates from the nucleus to the 
cytoplasm where it largely colocalizes with markers of active viral replication sites. 
Disruption of DDX1 function by means of siRNA treatment, dominant-negative 
mutants and stable knockdown cell lines, unanimously dampened virus replication 
efficiency [123].  
 
1.2.1.6 Other cellular proteins 
While yeast-2-hybrid and/or mammalian cell hybrid systems involving viral RNA 
and replicase remains the choice approach for identifying cellular proteins to be 
involved in coronavirus infection, an increasing number of cellular proteins have 
been identified using other viral protein baits or through the employment of 
alternative techniques. These studies are summarized in Table 1.5.  











NL63 IP Nsp3 (PLp2) 
Stimulator of interferon 
gene (STING) TMEM173 [127] 
IBV Y2H, IP, IF S 
Eukaryotic initiation 
factor 3 subunit f eIF3f [128] 
MHV SA, IP Nsp15 
retinoblastoma protein 
(pRb) RB1 [129] 
NL63 OE S 
Angiotensin converting 
enzyme 2 ACE2 [70] 
SARS Y3H, IP 5' UTR zinc finger CCHC-type 




SARS GST, IP E B cell lymphoma extra large (Bcl-xL) BCL2L1 [131] 





SARS IP M 
inhibitor of kappa light 
polypeptide gene 
enhancer in B-cells, 
kinase beta (IKKbeta) 
IKBKB [133] 
SARS Y2H, IP, GST, IF N 
pyruvate kinase protein 
(liver) PKL PKLR [134] 
SARS IP, IF N Chemokine (C-X-C motif) ligand 16 Cxcl16 [135] 
SARS 
SPR, MS, 
GST, IF N Proteasome subunit p42 PSMC6 [136] 
SARS Y2H N Human elongation factor 1 alpha EEF1A1 [137] 
SARS SA, IP N Ubiquitin conjugating enzyme 9 (Ubc9) UBE2I [138] 
SARS SPR, IP N Cyclophilin A (CyA) PPIA [139] 
SARS IP N Cyclin D1 CCND1 [140] 
SARS IP N SMAD family member 3 (Smad3) SMAD3 [141] 
SARS Y2H Nsp10 
Basic transcription 
factor 3 (BTF3) BTF3 [142] 
SARS Y2H Nsp10 
Activating transcription 
factor 5 (ATF5) ATF5 [142] 
SARS Y2H Nsp10 
NADH dehydrogenase 
subunit 4L (NADH-4L) ND4L [142] 
SARS Y2H Nsp10 
Cytochrome oxidase II 
(Cyto-II) COX2 [142] 
SARS Y2H Nsp15 
Retinoblastoma protein 
pRb RB1 [129] 
SARS MPT, IP Nsp2 Prohibitin 1 PHB [143] 
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SARS MPT, IP Nsp2 Prohibitin 2 PHB2 [143] 
SARS IP PLpro 
Interferon regulatory 
factor 3 (IRF-3) IRF3 [144] 
SARS PD Nsp5 
vacuolar-H+ ATPase 
G1 subunit ATP6V1G1 [145] 
SARS Y2H, IP ORF 7a Ap4A-hyrdolase NUDT2 [146] 
SARS Y2H ORF4/3b 
Runt related 
transcription factor, 
isoform b (RUNX1b) 
RUNX1 [147] 
SARS IP Orf6 Karyopherin alpha 2 KPNA2 [148] 
SARS IP S 
eukaryotic initiation 
factor 3 subunit f EIF3F [128] 
SARS IP S LSECtin CLEC4G [149] 
SARS FC S DC-SIGN CD209 [150] 
SARS FC S DC-SIGNR CLEC4M [150] 
SARS Y2H, CF, IF 
X1/Orf3a caveolin-1 CAV1 [151] 





SARS IP X4/Orf7a 
B cell lymphoma extra 
large (Bcl-xL) BCL2L1 [153] 
SARS IP X4/Orf7a 
Bcl2 like protein 2 
(Bcl-w) BCL2L2 [153] 
SARS IP X4/Orf7a 
myeloid cell leukemia 
sequence 1 (Mcl-1) MCL1 [153] 
SARS IP X4/Orf7a 
Bcl2 related protein A1 
(A1) BCL2A1 [153] 
SARS IP X4/Orf7a 
B cell lymphoma 2 
(Bcl-2) BCL2 [153] 
 
* FC: Flow cytometry, GST: GST pull down, IP: co-immunoprecipitation, IF: immunofluorescence, 
MPT: multidimensional protein identification technology (MudPIT), SA: sequence analysis, SPR: 
surface particle resonance, PD: Phage display, Y2H: yeast-2-hybrid, Y3H: yeast-3-hybrid 
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Recent advancement in high throughput techniques and data management has 
allowed for a more coordinated and comprehensive search for cellular cofactors 
through large-scale automated studies. Through a high throughout yeast-2 hybrid 
screen involving all the ORFs encoded by SARS-CoV, Pfefferle and colleagues 
[154] attempted to identify genome-wide protein-protein interaction between the 
human proteins and SARS-CoV (which they termed the SARS interactome). In their 
study, they observed that SARS-CoV Nsp1 interacts extensively with several 
cyclophilins/immunophilins such as PPIA, PPIG, PPIH and FKBP1A, FKBP1B. 
These proteins function redundantly in the calcineurin/NFAT pathway which in turn 
plays an important role in immune cell activation [155]. The authors also 
demonstrated that the calcineurin/NFAT pathway is enhanced during SARS-CoV 
infection, as well as in the presence of Nsp1. Collective inhibition of cyclophilins by 
cyclosporine A (CspA) was found to not only inhibit SARS replication, but also 
coronaviruses of other genera at relatively low doses.  
 
1.2.2 Cellular processes in coronavirus infection 
Coronavirus-host cell interaction is not just restricted to the recruitment of specific 
cellular proteins to aid in viral replication. The utilization of host endocytic and 
exocytic pathways for entry and release best illustrate how coronavirus can ‘hitch a 
ride’ by latching on existing host cell processes. On the other hand, the manipulation 
and perturbation of key cellular processes is another strategy coronavirus deploys to 
generate an environment that will best promote its propagation. In this section, some 
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of these cellular processes including cell cycle regulation, early secretory pathway, 
apoptosis and autophagy are discussed in brief below. The interplay between 
coronavirus infection and host innate immune response will also be examined in 
detail in Section 1.3. 
 
1.2.2.1 Role of cell cycle regulation in coronavirus replication 
Cell cycle refers to the highly ordered process of growth and division in eukaryotic 
cells and consists of four distinct phases: Dividing cells undergoing DNA replication 
and mitosis are respectively in S (synthesis) and M (mitotic) phase, separated by two 
gap periods known as G1 and G2. Intricately linked to mechanisms governing cell 
sustainability, surveillance of DNA integrity and excessive cell division, cell cycle 
progression from one phase to another is meticulously directed by cyclins and cyclin-
dependent kinases and also other regulatory factors [156]. 
 
IBV has been reported to arrest infected cells at both S and G2/M phase. The 
underlying mechanisms by which this is achieved is not clearly understood but there 
is mounting evidence to suggest that this could be achieved directly through the 
modulation of intracellular levels of cyclins (in particular cyclin A and D1) and other 
cell cycle regulatory protein (CDK2, pRb) [157,158], or indirectly through the 
manipulation of the cell cycle control checkpoints. Specifically, activation of DNA 
damage response through ATR (ataxia-telangiectasia mutated/Rad3 related) 
signaling [159] was found to be required for efficient IBV replication. Exactly how 
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IBV activates ATR signaling is not clear, but it may be linked to replicative stress 
resulting from aberrant function or localization of DNA polymerase δ - a polymerase 
functioning in single strand DNA repair – during IBV infection [160]. In any case, 
the arrest of infected cells appears to provide a favourable environment for 
replication as cells synchronised at G2/M phase is associated with improved 
replication and progeny production compared to other phases [158].  
 
1.2.2.2. Ubiquitin-proteasome system and coronavirus replication 
The ubiquitin-proteasome system (UPS) in coronavirus replication was first 
implicated in coronavirus replication when it was observed that coronavirus infection 
was suppressed in the presence of proteasome inhibitors [161]. It was later 
demonstrated a functional proteasome is required for the efficient transfer of MHV 
virus particles to the cytoplasm after entry. In cells treatment with proteasome 
inhibitor MG132, virus particles are instead misdirected to the lysosomes, and thus 
denied of entry into the cytoplasm for translation. Subsequently, Raaben et al [162] 
found that inhibiting the proteasome with a myriad of pharmalogical inhibitors not 
only impairs virus entry, but also viral RNA and protein synthesis of MHV, FIPV 
and SARS- CoV. In a separate study, the discovery that SARS-CoV N protein 
colocalizes with the p42 subunit of the 26S proteasome, further augments the role of 







1.2.2.3 Autophagy, ERAD and early secretory pathway in DMV biogenesis 
Autophagy refers to the process by which unwanted large cellular components are 
directed to the lysosomes for degradation via double membrane intermediates known 
as autophagosomes [163]. The striking resemblance in the morphology of 
autophagasomes and the double membrane vesicles (DMV) fuelled speculations that 
autophagy may be utilized by coronavirus for the purpose of replication complex 
formation. There are several findings that support this hypothesis. First, 
coronaviruses induce autophagy independently of nutrient deprivation [164] and the 
activation of autophagic vesicles formation from the ER is mediated by nsp6 of 
several coronaviruses - IBV, MHV and SARS-CoV, and also by nsp6 orthologues 
(nsp5-7) in arteriviruses [165]. Second, components of the viral replicase co-localizes 
with markers of autophagosomes and lastly depletion of autophagy 5 (Atg5), an 
essential component of the autophagy machinery, inhibits MHV replication [164]. 
However, the absolute requirement for autophagy was thrown into doubt when 
depletion of either Atg5 or Atg7, another gene required for autophagy, did not alter 
MHV replication in mouse embryonic fibroblast [166,167]. In addition, subsequent 
studies with regards to the immunostaining of autophagic markers on coronavirus 
induced DMVs also had contradictory outcomes [168]. 
 
On a separate note, the similarities between DMVs and EDEMosomes (ER origin, 
lack of traditional ER markers, association with light-chain protein 3-I (LC3-I)) 
prompted Reggiori et al to investigate if EDEMosomes, and not autophagic vesicles, 
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are sources of coronavirus DMVs. EDEMosomes are ER derived vesicles 
responsible for the removal of ER associated degradation (ERAD) regulator, 
EDEM1. A rapid turnover of EDEM1 via this pathway (ERAD tuning) prevents the 
untimely termination of protein folding program due to unwarranted ERAD 
activation [169]. In support of their hypothesis, they found EDEM1 and OS-9, 
another ERAD regulator, co-localizing with sites of viral RNA production. 
Accumulation of EDEM1 and OS-9 in MHV infected cells can also be attributed to 
inefficient clearance resulting from the assimilation of EDEMosomes by MHV for its 
own use [166].  
 
The early secretory pathway is the third mechanism implicated for the biogenesis of 
DMV. And the earliest step in the secretory pathway occurs at the ER. Proteins 
earmarked for secretion leave the ER via COP-II (coat protein complex II) decorated 
vesicles. They are then transported through the various compartments in the Golgi 
apparatus where they are modified and packaged in vesicles that will fuse with the 
plasma membrane. The assembly of COP II vesicles at discrete regions on the ER 
membrane, referred to as ER exit sites, is regulated by a small GTPase known as 
Sar1 (reviewed in [170,171,172]) A block in ER-Golgi transport by either disrupting 
the membrane association of Sar1 or over-expression of a catalytically inactive 
mutant completely inhibits the formation of coronavirus RTC [173]. The transport of 
vesicular cargo from Golgi-ER is regulated by another small GTPase, ARF1 (ADP-
ribosylation factor 1). ARF1 itself is activated by GBF1 (Golgi-associated brefeldin 
A (BFA) – resistant), a large guanine nucleotide-exchange factor (GEF) belonging to 
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the Sec-7 family (reviewed in [174]). As with the case of Sar1, Verhejie et al found 
that impairment of GBF1 by BFA treatment drastically suppressed MHV replication. 
What was strikingly different was that in contrast to the complete abolishment of 
RTC formation observed with Sar1 inhibition, RTC formation could still occur when 
GBF1 mediated ARF1 activation was impaired. The authors believed that this could 
be explained by the formation of a less active RTC, and hence suggested that GBF1 
and ARF1 have roles in RTC maturation and functioning [175]. These conclusions 
however, did not go unchallenged. In the work done by Knoops et al [176], they 
observed that SARS-CoV induced remodeling of the endoplasmic reticulum 
membranes (they termed reticulovesicular network or RVN) can not only occur in 
the presence of BFA, but also retained most of its general features previously 
documented [78]. Moreover, the absence of early secretory markers associating with 
the SARS-CoV replication site and the failure of BFA to interfere with RNA 
synthesis in vitro further argued against the fact that GBF1 and ARF1 play direct 
roles in coronavirus infection. Instead, the negating effect on viral replication 
corresponding to a disrupted early secretory pathway was thought to be an indirect 
consequence of compromised ER integrity and function, brought about by BFA 
treatment. An intact ER is therefore the key to supporting coronavirus infection. 
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Figure 1-7: Effects of defective early secretory pathway on coronavirus replication and 
DMV biogenesis. (Modified from [173]) Inhibition of Sar1 function by H89 (Protein kinase 
A inhibitor) or over expression of a catalytically inactive mutant, Sar1p-H79G completely 
abolishes replication complex (RC) formation. Treatment with BFA, depletion of Arf1 and 
GBF1 by small interfering siRNA and/or overexpression of inactive Arf1 mutants (Arf1-
T31N, prevent ‘maturation’ of RC but not its formation. 
 
1.2.2.3 Apoptosis and coronavirus infection 
Obligatory dependence on the host cell for propagation implies that the apoptosis, or 
self-induced cell death can be regarded as a means for the host to limit viral 
infectivity and spread [177]. Indeed, the induction of apoptosis, mediated by p53 and 
the Bcl-2 family of proteins [178], during viral infection is commonly reported [177]. 
Extensive membranous alterations during virus entry and fusion, among others, may 
serve as important pro-apoptotic cues during infection [179,180]. 
 
In spite of the above, some viruses have evolved strategies to both counteract and 
adopt the process of apoptosis in their favour. Induction of apoptosis during the late 
 ERGIC 
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stage of infection, may present an excellent channel for dispersing its progeny as the 
uptake of infected apoptotic bodies by surrounding cells via phagocytosis, allows for 
the bypass the host immune survelliance [181]. The induction of apoptosis has been 
reported for several coronavirus including IBV [182,183], and SARS-CoV. In 
particular, for the case of SARS-CoV, pro-apoptotic signals seemed to be derived 
from many of accessory proteins encoded by SARS-CoV [153,184,185,186]. 
 
The utilization of cleavage proteases functioning in apoptosis offers yet another 
reason how apoptosis work counter-intuitively in the favour of the virus. SARS-CoV 
N protein was observed to be a substrate for cysteine aspartyl specific proteases 
(caspases) 3 and 6. The processing of N by caspases appears to be dependent on a 
nuclear localization of N [187]. While the study observed a correlation between 
permissive infection, caspase processing, and a SARS-CoV N that is competent in 




HOST-VIRAL INTERACTIONS (II): CORONAVIRUS AND THE INNATE 
IMMUNE RESPONSE 
Perhaps the most important cellular response modulated by the virus is the host 
innate interferon response. Viral infection typically activates signaling cascades that 
lead to the rapid production of type I interferons (IFN) and the subsequent 
transcriptional activation of hundreds of interferon- stimulated genes. Collectively, 
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this results in the establishment of an anti-viral state that severely limits virus 
replication [188]. Therefore, to efficiently replicate within their host cells, it is of 
paramount importance for viruses to evolve mechanisms to either evade or surmount 
these host defense responses. This section reviews the interplay between coronavirus 
and host innate immune response.  
 
1.2.2.1 Interferons and Interferon stimulated genes 
Depending on the type of receptor they engage (IFR), interferons (IFNs) are 
classified into three classes: Type I (IFN-α, IFN-β and IFN-ω), Type II (IFN- γ) and 
the more recently identified Type III (IFN-λ1, IFN-λ2, IFN-λ3). Named after their 
ability to ‘interfere’ with viral propogation, IFNs are induced by infected cells and 
function mainly as messengers to ‘warn’ and prepare neighbouring cells for 
impending pathogenic threats. The binding of IFNs to their respective receptors 
triggers the onset of a variety of signaling pathways that serve to restrict viral 
replication. 
  
The downstream signaling of IFN is conveyed through signal transducer and 
activator of transcription (STAT) complexes via the Janus kinase-STAT (JAK-
STAT) pathway. Following IFR binding to IFR, JAKs at IFNR is 
autophosphorylated. Activated JAK then phosphorylate key tyrosine residues at the 
IFNR to recruit STAT via their Src homology domain (SH2). Phosphorylation by 
JAK induces STAT1 to associate with STAT2 and Interferon regulatory factor (IRF) 
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9, which together form a trimeric complex known as interferon-stimulated gene 
factor 3 (ISGF3). Binding of ISGF3 to nuclear import factors [189] transport the 
complex into the nucleus where it binds to specific sequences (IFN-stimulated 
response elements (ISREs)) in the promoter region of targeted genes collectively 
known as IFN- stimulated genes (ISGs) [190]. Over three hundred ISGs have been 
identified to date. Apart from functioning directly in host defence [191]. ISGs also 
carry out a myriad of other cellular functions such as transcription, metabolism and 
signalling [192].  
 
2′,5′oligoadenylate synthetase (2′-5′ OAS), protein kinase R (PKR) are examples of 
anti-viral enzymes encoded by ISGs. In addition to increased synthesis induced by 
IFN, phospho-activation of PKR is also triggered by the presence of dsRNA. 
Phosphorylation of eukaryotic translation initiation factor 2 (eIF2α ultimately leads 
to the ‘shut-down’ of protein synthesis, blocking translation of viral proteins and 
therefore virion progeny production [193]. 2′-5′ OAS is similarly activated by 
dsRNA. 2’-5’ OAS activates latent RNase L, which results in the degradation of viral 
RNA [193].  
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Figure 1-8: The JAK-STAT pathway. Modified from [194]. Binding of interferon (IFN) to 
interferon receptor (IFNR) leads to the activation of JAK. JAK phosphorylation of key 
residues at IFNR leads to the recruitment and STAT1. Activated STAT1 associate with 
STAT2 and IRF9 to form a trimeric complex capable of translocating to the nucleus to 
activate expression of ISGs.  
 
 
1.2.2.2 Pattern recognition receptors (PRRs) 
The induction of IFN production in host cells is initiated with the recognition of 
pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors 
(PRR). The PRR family can be divided into the following subtypes; toll-like 
receptors (TLR), RIG-like helicases (RLH) and nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLR) [195]. While NLRs are activated mainly by 
bacterial components, pathogens of viral origins are recognized by TLRs and RLHs. 
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Found mainly on cytoplasmic vesicles of endosomes and ER, TLR are 
transmembrane proteins responsible for the extracellular detection of PAMPs. Out of 
the eleven TLR identified so far, four appears to be associated with the detection of 
viral infection by recognition of different PAMPs: TLR3 detects double stranded 
RNA (dsRNA) intermediates produced during viral replication; TLR7 and TLR8 
recognizes viral single stranded RNA while unmethylated CpG 
oligodeoxynucleotides in DNA viruses are ligands for TLR9 (reviewed in [196,197]). 
TLR signaling downstream of each TLR is divergent and can differ from being 
MyD88 (myeloid differentiation primary response gene 8) dependent or TRIF (TIR-
domain-containing adapter-inducing interferon-β) dependent (Figure 1.8). TLR3 
signals through the MyD88 independent, TRIF dependent pathway leading to the 
activation of transcription factors such as interferon regulatory factor 3 (IRF-3) and 
nuclear factor-kB (NF-kB). The role of IRF-3 in interferon activation will be 





Figure 1-9: MyD88 dependent or MyD88 independent pathway in TLR signalling. 
Adapted from [197].  
 
In contrast to the extracellular surveillance performed by TLR, RLHs are 
cytoplasmic receptors that are responsible for the intracellular detection of viral 
pathogens. The RLH family of PRRs comprises mainly of three members: retinoic 
acid inducible gene I (RIG-I or DDX58), melanoma differentiation-associated gene 5 
(MDA5 or IFIH1) and laboratory of genetics and physiology 2 (LPG2). RIG-I and 
MDA5 share similarities in the two caspase recruitment domains (CARDs) at their N 
terminus, in addition to a DExD/H box RNA helicase domain. The helicase domain 
confers RIG-I and MDA5 their ability to sense dsRNA whereas the CARD domain is 
responsible for transmission of signals to downstream effectors mediating IFN 
activation. Although LGP2 (Laboratory of Genetics and Physiology 2) possesses a 
helicase domain of similar homology, the absence of CARD domain suggests that 
LGP2 may function as a negative regulator of the two other RLHs [198]. 
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In spite of the similarities in their helicase domain and a common affinity for 
dsRNA, RNA moieties are differentially recognized by RIG-I and MDA5. For 
example, MDA5 but not RIG-I respond to stimulation by polyinosinic poly- cytidylic 
acid (poly I:C), a dsRNA mimetic [199]. Conversely, RIG-I but not MDA5, 
recognizes 5’ -triphosphate RNA [199]. Knock out models also revealed different 
RNA viruses are differentially detected by RIG-I and MDA5 [199,200]. 
 
Table 1.6: The specificity of RIG-I-like receptors in virus recognition. 
Virus Genome RNA Host cytosolic 
PRR 








Influenza A virus 8 RNA segments, negative-sense, 
single strand 
RIG-I 
Ebola virus Non-segmented negative-sense, 
single strand 
RIG-I 
Reovirus 10 double-stranded segments RIG-I and MDA5 
Hepatitis C virus Non-segmented positive-sense, 
single strand 
RIG-I 
Dengue virus Non-segmented positive-sense, 
single strand 
RIG-I and MDA5 




Polio virus Non-segmented positive-sense, 
single strand 
MDA5 
(Adapted from [201]) 
 
1.2.2.3 The RIG-I Like Helicase signaling pathway 
Following binding with their respective RNA ligand, RIG-I and MDA5 undergo 
transformational changes that will allow their CARD domain to interact with the 
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CARD domain of an adaptor protein – mitochondrial antiviral signalling adaptor, 
MAVS (also known as IPS-1, VISA and Cardif) [202,203]. MAVS in turn recruits an 
E3 ubiquitin ligase, TNF receptor associated factor (TRAF) 3. Through the TRAF3 
interactions with NF-κB activator (TANK), the assembly of an IκB kinase-ε (IKKε) 
and TANK-binding kinase-1 (TBK1) complex promotes the phosphorylation and 
nuclear translocation of IRF3 and NFκB [204]. Binding of IRF3 and NFκB to IFN-
stimulated response elements (ISREs) then triggers the expression of type I IFNs and 
inflammatory cytokines (Figure 1.8). 
 
 
Figure 1-10: RLH signaling in response to viral infections. Adapted from [205]. RIG-
1/MDA5 binds to viral derived 5’-triphosphate RNA and/or dsRNA and interact with 
mitochondria associated MAVS (also known as IPS-1). MAVS in turn recruits TRAF3, 
which through TANK, stimulate the assembly of IKKε/TBK1 complex. Phosphorylation of 
IRF3 and NFκB phosphorylation by IKKε/TBK1 complex promotes their nuclear 
translocation to induce IFNs and inflammatory cytokines expression. 
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1.3.4 Modulation of the innate immune pathway by coronaviruses 
Since the innate immune response is a critical hurdle for effective pathogenesis, 
coronaviruses have evolved a milieu of strategies to thwart defense mechanisms 
mounted by the host. A number of coronavirus proteins have been shown to directly 
inhibit interferon signaling at different levels (Figure 1-11). For example, although 
SARS-CoV ORF3, ORF6 and N were identified to be interferon antagonists at the 
same time, further studies revealed that they antagonize interferon activation via 
distinct mechanisms: ORF6 blocks the nuclear translocation of STAT by 
sequestering nuclear import factors in the ER. This prevents the induction of ISGs in 
response to interferon signaling [148]. Targeting further upstream, over expression 
protein 3a was found to down-regulate type I interferon receptor by promoting its 
ubiquitination and subsequent degradation via the lysosomal pathway [206] In 
contrast, the antagonistic activity of SARS-CoV N protein seemed to target a very 
early step of IFN-β induction (purportedly at the step of RNA recognition by 
molecular receptors) when it was found to inhibit poly (I:C) and Sendai virus 
induced IFN-β but not IFN-β induction induced by over-expression of viral RNA 
sensors like TLR3, RIG-I and Mda5 [42]. MHV N on the other hand, has been shown 
to impede 2’-5’OAS activation that occurs downstream of IFN induction [43]. 
Targeting similarly downstream of IFN induction is TGEV 7 as an intact TGEV gene 
7 is necessary for the avoidance of a global translation shut down mediated by PKR-
eIF2 signaling [207]. Antagonism of IFN induction by PLP2 domain of MHV nsp3 
offers yet another example of how IFN antagonism can be attained via another 
radically different mechanism: MHV PLP2 prevents IRF3 nuclear translocation by 
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deubiquitinating both IRF3 and its activating kinase, TBK1. In addition, direct 
interaction of PLP with IRF3 and TBK1 in the cytoplasm further sequesters them in 
an inactive, hypo-phosphorylated complex [208,209]. Coincidentally, TBK1 is also 
the target for SARS-CoV M. Interaction between M protein with TRAF3 impede 
association of the latter with TBK1 and IKKε, thereby terminating the downstream 
activation of IRF3 [45]. 
 
                    
Figure 1-11: Coronavirus interacts with the innate immune response at multiple levels. 
Adapted from [210]. 
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1.4 OBJECTIVES 
Be it the conscription of cofactors for replication, perturbation of cellular processes 
to create an advantageous microenvironment, or the necessary subversion of immune 
defenses for the purpose of effective propagation, intricate interactions between the 
virus and its host are fundamental to viral pathogenesis. An improved understanding 
of these events will not only allows us to gain new insights into the complicated field 
of coronavirus biology, but may also provide new directions for therapeutic 
interventions. Therefore, using primarily the prototypic IBV as our model 
coronavirus, we aspire to explore two aspects of virus host interactions in this 
dissertion:  
 
(i) Identification of novel host proteins involved in coronavirus replication  
To fulfill this objective, a genome-wide siRNA screen was employed. In this large 
scale ‘loss-of-function’ studies, a total of ~22,000 both known and putative human 
genes were individually silenced and their effect on IBV replication scored. Genes 
important for IBV infection can be identified if they inhibit or suppress IBV 
replication when silenced. A few selected genes of interest were further characterized 




(ii) Characterisation of host innate response towards coronavirus infection 
and identification of coronavirus counter-strategies of immune evasion 
 
The second part of the dissertation sought to understand the interplay between host 
innate immune response and coronavirus infection. The host innate response, 
embodied by the induction of interferons (IFN) and interferon-stimulated genes 
(ISGs), is responsible for the rapid establishment of an anti-viral state that serves to 
limit virus spread. Using the prototypic Infectious bronchitis virus (IBV) as our 
model, the various aspects of IFN activation and signaling during coronavirus 
infection was examined. 
 
IRF3 is a key regulatory molecule for IFN induction. In our attempt to identify novel 
interferon antagonist(s), a screen for interaction between IRF3 and SARS-CoV 
encoded proteins were performed. In this screen, we observed that ORF8 consistently 
co-immunoprecipitated with IRF3. Functional characterization of this interaction was 
carried out to determine its role in IFN antagonism. 
 
Despite many of the early efforts in identifying host-virus interacting factors, known 
cellular factors that are involved in coronavirus replication remained limited. 
Through our functional studies on the various aspects of host-viral interactions using 
a genome-wide screen, we aspire to gain a deeper insight on the biology of 
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coronavirus infection. In particular, understanding how the virus is dependent on the 
host cell machineries for their replication may provide opportunities of host-directed 
drugs. On the other end, understanding how coronavirus interact with the innate 
immune system would allow us to better formulate strategies that can thwart the 
















2.1.1 General Reagents, Chemicals and Buffers 
The general reagents and chemicals utilized in this study, and their corresponding 
sources are presented in Table 2.1 in alphabetical order 
 
Table 2-1: List of reagents and chemicals  




Carboxymethylcellulose (CMC) Merck 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco 
Dithiothreitol (DTT) Sigma-Aldrich 
DNA ladder – 100bp New England Biolabs 
DNA ladder – 1kb New England Biolabs 
Deoxyribonucleotides (dNTPs) New England Biolabs 
Ethidium bromide Bio-rad 
Fetal bovine serum (FBS) Hyclone 
Formaldehyde Sigma-Aldrich 
Geneticin ® Reagent (G418) Invitrogen 
Kanamycin Sigma-Aldrich 
Luria Broth (LB) medium Biopolis Shared Facilities (A*STAR) 
Penicillin-Streptomycin stock solution Invitrogen 
Phosphate saline buffer Biopolis Shared Facilities (A*STAR) 
Polyriboinosinic polyribocytidylic acid (poly (I:C)) Sigma-Aldrich 
Protein Ladder (BenchMarkTM) Invitrogen 
Protein Ladder (PageRuler TM) Fermentas 
Protease inhibitor cocktail (Complete-EDTA free) Roche 
Roswell Park Memorial Institute medium (RPMI) Gibo 
Sodium Dodecyl Sulfate (SDS) Bio-Rad 
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Sodium deoxycolate (DOC) Sigma 
Toluidine blue Bio-Rad 
TRI Reagent ® Invitrogen 
TRIS 1st Base 
Triton ® X-100 BDH Merck 
Trypsin Biopolis Shared Facilities (A*STAR) 




All restriction enzymes, including T4 DNA ligase and calf intestinal alkaline 
phosphatase (CIP), were purchased from New England Biolabs. Pfu DNA 
polymerase and Taq DNA polymerase were obtained from Fermentas, whereas 
reverse transcriptase (Expand RT) from invitrogen. 
 
2.3 Antibodies 
Table 2.2 shows the list of commercial primary and secondary antibodies used in this 
study 
 
Table 2.2: List of Primary and Secondary antibodies 
Primary Antibody  
Actin polyclonal antibody (goat) Santa Cruz Biotechnology 
dsRNA monoclonal (mouse)  Scicons 
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EEA1 monoclonal (mouse)  BD Transduction Laboratories 
FLAG monoclonal (mouse) Sigma-Aldrich 
FLAG polyclonal (rabbit) Sigma-Aldrich 
IRF3 polyclonal (rabbit) Santa Cruz Biotechnology 
ISG56 (rabbit) Santa Cruz Biotechnology 
MAVS polyclonal (rabbit) Abcam 
MDA5 polyclonal (rabbit) Axxora Platform 
Myc monoclonal (mouse) Sigma-Aldrich 
Myc polyclonal (rabbit) Sigma-Aldrich 
RIG-I polyclonal (rabbit) Axxora Platform 
Tubulin Sigma-Aldrich 
Secondary Antibody 
Anti-rabbit  GE Healthcare 
Anti-mouse  GE Healthcare 
Anti-donkey  DAKO 
AlexaFluor ® 488 anti-Rabbit Invitrogen 
AlexaFluor ® 488 anti-Mouse Invitrogen 
AlexaFluor ® 594 anti-Rabbit Invitrogen 
AlexaFluor ® 594 anti-Mouse Invitrogen 
 
Polyclonal IBV-S, IBV-N, SARS-8b antibodies were raised in rabbits as described 
previously [211,212].  
 
2.2 Cells and Viruses 
2.2.1 Cell culture 
Vero cells (African green monkey kidney cells) and Huh7 (human hepatocarcinoma 
cells used in this were maintained in high glucose (DMEM) supplemented with 10% 
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FBS while H1299 cells (human non-small cell lung carcinoma cells) and a clonal 
derivative stably expressing Renilla luciferase gene (H1299-RL) was maintained in 
RPMI medium with 10% FBS. All cells were grown in a 370C incubator supplied 
with 5% carbon dioxide (CO2). To generate the stable cell line H1299-RL, H1299 
were transfected with pxj41neo vector encoding renilla luciferase and grown in 
media containing 500µg/ml of G418 (Sigma-Aldrich) for 3 weeks before expansion 
of antibiotics resistant single cell clones cell colonies.  
 
Cells were routinely subcultured/passaged in accordance to the following procedure: 
culture medium was first aspirated, followed by washing with PBS to remove 
residual medium. Cells were then dissociated by incubating the cells in trypsin 
(0.25% w/v, Ca2+- and Mg2+ free) for 3 minutes at 370C. Dissociated cells added to 
DMEM containing 10% FBS were then collected by centrifugation at 500xg for 
5min. Finally cell pellet was re-suspended in fresh DMEM containing 10% FBS and 
seeded onto new culture flasks or assay plates. 
 
2.2.2 Preparation of cell stock 
For preparation of cell stock, cells were trypsinised and pelleted as above. After 
resuspension of cell pellet in freezing medium (DMEM with 10% FBS and 20% 




The IBV utilized by this study is derived from the Vero cell-adapted Beaudette strain 
[213,214,215]. Virus stocks were prepared first by infecting Vero cells (in serum free 
medium) at an approximate concentration of 0.1 plaque forming unit (pfu), followed 
by incubation at 370C (with 5% CO2) for 16 to 20 hours. Virus stocks, obtained via 
freeze-thawing the infected flask for three cycles, were stored at -800C in 1ml 
aliquots until use. Virus stocks for dengue virus serotype 1 and 2 (Singapore strain) 
were prepared in ways similar to that for IBV, except that an insect cell line C6/36 
was used in place of Vero cells. 
 
A series of recombinant IBV was also used extensively in this study. Methodologies 
employed for their construction were as previously described in [212,216,217]. 
Briefly, five cDNA fragments (A, B, C, D, E) covering the entire IBV genome were 
obtained by RT-PCR from IBV infected vero cells. The resultant PCR products were 
purified and cloned into pCR-XL-TOPO (Invitrogen, Carlsbad, CA, USA) or pGEM-
T Easy (Promega) vectors. Fragment A was removed from pCR-XL-TOPO by 
digestion with NheI and EcoRI, and subcloned into the pKT0 vector. Plasmids 
containing fragment A were digested with BsmBI while the rest (B, C, D, E) with 
BsaI (fragments B, C, D and E). The digested plasmid were then separated on 0.8% 
agarose, stained with crystal violet, cut from the gel and purified with QIAquick gel 
extraction kit (Qiagen). Ligation was performed in two steps: First, fragment A is 
ligated to B and C, D, to E using T4 DNA ligase at 40C overight. The two reactions 
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were then mixed and further ligated under conditions similar to that of the first. The 
final products are purified with with phenol ⁄ chloroform ⁄ isoamyl alcohol (25:24:1) 
and precipitated with ethanol. Full-length transcripts were generated in vitro using 
the mMessage mMachine T7 kit (Ambion, Austin, TX). To prevent DNA 
contamination, DNAseI was added to the in vitro-synthesized full-length (and N 
transcript) and later purified with phenol ⁄chloroform. For electroporation of 
transcripts, Vero cells (approximately 90% confluent) were trypsinized, washed 
twice with ice-cold NaCl ⁄ Pi, before finally resuspended in 400µl of NaCl ⁄ Pi. RNA 
transcripts were then introduced to the cell suspension in an electroporation cuvette, 
and electroporated with one pulse at 450 V and 50 lF using the Bio-Rad Gene Pulser 
II electroporator. Transfected Vero cells were cultured overnight in 1% fetal bovine 
serum-containing MEM in a 60 mm dish or a six-well plate, and further cultured in 
serum free DMEM until recovery of virus was observed. Recombinant IBV (rIBV) 
containing luciferase reporter gene (IBV-Luc) was constructed by replacing 
ORF3a/3b with the firefly luciferase gene and while rIBV expressing SAR-CoV 8a, 
8b and 8ab were incorporated into the IBV genome between the N gene and the 3’-
UTR under the regulation of the TRS for the subgenomic mRNA5 of IBV. For the 
purpose of this study, rIBV expressing the 8b mutant (8bm) was also generated using 
the fragment containing ORF8 used in synthesis of rIBV-8b. All three lysine residues 





2.2.4 Virus infection 
For all infections involving IBV, confluent monolayers were first subcultured and 
seeded in appropriate culture vessels overnight. Cells were then washed twice using 
PBS as wash medium, and changed to serum free medium before infection. For 
dengue virus infection, cells were directly incubated directly with the virus at 370C 
after washing with PBS. Virus was removed two hours post incubation, and with the 
addition of fresh serum free medium, the infected cells were incubated for a further 
24 to 72 hours. 
 
2.2.5 Virus titration 
To obtain virus titer, a standard plaque assay comprising of the following steps was 
performed: First, confluent monolayers of Vero cells seeded in six-well plates were 
infected with 100μl of ten-fold serially diluted virus stock. 1hour post incubation at 
370C, cells were washed twice with PBS and cultured in 3ml of DMEM containing 
0.6% carboxymethyl cellulose (CMC) for 3 days. Infected cells were then fixed with 
4% formaldehyde for 15minutes prior to and staining with 0.1% toluidine blue. The 
number of plaques, over an average of 3 samples, was counted and virus titre was 





2.3 MOLECULAR CLONING 
2.3.1 Preparation of competent cells 
Escherichia coli (E. coli) strain DH5α was streaked onto a LB agar plate (1% bacto-
tryptone, 0.5% bacto-yeast extract, 1% NaCl and 1.5% agar, pH7.0) and incubated 
overnight at 370C. A single colony was then picked and inoculated in 8ml of LB 
broth. Culture was allowed to grow overnight at 370C with aeration by shaking at 
220rpm. An inoculum of the overnight culture was diluted 100 times in 500ml of LB 
medium and incubated at 370C with shaking until a reading of 0.6-0.8 was attained 
for the absorbance at 660nm (A660). This was followed by chilling the culture on ice 
for 30minutes before they are pelleted by centrifugation at 4,000g for 10minutes at 
40C. The pellet was re-suspended in 40ml of pre-chilled 0.1M CaCl2 solution and 
incubated on ice for a further 1hour. The process of centrifugation was repeated and 
cells were re-suspended in 4ml of 0.1M 0.1M CaCl2 with 20% glycerol.  Competent 
cells were aliquoted (50μl) and stored at -800C. 
 
2.3.2 Polymerase chain reaction 
The PCR reaction mix is typically prepared using the recipe below: 
Template DNA (10-100ng) variable 
Forward primer (10μM)  0.5μl 
Reverse primer (10μM)  0.5μl 
dNTPs (10uM)  1.0μl 
Taq/Pfu polymerase  1.0μl 
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Water    variable 
Total volume:      50μl 
 
The reaction was typically carried out by 1 cycle of denaturation at 940C for 
4minutes, followed by 25-35 cycles (depending on purpose and amount of template) 
of denaturation at 940C for 1minute, primer annealing for 30-60seconds at 
appropriate temperature (see Table 2.3) and DNA polymerization at 720C. The time 
required for extension at 720C is dependent on the length of amplicon and was 
calculated based on the polymerase’s extension rate of approximately 25 base pairs 
(bp) per second. Taq polymerase was used for all PCR reactions except in conditions 
where high fidelity DNA synthesis is required. For these purposes (for instance, 
amplification for molecular cloning), Pfu DNA polymerase was used in view of its 
proof-reading activity. The primers utilised in this study, as well as the optimized 
annealing temperature used during PCR is listed below: 
 




IFN-β Fwd 5’-GCTCTCCTGTTGTGCTTCTC-3’ 550C 
 IFN-β Rev 5’-AGTCTCATTCCAGCCAGTGC-3’ 
ISG56 Fwd 5’-TCTCAGAGGAGCCTGGCTAAG-3’ 550C 
 ISG56 Rvs 5’-CCACACTGTATTTGGTGTCTAGG-3’ 
GAPDH Fwd 5’-GACAACTTTGGTATCGTGGAA-3’ 500C 
 GAPDH Rvs 5’-CCAGGAAATGAGCTTGACA-3’ 
MDA5 Fwd 5'-ATCTGCCTCCCTACAGGGAGTG-3' 550C 
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MDA Rvs 5'-ACACCAGGTGAAGCTGTTAGTCC-3' 
RIG-I Fwd 5'-AGATCCCAGTGTATGAACAGC-3' 550C 
RIG-I Rvs 5'-GCTCCAGTTCCTCCAGATTGT-3' 
* Fwd: forward primer; Rvs: Reverse primer 
 
2.3.3 DNA Agarose Gel electrophoresis 
6X DNA loading buffer (0.25% (w/v) bromophenol blue and 0.25% (w/v) xylene 
cyanol FF and 20% (w/v) glycerol) was added to DNA samples prior to their 
separation by electrophoresis in 1.0-1.5% (w/v) agarose in TAE buffer (40mM Tris-
acetate and 2mM EDTA) supplemented with 1μg/ml ethidium bromide, at constant 
voltage of approximately 100-120V. DNA bands were visualized with UV 
illumination. 
 
2.3.4 Gel purification 
Purification of DNA fragments following gel electrophoresis was performed using 
QIAquickTM Gel Extraction Kit (Promega) according to manufacturer’s protocol, 
except that elution of DNA from silica columns were deionized water (ddH20). DNA 
products obtained were quantitated using NanoDropTM 1000 Spectrophotometer to 




2.3.5 Recombinant DNA technique – construction of plasmids 
Restriction digestions of PCR products or plasmids were performed with appropriate 
restriction enzymes according to manufacturer’s recommendations. Typically, 1-3μg 
of DNA was digested by 10U of each restriction enzyme in a 20μl reaction mix at 
370C for at least 1 hour. To avert self-ligation, Plasmids were incubated for a further 
30 minutes with calf intestinal alkaline phosphatase (CIP) at the end of the restriction 
digest reaction. Purified vector and the DNA fragment insert were ligated (molar 
ratio between 1:3 to 1:5) using T4 DNA ligase. The ligation mixture was incubated at 
room temperature for 3-4 hours or overnight at 160C. 
 
For transformation, 10μl of the ligation mix were added to 50μl of DH5α (see 
Section 2.3.1) that was pre-incubated on ice for 30minutes. The mixture was then 
heat shocked at 420C for 1 minute followed by incubation for 5minutes in ice. 
Subsequently, 1ml of LB broth was added into the mixture and a recovery period of 
1hour at 370C (with vigorous shaking) was given. Finally, the mixture was plated on 
LB agar plates containing appropriate antibiotic (either 100μg/μl of ampicillin or 
50μg/μl kanamycin) for selection of successful transformants. A single colony was 
picked, amplified and screen for incorporation of DNA insert through PCR or 




2.3.6 Plasmid purification 
The Nucleospin® plasmid QuickPure kit (Macherey-Nagel) was utilized for 
extraction of plasmids from E. coli cells. Briefly, single colony picked after antibiotic 
selection were scaled up into a 5ml culture by shaking overnight at 370C. Bacteria 
cells were pelleted by centrifugation at 14,000rpm for 1minute and re-suspended in 
P1 solution in the presence of RNAse A (100mg/ml). This was followed by cell lysis 
with the addition of P2 and finally neutralization with P3 solution. The precipitates 
were cleared by centrifugation at 14,000rpm for 1minute and the supernatant was 
applied into the silica column provided. After 2 rounds of washing with the wash 
buffer solution provided, plasmid was eluted with 30-50μl of ddH20. 
 
2.3.7 DNA sequencing 
Plasmid DNA (300-500ng) was added to a sequencing mix comprising of 1X Big 
Dye termination mix (1stBase), 3.2pmol of appropriate primer topped up to 10ul with 
ddH20. Thermal cycling was carried out by 25 cycles of 1) denaturation at 960C for 
10 seconds, 2) annealing at 500C for 5 seconds, and 3) extension at 650C for 
4minutes. The reaction products were precipitated by addition of 2 volumes of 100% 
ethanol with 0.1 volume of 3M sodium acetate (pH5.2), incubation on ice for 
10minutes and finally centrifugation at 14,000 rpm. The pellet was washed with 70% 
ethanol, air-dried and sequenced by an automatic DNA sequencer (Applied 




The pXJ40-flag and pXJ40-myc plasmid used in this study is derived from the pXJ40 
plasmid generated by J.H. Xiao in 1990. The Flag (MDWKDDDDK) and Myc 
(EQKLISEEDL) tag sequences were inserted between the T7 promoter and the 
multiple cloning site (MCS). For achieve expression independent of vaccinia virus, 
the pKTO-Flag 8b and 8ab plasmids previously described [212] were sub-cloned into 
pxJ40-Flag vectors using the same restriction sites.  
 
For the construction of the pxjMyc-IRF3 plasmid, the human IRF3 gene was 
amplified from total RNA isolated from H1299 cells using the forward primer (F) 5’-
AACGCCTCGACGGAACCCCAAAGCCACGGAT-3’and the reverse primer (R) 
5’-GCCGGTACCTTATTGGTTGAGGTGGTGGGG-3’ for PCR prior to ligation 
into pxj40My plasmid at XhoI and KpnI restriction sites. Truncated mutants were 
then constructed based on Myc-IRF3 construct using the following primers for PCR 
amplification: for IRF3 (1-133): F 5’-CCGCTCGAGCGGATGATGGGAA 
CCCCAAAGCCACG–3’and R 5’-
GGGGTACCCCTCAAGAAGTACTGCCTCCACC AT–3’; for IRF3 (399-379), F 
5’-CCGCTCGAGCGGATGGATACCCAGGAAGA CATTCT-3’ and R 5’-
GGGGTACCCCTCATCCAGGCAGCGTCCTGTCTC-3’; for IRF3 (241-427), F 5’-
CCGCTCGAGCGGATGTGGCCAGTCACACTGCCAGA-3’ and R 5’-
GGGGTACCCCTCAGCTCTCCCCAGGGCCCT-3’; for IRF3 (134-427): F 5’-
CCGCTCGAGCGGATGGATACCCAGGAAGACATTCT-3’ and R 5’-
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GGGGTACC CCTCAGCTCTCCCCAGGGCCCT-3’. Constitutively active mutant 
pxjIRF3-5D was generated by performing sequential site-directed mutagenesis PCR 
(QuikChange II site-directed mutagenesis kit; Stratagene) to replace amino acids at 
positions 396, 398, 402, 404, and 405 with the phosphomimetic aspartate amino acid.  
 
The rest of the plasmids were kind gifts from the following: pXJ40-HA-MAVS was 
from Dr. Wang Li (formerly of Nanyang Technological University, NTU); pIFN-β 
luciferase reporter (pIFN-β-Luc) from Dr Xiao Han (formerly of University of St. 
Andrews, Scotland);  pXJ40-flag-MDA5, pXJ40-flag-RIG-I were constructed by Dr 
Fang Shouguo (NTU); pKTO-SARS8b, pKTO-SARS8ab were generated by Ms Le 
Tra My (formerly of National University of Singapore, NUS) 
 
The pGEM®-T vector (Promega), pRL-TK vector (Promega) and pXL-TOPO 
cloning kit (Invitrogen) were purchased from the respective companies. 
 
2.4: RNA MANIPULATION 
2.4.1 Extraction of total RNA from mammalian cells 
Total RNA was isolated from cells using TRI Reagent® according manufacturer’s 
protocol. Briefly, cells washed with PBS were lysed by addition of TRI Reagent®. 
After incubation of about 15minutes with shaking, the lysates were transferred to 
sterile microcentrifuge tubes. Chloroform was added (200μl for every 1ml of TRI 
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Reagent®) and after vigorous mixing, the mixure was subjected to centrifugation at 
14,000rpm for 20minutes at 40C. The aqueous phase containing the isolated RNA 
was transferred to a fresh tube and mixed with an equal volume of isopropanolol and 
incubated either on ice or at room temperature for at least 30 minutes. The 
precipitated RNA was then centrifugation at 14,000 rpm, 40C, for 20minutes. The 
RNA pellet was then washed with 100% ethanol, air-dried and finally re-suspended 
in RNAse-free water. 
 
2.4.2 Reverse Transcription 
RNA was reverse transcribed using the Expand reverse transcriptase kit (Roche) in 
two steps. In the first step, a reaction mix consisting of 2-3μg RNA, 20pmol 
oligo(dT)18 primers and nuclease free water (in a total volume of 11μl) was subjected 
to denaturation at 650C for 10 minutes. The mix was transferred to ice for 5 minutes. 
Then, after addition of a RT reaction mixture comprising of 4μl of 5X Expand 
reverse transcriptase buffer, 2μl of 100mM DTT, 2μl dNTPs, 50U Expand RT (1μl) 
and 20U RNAse inhibitor (0.5μl), the second step of the reaction involved incubating 
the reaction mix at 430C for 1 hour. An aliquot of the cDNA produced was used for 





2.4.3 Quantitative real-time PCR (qPCR) 
In this study, the relative abundance of IFN-β, ISG15, ISG56 and RANTES mRNAs 
in treated samples with respect to their mock treated counterparts were determined by 
real time quantitative RT-PCR using the SYBR Green method (Roche). Briefly, a 20 
μL PCR reaction containing cDNA transcribed from 1-5μg of total cellular RNA, the 
respective primers and LightCycler FastSart DNA Master SYBR Green I (Roche) 
real-time PCR was accomplished using the LightCycler (Roche), using the PCR 
cycling conditions comprising of an initial denaturation step at 94°C for 10 min 
followed by an amplification program for 40 cycles of 30 seconds at 95°C, 10 
seconds at 55°C, and 20 sec at 72°C with fluorescence acquisition at the end of each 
extension. The relative expression of each gene is calculated using the comparative 
CT method, using the mock treated sample as calibrator and housekeeping gene 
GAPDH as internal control. 
 
The following primer pairs were used: for GAPDH F 5’-GACAACTTTGGTAT 
CTTGGAA-3’and R 5’-CCAGGAAATGAGCTTGACA-3’; for ISG56 F 5’-
TCTCAG AGGAGCCTGGCTAAG-3’ and R 5’-
CCACACTGTATTTGGTGTCTAGG-3’; for ISG15 F 5’-TGG 
TGGACAAATCGCACGAA-3’ and R 5’-CAGGCGCAGATTCAT GAAC-3’; for 
RANTES F 5’-GGCACGCCTCGCTGTCATCCTCA-3’ R 5’-CTTGATG 
TGGGCACGGGGCAGTG-3’; and for IFN-β F 5’-
CTCTCCTGTTGTGCTTCTCCAC-3’ and R 5’-TAGTCTCATTCCAGCCA 
GTGCT-3’. 
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2.4.3 RNA interference 
Silencing of VCP, Ufd1L, GBF1, Arf1 using siRNA was performed using 
HiPerFect® Transfection reagent by the reverse transfection method. Briefly, the 
transfection reagent was incubated with serum free media for 5 minutes before 
addition of gene specific siRNA. The transfection mix was spotted onto the 
well/plate after a further 20minutes of incubation. Trypsinised cells diluted in 
appropriate volume of serum-containing medium were then added to the wells. The 
initial seeding density, amount of siRNA and volume of transfection reagent used 
vary accordingly with the culture format employed and were added according to 
manufacturer’s recommendations. The following conditions were used for the studies 
presented in this dissertation. 
 













384 well 3.0 x 103 40 2.5 a 0.3 
24 well 3.0 x 104 400 25.0 a 3.0 
6 well 0.5 x 106 2000 2.0 b 10.0 
100mm dish 3.5 x 106 8000 16.0 b 40.0 
a: Volume of 0.5μM stock; b Volume of 50μM stock 
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2.5 GENOME WIDE RNAI SCREEN 
2.5.1 Screen setup 
To identify cellular cofactors supporting coronavirus infection, an RNAi based 
screen was performed using a commercial genomic siRNA library (Dharmacon 
siGenome) (Thermo-Fisher) in 384 well format (384 black µclear, Grenier). The 
RNAi library consisted of pools of four distinct siRNAs targeting each of the known 
22,909 human genes. Using the reverse transfection protocol, siRNAs were 
transiently transfected at a final concentration of 25nM per well using 0.25µl 
DharmaFECT 2 siRNA transfection reagent in 7.25 µl of RPMI media according to 
manufacturer’s protocol. After 20 minutes of complex formation, cells were 
dispensed at cellular density of 3000 per well using Multidrop Combi (Thermo 
Fisher Scientific).  72 hours post transfection, medium was removed and cells were 
washed with PBS twice before infected with IBV-Luc for 16 hours. Cells were then 
harvested with DualGlo (Promega) and luminescence signals for both firefly and 
renilla activities were acquired with Infinite M200 luminometer (Tecan). 
 
2.5.2 Data Formating, normalization and screen quality control  
Screen quality control was done using the ScreenSifter software developed in our 
laboratory (www.screensifter.com).  The Pearson correlation coefficient between 
Firefly scores of two replicates is 0.61. Each replicate’s Firefly and renilla scores 
were normalized by Z score by plate. After normalization the Pearson correlation of 
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Firefly scores improved to 0.71.  Thereafter, the normalized luciferase and renilla 
scores of the replicates were averaged.    
 
2.5.3 Z-score calculation and primary hits determination 
In sample based normalization, the Z score was calculated for each gene using the 
following formula:  Z = (Xi-X)/σx. Where Xi is firefly signal intensity of the gene i, 
X is average of the of firefly signal intensities of all the genes per plate and σx is the 
standard deviation of firefly signal intensities of the genes per plate.  
 
The scatter plot of Firefly Z Score versus Renilla Z Score visually appeared to be 
non-linearly correlated (Figure 1B). The shape of data cloud matched to the 
Michaelis-menton curve. Michaelis menton equation is generally used to model 
enzyme substrate reactions. It has also been being used to model antigen-antibody 
reaction, protein-protein interaction, DNA hybridization and growth of 
microorganisms. We also applied the Michalis-menton equation assuming limiting 
virus concentration for the increasing cell number (Renilla signal). We also 
performed the experiment to validate our idea by measuring Firefly and Renilla 
signal intensities for single control gene knockdown with changing cell numbers. The 
plot of Firefly versus Renilla score (Figure 1C) for this validation experiment fits 
with the Michaelis-menton equation, hence confirming our hypothesis. We thus 
identified the best fit non-linear line for the Firefly versus Renilla score in the 
genome wide screen (Figure 1D). We then draw parallel lines to this best fit line, 2.5 
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standard deviation (calculated for all genes excluding controls) away in both 
directions. In this manner, we thus identified 263 hits (in purple color in Figure 1D) 
 which are host genes supporting the virus infection and 131 hists (in red color in 
Figure ID) which are host genes inhibiting the virus infection.   
 
2.5.4 Deconvoluted screen 
After filtering non expressing genes from the primary hits, a customised siRNA 
library consisting of 4 individual siRNAs targeting the selected genes in 384 well 
format was ordered (Dharmacon). Similar to the genome wide screen, reverse 
transfection of 3000 cells were performed by transiently transfecting siRNAs at a 
final concentration of 25nM over 72 hours. Luciferase activity was measured 16 
hours post IBV-Luc infection. Luciferase activity was normalized with renilla 
expression and the average normalised ratio from two screens was scored. Genes 
with 2 or more siRNA scoring significantly lesser than that of non-targeting controls 
(± 2 standard deviations) were considered as validated hits. 
 
2.5.5 Bioinformatics Analysis: Gene annotation and protein networks  
Annotation information for each genes were gathered from Gene Ontology [218], 
GeneCards (www.genecards.org) [219] and NCBI 
(http://www.ncbi.nlm.nih.gov/gene). Gene enrichment was analysed using a 
combination of DAVIDS bioinformatics (http://david.abcc.ncifcrf.gov/) [220] and 
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ScreenSifter software. Protein network was created using STRING (http://string-
db.org/) [221] and the ScreenSifter software developed in our laboratory. 
 
2.6 PROTEIN EXPRESSIONS AND ANALYSIS 
2.6.1 Transient expression of plasmid DNA in mammalian cells 
For transfection using the recombinant vaccinia virus system, cells were grown to of 
90% confluency in 6-well plates prior to their infection with recombinant 
vaccinia/T7virus (vTF7) at a multiplicity of infection (M.O.I) of 1 for 1 h at 37°C 
with 5% CO2. Supernatant was then aspirated and cells were washed once with PBS 
before being transfected with 0.4μg plasmid DNA each, using the Effectene 
transfection reagent according to the manufacturer’s instructions, and incubated at 
37°C with 5% CO2 for 18-24 h. Cells were then harvested for further analysis. 
 
Transfection using a non-recombinant vaccinia virus system was performed 
using Lipofectamine 2000 according to the manufacturer’s instructions. Briefly, 
confluent cells (more than 95%) were transfected with a serum-free DNA 
transfection mixture consisting of DNA and Lipofectamine 2000 transfection 
reagent. The amount and ratio of DNA and transfection reagent used were dependent 
on the size of the culture vessel, as advised by manufacturer’s specifications. 
Transfected cells were incubated at 37°C with 5% CO2 for 6 h, following which the 
transfection mixture was removed and culture medium containing 10% FBS was 
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added to the cells. The cells were then incubated for another 16-24 h before 
harvesting for further analysis. 
2.6.2 SDS-PAGE  
Proteins were prepared by adding 2X sample buffer [100mM Tris-HCl pH 6.8, 4% 
SDS, 0.5% (w/v) bromophenol blue, 20% (v/v) glycerol and 10mM dithiothreitol 
(DTT)] and heated at 95°C for 5 min before loading onto SDS-PAGE. For SDS-
PAGE used in the study of SARS 8b protein, the Bio-rad gel system was used. 
Briefly, the resolving gels of various concentrations (8%, 10%, 12% or 15%) and 5% 
stacking gels were cast between two glass plates (Bio-Rad). The gels were run in the 
Bio-Rad 88 Mini-PROTEAN II system in a reservoir of running buffer [25 mM Tris-
HCl pH 8.3, 192 mM glycine and 0.1% SDS] at 20 mA per gel. The gels were then 
electrophoretically transferred to nitrocellulose membranes (Bio-Rad) at 4°C using 
the Bio-Rad Trans-BlotTM system. The transfer buffer contains 24mM Tris-base, 
192mM glycine and 20% ethanol. In the genome wide study for cellular host factors, 
samples were resolved by SDS-PAGE electrophoresis using bis-tris Nu-Page gels in 





2.6.3 Western Blot analysis 
After transfer, membranes were blocked in blocking buffer [PBS with 10% non-fat 
milk powder and 0.1% Tween 20] at room temperature for 1 h, and incubated for 1 h 
at room temperature (or at 40C overnight) in a dilution of a specific primary antibody 
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in blocking buffer. After 3 washes with PBST [PBS with 0.1% Tween 20] at 10 min 
per wash, membranes were incubated with appropriate IgG conjugated with 
horseradish peroxidase (HRP) diluted in blocking buffer, for another hour at room 
temperature. After three washes with PBST as above, membranes were subjected to 
chemiluminescence detection with appropriate ECL kits (Amersham/PerkinElmer), 
depending on the strength of the signals. To re-probe the same membrane with 
another antibody, the membrane was incubated in stripping buffer [62.5mM Tris-HCl 
pH 6.7, 100mM ß mercaptoethanol, 2% SDS] at 55°C for 20 min, washed thrice with 




Cells were lysed in buffer containing 50mM Tris HCL (pH7.4), 150mM NaCl, 1mM 
EDTA, 1% NP-40, protease inhibitors (Complete, Roche) and phosphatase inhibitors 
(Halt Phosphatase Inhibitor Cocktail, Pierce) for 30min at 4 0C. Proteins were then 
separated by electrophoresis in 8% non-denaturing polyacrylamide gels, with 1% 
sodium deoxycolate (Sigma) in the cathode buffer. IRF3 monomers and dimers were 
detected by Western blot analysis using polyclonal antibodies against full length 




Monolayer cells grown overnight in 6 well plates (Nunc) were infected with 
recombinant vaccinia virus encoding the bacteriophage T7 RNA polymerase before 
transfection of plasmids using Effectene reagent (Qiagen), in accordance to 
manufacturer’s instructions. 20 h post-transfection, cells were harvested with 500 µl 
of RIPA buffer in the presence of protease (Roche Diagnostics) and phosphatase 
inhibitors (Pierce). Lysates were centrifuged at 13,000 g at 4 0C for 15 min, and the 
supernatant obtained were immunoprecipitated directly with antibody conjugated 
agarose beads for 2 h or with appropriate antibodies followed by incubation with 
protein A agarose beads (Sigma) for another 2 h at room temperature. The 
immunoprecipitated proteins were separated on SDS-PAGE and analyzed by western 
blot using appropriate antibodies. The HRP conjugated anti-Myc and Flag tag 
antibodies used were purchased from Sigma while antibodies against IgG, ISG56, 
actin and full length IRF3 were from Santa Cruz Biotechnology.  
 
2.7 LUCIFERASE ASSAYS 
2.7.1 IFN-β reporter assays 
Huh7 cells seeded on a 12 well plate were transfected with a total of 4 µg of the 
appropriate plasmids using Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instructions. pIFN-β-Luc was generously provided by and the control 
pRL-TK plasmid was purchased from Promega. 10ug of poly(I:C) complexed with 
Lipofectamine 2000 in 1:1 ratio were then introduced into the cells 20 h later. Cells 
were then lysed 20 hours post treatment in passive lysis buffer (Promega) and an 
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aliquot of the lysates was measured for their firefly and Renilla luciferase activities 
as described by the manufacturer’s protocol (Promega). 
 
2.7.2 Luciferase assay with IBV-Luc 
H1299 cells were reverse transfected with VCP, GBF1, ARF1, UFD1L and non-
targeting (NT) control siRNAs, using HiPerfect® Transfection reagent (see Section 
2.4.2). At 72 hours post-transfection, cells were infected with IBV-Luc containing 
the luciferase reporter gene at an MOI of 1, and harvested at the indicated time points 
(0-16 hours post-infection). Cells were washed with PBS and lysed with 1X Passive 
Lysis Buffer (Promega). Luciferase reporter assay was performed in duplicates using 
the Luciferase Assay System kit, according to the manufacturer’s instructions. 




For immunofluorescence staining of viral dsRNA, cells adhered to coverslips were 
fixed with 4% formaldehyde, permeabilized with 0.2% Triton-X and incubated with 
one of the following primary antibodies: mouse anti-dsRNA (English & Scientific 
Consulting Bt. Hungary) (1:500), rabbit anti-Flag (1: 250), mouse anti-Flag (1:250). 
This is followed by incubation with the appropriate secondary antibodies conjugated 
with FITC or TRITC. Nucleus was stained with Hoescht (Invitrogen) at a dilution of 
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2.9 SUBCELLULAR FRACTIONATION 
Fractionation of endosomal fractions 
Reverse transfection of 4 million cells (10cm dish, Nunc) was performed with 
siRNAs was at a final concentration of 30nM per well using 160 µl DharmaFECT 2 
siRNA transfection reagents in 1.6ml of RPMI media. 72 hours post transfection, 
cells were incubated with IBV (MOI=0.25) for 4 hours at 370C. Infected cells were 
then washed with ice-cold PBS, scraped down in homogenization buffer (HB) (250 
mm sucrose, pH 7.4 Tris, 1 mm EDTA) in the presence of protease (Complete EDTA 
Free, Roche) and phosphatase (PhosphoHalt, Roche) inhibitors and homogenized 
using a 22-gauge needle. Postnuclear supernatant (PNS) was obtained after 
centrifugation at 2,000 × g for 5 min at 4 °C and crude separation of the endosomal 
fractions was achieved via a sucrose floatation discontinuous gradient. In brief, the 
sucrose concentration of the PNS was adjusted to 40.6% by adding 62% sucrose 
(1:1.2, v/v) and loaded on the bottom of an SW41 ultracentrifuge tube (Beckman). It 
was overlaid sequentially with 35% sucrose, (2.5 ml), 25% sucrose (2ml) and finally 
HB (1.5ml). After 1 h of centrifugation at 100,000 × g at 4 °C, every 1 ml fractions 
collected was subjected to RNA and protein extraction using Trizol (Invitrogen) 
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CHAPTER THREE: GENOME WIDE RNAI SCREEN REVEALS 
CELLULAR COFACTORS IN CORONAVIRUS REPLICATION 
 
3.1 INTRODUCTION 
The infectious cycle of coronavirus is a multistep process [9,21,222].  Briefly, 
attachment of the spike protein to cell surface receptors is followed by virus entry via 
fusion of viral membrane with the plasma membrane or endocytic compartments. 
The viral particle then undergoes an un-coating process that allows the delivery of 
viral genome into the cytosol. Translation of the viral replicase gene by host 
ribosomes yields two poly-proteins that upon co-translational cleavage by virally 
encoded proteinases, eventually form the viral replication complex (RTC). The RTC 
is responsible for the transcription of full-length genomic RNA as well as the 
synthesis of sub-genomic RNAs species via a unique discontinuous transcription 
mechanism. Translation of these subgenomic species produces the virus structural 
proteins: nucleocapsid (N) protein, membrane protein (M), envelope protein (E) and 
spike protein (S), along with group-specific accessory proteins that, although do not 
directly participate in viral replication, have roles in modulating virus pathogenesis 
[61,223]. Finally, together with the newly synthesised genome, the structural proteins 
are packaged into new virions for release via the secretory pathway. 
 
To achieve the processes described above, coronavirus exploits the existing host 
proteins and cellular pathways. For instance, the importance of early secretory 
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pathway [173,175,176] and DNA damage response [160] was demonstrated through 
drug inhibition or siRNA studies. There are also emerging reports of host cell 
proteins directly interacting with the viral replication machinery [123,160,224,225] 
to possibly aid in its assembly or function. Recently, a genome wide yeast-2 hybrid 
screen using SARS-CoV non-structural protein 1 (Nsp1) revealed the involvement of 
cyclophilins and the Calcineurin/NFAT pathway in SARS-CoV replication and 
pathogenesis [154].  Conversely, coronaviruses are known to express several proteins 
that inhibit cellular proteins or processes that may otherwise impede its replication. 
Examples of such interaction include interferon antagonists that target the effective 
activation host immune response [63,207]. 
 
In spite of the above, there is still limited information with regards to the role of host 
cellular factors in coronaviral biology and propagation. In this chapter, we describe 
the use of a genome wide RNAi screen to identify host genes required for 
coronavirus replication. For the ease of large scale handling and genetic 







3.2 RESULTS (I) Genome-wide RNAi screen reveals cellular factors involved in 
Coronavirus infection 
3.2.1 Optimization of Genome wide RNAi screen 
For the ease of assessing RNAi associated cellular toxicity, a genome wide siRNA 
screen (Dharmacon siGenome) was conducted in stable cells expressing renilla 
luciferase that correlate with cell numbers (H1299-RL) (Figure 3-1A). At 72 hours 
post siRNA transfection, cells were then infected with IBV-Luc - a recombinant 
strain of IBV that expresses firefly luciferase during replication [93]. The firefly 
luminescence emitted would thus provide a convenient readout for viral replication 
in the infected cells.  
 
The screen was optimized for acquisition of firefly and renilla luminescence at 16 
hours post infection (h.p.i.) as this time point corresponds to the peak of 
unadulterated virus replication (Figure 3-1B). Moreover, the secondary infection of 
neighbouring cells that would have occur within this time frame would also allow for 
the identification of host factors involved in all stages of the coronavirus life cycle 
such as entry, translation, transcription, replication, as well as viral 




Figure 3-1: The use of renilla and firefly luciferase activity as markers for cell numbers 
and virus replication efficiency respectively. (A) H1299-RL cell line stably express renilla 
luciferase in proportional to cell numbers. Cells were serially diluted and plated in 384 wells 
at different cellular densities and maintained in medium supplemented with low amounts of 
serum (2%) to delay cell expansion.  Renilla activity analysed 14 hours after cell plating 
revealed that renilla activity increased proportionally with the number of cells plated. Each 
data point corresponds to the average signal obtained from 50 wells at each cellular density. 
(B) H1299-RL cells were infected with IBV-Luc and harvested at the indicated time points. 
Analysis of firefly luciferase activity at the different time points revealed that luciferase 
signal peaked at 16 hours after which it started to decline. The experiment was repeated 




A common strategy to eliminate false positives arising from siRNA induced toxicity 
entails the exclusion of samples with cell numbers below a stipulated threshold 
[226,227,228]. The thresholds set however, were often arbitrary and could lead to the 
exclusion of false negatives that had impact on viral infection beyond the level of 
cytotoxicity induced. Unsurprisingly, toxicity thresholds are critical determinants of 
the outcome of hits selection. [229].  
 
To circumvent this, we first determined how IBV replication varies with cytotoxicity 
by plotting the average Z score (Materials and methods, Section 2.5.3) of renilla 
against that of firefly luciferase. Across the genome, most genes fell were 
concentrated within a tight ‘cluster’ that possibly corresponded to the background 
variation / ‘noise’ in our screen (Figure 3-2). In contrast, the subset of genes found 
outside this cluster was likely to represent hits that affect virus replication beyond the 
inherent level of variation in siRNA-induced toxicity. In a bid to determine an 
appropriate cut off for the selection of these genes, the trend between firefly 
expression and renilla levels was analysed in detail. Expectedly, for most of the 
genes, there was a direct correlation between the firefly and renilla activities. 
However, this trend deviated from linearity and saturated at higher cell numbers.  
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Figure 3-2: Distribution of genes in genome wide screen. Average Z scores of renilla and 
firefly luciferase activity obtained from two replicates of the genome wide screen were 




To affirm that the saturation is linked to high cell density, H1299-RL cells plated at 
cellular densities ranging from 1000 to 16000 cells were infected with IBV-Luc for 
16 hours. Adopting a trend similar to that of the screen, firefly luciferase expression 
increased with cell density (indicated by renilla expression) until attaining saturation 
at higher cell numbers (Figure 3-3). This apparent ‘saturation’ observed with virus 
replication at high cell numbers could be consequential of inhibitory signals 
contributed by overly confluent cells [230] or due to limited viral replication capacity 
inherent with the amount of infecting particles inoculated.  
 
 










                   
Figure 3-3: Virus replication efficiency varies non-linearly with cell numbers. Cells 
were seeded at various cellular densities, 14 hours prior to infection with IBV. The cellular 
density of 1000, 2000, 4000, 8000 and 16000 are represented by red, green, light green, grey 
and dark grey respectively. Average Z scores of firefly and renilla activity from a total of 50 
wells were calculated for each density. 
 
Attempts to fit the graph into various existing mathematical models found the 
Michalis Mention equation to best describe this distribution of signals (Fig 1C). 
Hence, data from the genome wide screen was similarly fitted into the Michalis 
Menton equation. By following the distribution of control wells, and setting the 
threshold at 2.5 standard deviations away from non-targeting controls, we identified 
263 genes that decreased IBV firefly luciferase activity when silenced, thus revealing 
the requirements of these genes in virus replication. On the other end, the 
enhancement of virus replication by depletion of 130 genes suggests that these genes 




                                   
 
Figure 3-4: Novel hit selection method reveals cellular cofactors for coronavirus 
replication. Genes positioned 2.5 standard deviations (demarcated by black lines) away 
from the non-targeting controls (in blue) were considered as hits. Genes that suppressed IBV 
replication when depleted were highlighted in red while those that enhanced, in purple. 
 
 
3.2.2 86 cellular cofactors of Coronavirus replication validated by at least two 
independent siRNAs 
Of the 263 genes identified to be supporting coronavirus infection, genes that do not 
encode for mRNA (pseudogenes, RNA genes, or withdrawn mRNA records) were 
excluded from further analysis. The remaining 224 genes were subjected to a 
subsequent round of validation screen where each of the four siRNAs from the 
combined pool used in the primary screen was individually tested for effects on 
coronavirus replication. 86 (38.8%) of these genes had at least two out of four 











controls (± 2 s.d), hence increasing the confidence that they are unlikely to be false 
positives owing to off target effects (Table 3-1).  
 
Table 3.1: List of Cellular cofactors that were validated by at least two independent 
siRNA 
Gene Name GeneSymbol GeneID No. of  
siRNA* 
ATP-binding cassette, subfamily E, member 1 ABCE1 6059 3 
ADP-ribosylation factor 5 ARF5 381 2 
ATPase, Ca++ transporting cardiac muscle slow 
twitch 2 
ATP2A2 488 4 
BEN domain containing 3 BEND3 57673 2 
Brain expressed X-linked 2 BEX2 84707 2 
Biogenesis of ribosome 1  BRIX1 55299 4 
Chromosome 2 open reading frame 27 C2orf27 285636 2 
Chromosome 5 open reading frame 51 C5orf51 285636 3 
Complement component 6 C6 729 3 
Cysteine conjugate-beta lyase 2 CCBL2 56267 3 
Chemokine (C-C motif) ligand 27 CCL27 10850 3 
Cell division cycle like (S.pombe) CDC5L 988 2 
Cell division cycle associated 5 CDCA5 113130 2 
Chromatin modifying protein 4B CHMP4B 128866 2 
Creatine kinase, muscle CKM 1158 2 
Claudin 5 CLDN5 7122 2 
Coatomer protein complex, subunit zeta 2 COPZ2 51226 2 
Crystalline, zeta (Quinone reductase) CRYZ 1429 2 
Cullin-3 CUL3 8452 2 
CWC15 Spliceosome-associated protein homolog CWC15 51503 2 
DNA damage inducible 1 homolog 1 
(S.cerevisiae) DDI1 414301 3 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 DDX24 57062 3 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X- DDX3X 1654 2 
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linked 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 DDX51 317781 3 
DEAH (Asp-Glu-Ala-His) box polypeptide 8 DHX8 1659 3 
DnaJ (Hsp40) homolog, subfamily B, member 8 DNAJB8 165721 2 
Eukaryotic translation initiation factor 3, subunit 
E EIF3E 3646 4 
Ellis van Creveld syndrome 2 EVC2 132884 2 
Family with sequence similarity 131, member A FAM131A 131408 3 
Family with sequence similarity 58, member B FAM58B 339521 2 
Fibulin 2 FBLN2 2199 2 
Golgi brefeldin A resistant guanine nucleotide 
exchange factor 1 GBF1 8729 4 
Gap junction protein, delta 3 GJC2 57165 2 
Hypoxia inducible domain family, member 2A HIGD2A 192286 2 
Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3 3189 2 
Heterogeneous nuclear ribonucleoprotein L HNRNPL 3191 3 
Potassium voltage-gated channel, subfamily G, 
member 1 KCNG1 3755 3 
Uncharacterised LOC255411 LOC255411 255411 2 
Malate dehydrogenase 1 MDH1 4190 4 
Neural precursor cell expressed, developmentally 
down regulated 8 NEDD8 4738 3 
Nucleolar protein 8 NOL11 25926 2 
Nuclear receptor subfamily 0, group B, member 
2 NR0B2 8431 2 
Neuregulin 2 NRG2 9542 2 
Organic solute carrier partner 1 OSCP1 
C12orf102 127700 3 
Programmed cell death 11 PDCD11 22984 2 
Pescadillio homolog 1 PES1 23481 3 
Phosphatidylserine decarboxylase PISD 23761 2 
Polymerase (RNA) 1 polypeptide A POLR1A 25885 3 
Polymerase (RNA) 1 polypeptide B POLR1B 84172 3 
POU class 3 homeobox 2 POU3F2 5454 2 
Peter pan homolog (drosophila) PPAN 56342 3 
Pre-mRNA processing factor 18 homolog 
(S.cerevisiae) PRPF18 8559 2 
Pre-mRNA processing factor 6 homolog PRPF6 24148 3 
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(S.cerevisiae) 
Proteasome 26S subunit 14 PSMD14 10213 2 
Ring-box 1, E3 ubiquitin protein ligase RBX1 9978 4 
Rhomboid domain containing 3 RHBDD3 25807 2 
Ribosomal L1 domain containing 1 RSL1D1 26156 2 
ribosomal L24 domain containing 1 RSL24D1 51187 2 
Squamous cell carcinoma antigen recognized by 
T cells SART1 9092 3 
Stearoyl-CoA desaturase SCD 6319 4 
Serpin peptidase inhibitor, clade F, member 2 SERPINF2 5345 2 
SET domain containing 8 SETD8 387893 3 
Snail homolog 3 (Drosophila) SNAI3 333929 4 
Small nuclear ribonucleoprotein D1 SNRPD1 6632 4 
Transducin (beta)-like 2 TBL2 26608 3 
Transmembrane channel-like 8 TMC8 147138 2 
Transmembrane and coiled-coil domains 5A TMCO5A 145942 2 
Transmembrane protein 18 TMEM18 129787 2 
Transmembrane protein 41B TMEM41B 440026 3 
Tetratricopeptide repeat protein 33 TTC33 23548 2 
Tetratricopeptide repeat domain 9C TTC9C 283237 2 
U2 small nuclear RNA auxillary factor 1 U2AF1 7307 2 
U2 small nuclear RNA auxillary factor 2 U2AF2 11338 3 
Ubiquitin-cojugating enzyme E2M UBE2M 9040 3 
Ubiquitin fusion degradation 1 like (yeast) UFD1L 7353 4 
Ubiquitin specific peptidase 9, X-linked USP9X 8239 2 
Valosin containing protein VCP 7415 4 
Vanin 1 VNN1 8876 2 
WD repeat domain 26 WDR26 80232 3 
WD repeat domain 75 WDR75 84128 3 
Zinc finger protein 256 ZNF256 10172 2 
Zinc finger protein 706 ZNF706 51123 4 
Zinc finger and SCAN domain containing 2 ZSCAN2 54993 3 
* Out of a total of four individual RNAs tested. Genes are considered on-target hits when 2 and above 




3.2.3 Bioinformatics analysis of screen hits 
76.2%, 70% and 66.2% of the 86 genes identified from the screen can be classified 
using Gene Ontology (GO) cellular components, biological processes and molecular 
processes respectively. A cellular map illustrating their predominant subcellular 
locations and functions of these hits is presented in (Figure 3-5). Among the enriched 
biological processes, we found genes involving in transcription regulation, signal 
transduction, protein neddylation and RNA splicing. Analysis for functionally 
enriched cellular components revealed a significant number of genes localized to 
membranous compartments in the cell, including those residing on the plasma 
membrane, endosomes, endoplasmic reticulum and Golgi apparatus. Coronavirus 
infection typically involves extensive interactions and modifications of the host 
membranous structures for processes such as viral entry, fusion, replication or 
secretion. It would hence be interesting to investigate how each of these membrane 
proteins is co-opted by the virus for each of these processes.  
 
Apart from the membranes, our screen also found an enrichment of genes (n=38) 
localized to the nucleus. This is in spite of coronavirus replication and transcription 
occurring almost exclusively in the cytoplasm. Biological functions associated with 
these genes include transcriptional regulation, ribosome biogenesis and RNA 
splicing. Among genes possessing RNA splicing activity, CDC5L, CWC15, DHX8, 
PLRG1, PRPF18, PRPF6, SART1, SNRPD1, U2AF1, U2AF2 are integral 






















Gene Ontology analysis of validated screen hits. Statistically significant (p<0.05) 
enrichment of (A) cellular components, (B) molecular functions, (C) biological processes are 
presented in the graphs above. 
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Figure 3.6: Cellular Map of screen hits. Genes interacting in a complex is encircled in red. 
 
 
3.2.4 Comparison of screen with SARS interactome  
Much of the known host-virus interactions are derived from interaction studies 
involving specific viral RNA sequences or proteins as ‘baits’. For a long time, these 
isolated studies identified only a handful of host factors and the list of cellular 
proteins associated with coronavirus replication remained ill defined. A breakthrough 
was achieved recently when Pfefferle and colleagues’ high throughput genome wide 
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yeast-two hybrid screen [154] identified more than 100 proteins to be interacting 
with all the SARS-CoV ORFs. Mapping all these known coronavirus-host 
interactions to our screen, we found none to drastically impair IBV replication during 
our screen (Figure 3-7A). Apart from virus specificity, a few factors likely explain 
these results. First, the functional redundancy of some of these proteins could render 
the silencing of just one gene inefficient to affect virus replication. For example, 
although Pfefferle and colleagues found SARS-CoV interacting with several 
cyclophillins/immunopilins and the collective inhibition via cyclosporine A can 
strongly impair replication in the panel of coronaviruses tested; these family of 
proteins are known to be functionally redundant and will not be captured in our 
screen. Secondly, not all the interactions serve to enhance virus replication. Lastly, 
interactions identified with accessory proteins or specific RNA sequences unique to 
the particular coronavirus tested may not affect IBV. Nonetheless, we found 
extensive interactions between our screen hits and some of known host-virus 
interacting partners, some of which containing hits interacting within the same 
complex (Figure 3-7B). For instance, our screen identified EIF3E as a positive 
regulator of IBV infection. Two other members of the EIF3 family had been 
previously identified to be involved in SARS-CoV replication. While the function of 
EIF3D in SARS-CoV replication is yet fully characterized, physical interaction 
between the spike protein and EIF3F was found to be important for modulating host 
translation of inhibitory cytokines and chemokines.  




Figure 3-7: Comparison between IBV genome wide siRNA screen and SARS yeast-2 
hybrid screen. Protein-protein interaction networks were obtained using STRING database 
and modified using the Cytoscape software. Only interactions confirmed by experimental 
data were included. Red circles represent “hits” from IBV siRNA screen and yellow circles 
represent “hits” from the SARS-CoV Y2H screen. Blue squares indicated SARS-CoV 
structural or replicase ORFs while diamonds symbolize accessory ORFs. Purple and pink 





3.3.5 Screen recovered genes associated with cellular processes/molecular 
functions that are known to modulate coronavirus infection. 
Although there is limited overlap between our hits and known coronavirus 
interacting host factors, the screen did identify ‘closely related’ genes that either 
belong to the same protein family or functioning in common cellular pathways 
(Figure 3-8). Some of these are reviewed in Figure 3-8. 
 
Figure 3-8: Genome-wide screen reveals proteins or proteins involved in pathways 
previously implicated in coronavirus infection.  
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HnRNP family of proteins 
Interactions between cellular proteins and regulatory RNA sequences in the virus 
genome are essential in governing coronavirus replication and transcription 
[231,232]. Many of these cellular proteins were found to belong to the heterogenous 
nuclear ribonucleoprotein (hnRNP) family of RNA binding protein and the 
interaction between hnRNPA1 and the MHV genome is well studied. HnRNP A1, a 
regulator of alternative mRNA splicing [233], belongs to the heterogenous nuclear 
ribonucleoprotein (hnRNP) family of RNA binding proteins that predominantly 
reside in the nucleus. During coronavirus infection, hnRNP A1 translocates to the 
cytosol [97] where the binding to either viral regulatory RNA (TRS) [99,100,103] 
and/or protein [104,105] leads to the formation of ribonucleoprotein complexes that 
help regulate viral RNA synthesis. Although hnRNP A1 was not one of the genes 
identified, it scored very close to the threshold. And despite its definitive role in 
MHV infection, subsequent studies found that hnRNP A1 function in MHV RNA 
synthesis can be substituted with closely related hnRNPs [106]. Our screen identified 
2 other members of the hnRNP family – hnRNP L and hnRNPN3 to participate in 
coronavirus infection. Like hnRNP A1, hnRNP L regulates mRNA splicing [234] 
and in addition was found to promote IRES-mediated translation in hepatitis C virus 
[235,236]. Little is known regarding the function of the other members of the hnRNP 




2',5'-oligoadenylate synthetase (OAS)-RNase L pathway  
A successful viral infection cannot be achieved without surmounting the host innate 
immune response and the crux of host’s antiviral defense relied on the induction of 
type I interferons. Activation of the 2', 5'-oligoadenylate synthetase (OAS)-RNase L 
pathway downstream of interferon induction averts viral infection by promoting 
degradation of viral RNA. Coronaviruses are known to devise various strategies to 
dampen RNAse L activation [237,238]. The identification of RNAase L inhibitor, 
ABCE1, as an independent determinant for efficient IBV infection firmly augments 
the protective role of OAS/RNaseL pathway against across different types of 
coronaviruses.  
 
Cell cycle regulation and DNA Damage Response 
Our screen identified Cdc5L as a novel co-factor for IBV replication. While 
commonly known for its pre-RNA splicing activity, Cdc5L role in IBV replication 
may rest upon its newly ascribed role in DNA damage response. Exploitation of the 
host’s DNA damage response has been described as a mean by which coronaviruses 
exploit to attain cell cycle arrest at S and G2/M phase. Stalling the cell in this phase 
promotes viral RNA and protein synthesis. IBV infection activates DNA damage 
response in infected cells by signaling specifically through ataxia-telangiectasia and 
Rad3-related (ATR), a cell cycle checkpoint protein kinase. In the absence of 
functional ATR, IBV replication efficiency is severely compromised [160]. Cdc5L 
directly interacts with ATR and is required for the activation of effectors downstream 
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of ATR. A defective S-phase cell-cycle checkpoint due to depletion of Cdc5L [239] 
may hence deprive the virus of a favorable environment for replication.  
 
Early secretory pathway 
Although not known to interact with any of viral encoded proteins, the definitive role 
of Golgi-associated brefeldin A (BFA)-resistant GEF 1 (GBF1) in coronavirus 
infection has been established for MHV [240] and SARS-CoV. GBF1 was one of the 
strongest hits in our screen (Figure 3-9A). The introduction of pharmalogical 
inhibitors such as brefeldin A (BFA) [241] and golgicide A (GCA) [242] at different 
time points post infection confirmed that, similar to MHV and SARS-CoV infection, 
GBF1 supports post entry/internalization steps during early IBV replication (Figure 
3-9). Briefly, BFA and GCA were added to IBV infected cells at 1, 2, 4, and 6 hours 
post IBV-Luc infection. Cells were then lysed and analysed for their luciferase 
activity at 8 hours post infection. The results demonstrated that the decrease in viral 
replication most pronounced when GBF1 function is disrupted at early, post-
internalization steps of infection.  
 
One of the cellular roles of GBF1 is the regulation of coat protein complex I (COPI) 
vesicles biogenesis on Golgi membranes [243,244]. COPZ2, a component of the 
COPI vesicles was also identified as an IBV cofactor in our screen (Figure 3-9).  
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Figure 3-9: RNAi screen identified components of the early secretory pathway as 
cofactors for IBV replication. The primary hits were highlighted in pink while NT controls 
were highlighted in blue. Components of the early secretory pathway identified to be 
important for IBV replication were labeled in red. 
 
 
The regulation of COPI vesicle formation by GBF1 is mediated via ADP-
ribosylation factor 1 (Arf1). Despite not being a direct ‘hit” in our screen, Arf1 
scored close to the threshold. A follow up experiment involving RNAi mediated 
knock down of Arf1 confirmed its role in IBV infection (Figure 3-10A). A member 
of the Arf family that did score in our screen was Arf5. Like Arf1, Arf5 promotes 
COPI coated vesicles formation [245]. Arf5 was also recently identified to be 
required for promoting efficient secretion of dengue virus [246]. The role of Arf5 in 










Figure 3-10: GBF1 and ARF1 are involved in IBV replication. A) Cells transfected with 
25nM siArf1 and siGBF1 had reduced levels of firefly luciferase activity at the end of a 10 
hours infection, compared to control. The error bars represent the standard deviation from 
two independent experiments performed in triplicates and calculated in relative to those 
obtained from non-targeting controls. (B) BFA treatment (C) GBF1 suppressed IBV 
replication at early stages. 5µg/ml BFA or 10µM of golgicide A was added to medium of 
infected cells at the indicated time points and firefly activity was measured after 10 hours of 
infection. Error bars represent the standard deviation from two independent experiments 

















































































Apart from Coronaviruses, GBF1/Arf1 had also been shown to be important for other 
plus strand RNA viruses such as enterovirus [240,247,248,249], and hepatitis C virus 
(HCV) [250]. We tested the effect of GBF and Arf1 knockdown on dengue virus 
infection. Dengue virus is a positive RNA virus belonging to the Flavivirus family 
with four known serotypes. In two of the serotypes tested (1 and 2), the depletion of 
GBF1 and Arf1 similarly suppressed dengue infection (Figure 3-11). Altogether, our 
results strengthened the current view that the requirement for functional GBF1/Arf is 
shared among positive stranded RNA viruses.  
 
 
                              
 
Figure 3-11: Depletion of GBF1 and Arf1 suppress replication of type 1 and type 2 
dengue viruses. Cells transfected with GBF1 and Arf1 siRNA were infected with type 1 or 
type 2 dengue virus (MOI=1). Infected cells were harvested after 72 hours of dengue 
infection and probed for NS3B. The monoclonal antibodies used target a common epitope in 






NT GBF1 NT Arf1 
DV1 




3.2.6 Ubiquitin-Proteasome pathway and ER and Associated Degradation in 
Coronavirus replication 
From our screen, we also identified genes involved in the ubiquitin-proteasome 
(UPS) pathway, and several of them were found to associate within a common 
complex (Figure 3-12). For instance, cullin 3 complexes with ring box1 (Rbx1) to 
form the core of BTB-CUL3-RBX1 E3 ligase complex, through association with 
different BTB containing adaptor proteins, catalyses the ubiquitination of various 
protein substrates [251]. Activation of this complex requires covalent attachment of 
neural-precursor-cell-expressed and developmentally down regulated 8, (nedd8) by 
ube2m, ubiquitin conjugating enzyme [252,253]. Both nedd8 and ube2 were 
identified from our screen. Elucidation of possible ubiquitinated viral substrates 
might yield further insights on how this complex is important for the virus. The 
recovery of S26 proteasome subunit PSMD14 corroborates with previous findings on 
the inhibitory effect of proteasome inhibitors on coronavirus replication [162]. In 
addition, physical interaction between SARS Coronavirus N protein and another 
component of the S26 proteasome subunit had also been reported [136].  
 
 
The ERAD (ER Associated Degradation) process is intrinsically linked to the UPS. 
ERAD process can be broadly classified into two stages: (1) the selective recognition 
of misfolded or defective proteins in the ER via a quality surveillance system and (2) 
the export of these unwanted proteins to the cytosol for degradation via the UPS. The 
ternary complex of Vcp-Ufd1L-Npl4 is one of the key mediators of these two 
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processes. By recognizing and extracting polyubiquitinated substrates, the complex 
functions in the dislocation of ERAD substrates from the ER membrane to the 
cytosol in an ATP-dependent fashion [254,255]. All three components were 
identified as primary hits from our screen (Figure 3-12). However, only VCP 
(valosin containing protein also known as p97 or Cdc48p in yeast) and Ufd1L 
(Ubiquitin fusion degradation protein 1 like protein) were validated in the 
deconvoluted screen. Apart from function in the ERAD pathway, VCP is associated 
with multiple cellular processes [256]. VCP was also previously identified in our 
pilot screen that involves a subset of membrane trafficking library. In view of the 
consistency that VCP is identified in our screens, coupled with the fact that two of its 
interacting partners are also identified in parallel, we further characterized the role of 







Figure 3-12: Genes involved in UPS and ERAD regulation identified from the RNAi 
screen. (A) Relative Z scores of UPS and ERAD related genes in the screen.  (B) Several of 
the genes were found to associate within a complex (encircled in red). Primary hits that were 
validated by deconvoluted screen were highlighted in pink while primary hits that did not 





3.3 RESULTS (II): CHARACTERIZATION OF THE ROLE OF VCP IN IBV 
REPLICATION 
3.3.1 VCP is involved in the early stages of virus replication 
To determine if VCP knock down affects virus replication at an earlier time point, 
IBV infected cells were harvested for firefly luciferase activity at 10 h.p.i when the 
secretion of virus and secondary infection is minimal. The inhibitory effect of siVCP 
treatment on virus replication was evident as silencing of VCP reduced firefly 
luciferase activity close to 10 fold of those treated with non-targeting siRNA control 
at 10 h.p.i (Figure 3-13A). The results demonstrated that VCP is required for steps in 
early virus infection that precedes virus release and reinfection. 
 
The production of double stranded RNA (dsRNA) intermediates is a hallmark of 
viral replication and transcription. The effect of VCP on viral transcription was 
confirmed by immunofluorescence using monoclonal antibodies specific for dsRNA.  
8 hours post infection, silencing of VCP also led to a decrease in dsRNA 
immunofluorescence staining (Figure 3-13B). The decrease in dsRNA production 
corresponded to a decrease in viral protein (N protein) expression detected by 
western blot analysis (Figure 3-13C). The data so far pointed to VCP having a role in 
very early stage of IBV replication that possibly occurs at or before viral 









Figure 3-13: Depletion of VCP affects virus replication at early stages. (A) Cells infected 
with IBV-Luc were harvested at either 10 or 16 h.p.i. Compared to cells transfected with 
non-targeting siRNA, luciferase activity (indicative of virus replication) was greatly reduced 
in cells where VCP is silenced. A reduction in luciferase activity was evident as early as 
10.h.p.i. (B) Depletion of VCP by RNAi also resulted in decreased levels of dsRNA. This 
was revealed by immunofluorescence staining of dsRNA (red) and Hoesct (blue) at the end 
of 8 hours of infection. (C) Reduction in VCP protein levels correspond to decrease in viral 
protein expression, as indicated by the decrease in IBV-N levels at 8 and 16 h.p.i. Tubulin 




















3.3.2. VCP is not required for viral attachment to cell surface and virus entry 
To determine if VCP is required for attachment to the cell surface, we next examined 
if virus attachment to cell surface is compromised by the absence of VCP. For the 
assay, cells treated with either control non-targeting siRNA or siVCP were incubated 
with IBV-Luc at approximately MOI 0.5 for 1 hour at 40C to allow for virus 
adsorption. Unbounded virus particles were removed by washing and bound viruses 
were quantitated with standard plaque assay.  The number of plaques obtained from 
siVCP samples was comparable to control cells treated with siNT, suggesting that 
knocking down VCP does not significantly alter the ability of virus to bind to host 
cell Figure 3-14A). Similar conclusions can be drawn with the quantification of 
bound virus using RT-PCR as silencing of VCP did not result in decreased amount of 
viral positive genomic RNA detected on the surface of the infected cells (Figure 3-
14B). Hence, VCP is not needed for virus attachment to the cell surface. 
 
Next, we determine whether VCP is a pre-requisite for virus internalisation. Similar 
to viral attachment assay, cells were first incubated with IBV-Luc at approximately 
MOI 0.5 for 1 hour at 40C. At one hour post incubation, excess virus were removed 
and cells were shifted to 370C for another hour to allow synchronized entry. After 
treatment with proteinase K to remove un-internalized virus, infected cells were 
harvested by freeze-thawing and the amount of internalized virus particles were 
quantified by either titration plaque assay or RT-PCR. Again, no significant 
reduction of internalized viral particles was detected in VCP knocked down cells, 
suggesting that VCP was also not required for virus entry (Figure 3-14C and 3-14D). 
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Figure 3-14: VCP is not required for virus attachment and entry (A) A) H1299 cells 
were incubated with IBV at 40C for 1 hour to allow for virion attachment but not entry. 
Unbound virions were washed off with using PBS and cells were either harvested by 3 
freeze-thaw cycles to quantitate number of attached particles by (B) standard plaque assay or 
had their total RNA extracted for (C) RT-PCR of genomic RNA (+gRNA). There were no 
observable differences between cells treated with siNT or siVCP in both assays. For the 
entry assay, cells were first incubated with IBV at 40C for 1 hour to allow for virion 
attachment before being shifted to 370C for synchronized entry. Infected cells were treated 
with proteinase K (30 minutes, 40C) to remove bound but un-internalized virus. Finally, 








3.3.3 Silencing of VCP inhibits disassembly of virus particles 
During one of our time course experiments, we noticed that despite a marked 
decrease in N protein expression at 8 h p.i., silencing of VCP consistently resulted in 
a higher level of N protein detected at 4 h p.i. (Figure 3-15A). To determine if this 
phenotype could be recapitulated with other genes known to affect early coronavirus 
replication, we compared this to those treated with siGBF1 and siArf1 and found that 
the elevated N protein level observed at 4 h p.i. is unique to cells treated with siVCP 
(Figure 3-15B). In contrast, this phenotype of increased N protein detection was 
replicated in cells treated with proteasome inhibitor, MG132, albeit to a lesser extent 
(Figure 3-15C). Inhibition of ubiquitin-proteasomal system by MG132 treatment 
results in the aberrant accumulation of virus particles in the endosomal and 
lysosomal compartments [161]. We hypothesized that the higher N protein levels we 
observed at 4 h p.i. in cells with VCP knocked down could be due to a similar 
mechanism. 
 
To first verify that the higher levels of N protein detected at 4 h p.i. originated from 
the infecting virus and not a consequence of anomalous synthesis, cells were pre-
treated with transcription inhibitor, cycloheximide prior to IBV infection. In 
agreement with the previous data, in the absence of transcriptional inhibition, 
infection of cells treated with siVCP resulted in decrease N protein expression at 8 
h.p.i. (Figure 3-13D). Inhibition of neo-synthesis by cycloheximide, however, 
resulted in more N protein detected. These results demonstrated that more N protein 
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from the infecting virus could be ‘retained’ in the absence of VCP. Coronavirus 
nucleocapsid protein was observed to rapidly degrade and unfolds at low pH. Its 
inherent instability could be linked to the lack of intramolecular and hydrophobic 
bonds and a disordered region in its C terminus [257,258,259]. While the 




Figure 3-15: Depletion of VCP resulted in N protein accumulation at early time points. 
(A) Cells transfected with the respective siRNAs (non-targeting (NT) and VCP) were 
infected with IBV for either 4 or 8 hours before probed for IBV-N expression using western 
blot analysis. A mock infected sample was included as negative control. The membrane was 
also probed for VCP to ensure a good knock down efficiency, and tubulin for loading 
control. The experiment was repeated to compare the siVCP phenotype with that of (B) 
siGBF1 and (C) MG132 (MG) treatment. For MG132 treated cells, 10µM of MG132 was 
added to cells 2 hours prior- to and also throughout the entire infection. (D) Cycloheximide 
(CHX) was added to cells at 100µg/ml to inhibit protein translation. Cells were then 
harvested at 8 h.p.i to compare the levels of IBV N in VCP knockdown cells that were either 
treated or not treated with CHX. For these experiments, either actin or β-tubulin served as 
loading controls. 
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3.3.4 Silencing of VCP results in accumulation of virus in the early endosomal 
fractions 
Drawing on the similarities between VCP knockdown and MG132 treatment, we 
hypothesized that the accumulation of N protein is also a result of aberrant 
accumulation of virus in the endocytic compartments post virus internalization. To 
investigate the localization of virus particles in the absence of VCP, subcellular 
fractionation by sucrose floatation step/discontinous gradient was performed. Using a 
modified protocol first described by Gorvel et al. for endosomal fractionation, late 
and early endosomes were concentrated in the 8%/25% (Fraction 2, 3) and 25%/35% 
(Fraction 5, 6) interphase respectively. Western blot analysis was then performed to 
detect for the presence of viral structural proteins.  
 
In the control-infected cells, the viral structural proteins, N and S proteins, can be 
detected in fractions that corresponded to late endosomal compartments. This is 
consistent with previous reports that suggest that IBV fusion may occur in the late 
endosomal compartments. In contrast, knocking down VCP resulted in a shift in 
accumulation of both IBV-N and IBV-S in fractions 5 & 6 that were enriched with 
EEA1 (early endosome antigen 1 protein) (Figure 3-16B & C). The results so far 
strongly suggest that in the absence of VCP, coronavirus replication is inhibited due 




Figure 3-16: Depletion of VCP resulted in accumulation of viral particles in early endosome 
vesicles. Infected cells treated with siVCP or control siNT were subjected to subcellular fractionation 
using step sucrose gradient floatation for the crude isolation of endosomal vesicles. (A) Western blot 
analysis of whole cell lysate derived from post nuclear clearance (PNC) showed good efficiency in 
VCP knockdown. (B) Western Blot analysis of sucrose fractions using anti-sera against IBV-N and 
IBV-S showed that the depletion ofVCP resulted in accumulation of virus structural proteins in 
fractions that co-fractionate with early endosome markers (C) representative gel showing the different 







3.3.5 N protein degradation as an assay to detect genes involved in early 
replication 
While performing western blot analysis based time course assays to validate our 
screen results, we consistently observed the ‘accumulation’ IBV N protein at early 
time points with when VCP is depleted. The subcellular fractionation experiment 
confirmed that the accumulation of N protein is due to the sequestration of viral 
particles as a consequence of aberrant endosomal trafficking. Sequestration of viral 
particles in the endocytic compartment protects IBV N from degradation that occur 
post viral fusion. The study of host factors involved in early stages of virus infection 
had been encumbered by the lack of simple assays that specifically targets the early 
events such as endocytic trafficking and viral-host fusion. To test the feasibility of 
using IBV N as a detection marker for disruption to these events during virus 
infection, we treated infected cells with bafilomycin A1 which inhibits endosome 
maturation by targeting vacuolar ATPases. MG132 was used as a positive control as 
it is known to trap virus in the endosomal compartments. Brefeldin A (BFA) and 
golgicide A1 (GCA) on the other hand were employed as negative controls as 
although they too inhibit early stages of virus infection, they are likely to target 
events post fusion. Similar to results obtained with MG132 treatment, inhibiting of 
viral endosomal trafficking with bafilomycin A1 resulted in higher levels of IBV N 
protein detected (Figure 3-17). Levels of IBV N remained comparable to that of 
control in BFA and GCA treated cells. The results showed that IBV N detection 
could be used as a rapid assay to study cellular factors involved in similar pathways. 
 
 116 
                          
 
Figure 3-17: Lack of IBV N degradation is a marker for disruption to early replication 
events of coronavirus infection. Cells in 24 well were pretreated with either DMSO, 
MG132 (10µM), brefeldin A (10µg/ml), golgicide A (10µg/ml) or bafilomycin A1 (1µM) 2 
hours prior to infection with IBV (MOI=0.5). After incubation at 370C for 4 hours, infected 
cells were washed 3 times with PBS, lysed in SDS loading buffer and separated by 
electrophoresis.  Gel was probed for viral structural proteins, N, and M with the appropriate 





Through a genome wide RNAi screen against IBV, we identified 86 cellular 
cofactors supporting coronavirus replication. Apart from recovering genes previously 
implicated in coronavirus replication, most of the novel genes identified helps in 
expanding our current limited knowledge about the molecular interactions between 
coronavirus and host cells. Furthermore, the fact that many of these genes function 
cooperatively in common cellular pathways and complexes provide compelling 
evidence for their importance in coronavirus replication.   
 
Genome wide RNAi screening had been used to delineate cellular factors that have 
roles in other positive RNA viruses such as Hepatitis C, West Nile and Dengue 
viruses. A comparison of our screen with the findings of these previously described 
screens yield little overlaps. This is perhaps not surprising, as multiple experimental 
and statistical parameters are known to contribute to this lack of overlap. How some 
of these factors such as statistical cut-off, virus strains, and experimental readouts 
may contribute to the lack of overlapping genes involving has been extensively 
reviewed. Given that even genes identified from screens involving the even same 
virus can differ, the lack of extensive overlaps between coronavirus and the other 
virus screens mentioned above is then perhaps hardly unexpected. Nonetheless, the 




The role of UPS in coronavirus replication has long been described. Previous studies 
investigating UPS role in coronavirus replication revolved around the use of 
proteasome inhibitors. However, the mechanistic link between UPS and coronavirus 
and the involvement of any specific gene(s) remained elusive. In our study, knock-
down of valosin containing protein (VCP) sufficiently suppress IBV replication at 
early stages. Depletion of VCP led to the sequestration of viral particles at the early 
endosomal compartment thus impeding the delivery of viral genome to the cytosol 
for translation. These findings are congruent with emerging evidence of VCP role in 
endocytic trafficking. Ramanathan and Ye [260] identified endosomal sorting factor 
EEA1 (early endosome antigen 1) as a novel substrate of VCP and inhibition of VCP 
led to aberrant intracellular trafficking of endocytic cargo as a result of abnormal 
aggregation of enlarged EEA1 positive endosomes. Our study demonstrated for the 
first time that the endosomal maturation process mediated by VCP is utilized by 
coronavirus. This process is unlikely to result from aberrant trafficking and/or 
localization of IBV receptors as viral attachment and initial internalization was not 
altered in the absence of VCP.  
 
The functional specificity of VCP requires conscription of additional host factors. 
The two VCP binding partners, Ufd1 and Npl4, identified from our screen complex 
with VCP at the ER where they aid in the retrotranslocation of ERAD substrates 
from ER membranes to cytosol for proteasomal degradation. The involvement of this 
complex in the regulation of endocytic processes was dismissed as unlike for the case 
of VCP, RNAi mediated depletion targeting Np14 did not cause similar perturbations 
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to endosome morphology. The effect of silencing Ufd1l on the other hand was not 
assessed; hence it would be interesting to determine if Ufd1 functions independently 
of Npl4 in this process. In support of this notion, we found that silencing of Ufd1, but 
not Npl4, accumulated N protein during early virus infection (Figure 3-15). Ufdl is 
also common hit in Krishnan et al’s screen for cofactors in West Nile and dengue 
virus [228]. Finally, Ufd1 and Npl4 may affect virus replication through alternative 
distinct mechanisms as other RNAi studies had revealed that Ufd1L and Npl4 can 
perform cellular functions independent of their association with VCP [261,262,263].  
 
While our studies confirmed VCP role in facilitating endosome trafficking of 
coronavirus particles, the possibility of VCP supporting coronavirus infection in 
multiple ways cannot be disregarded since various cellular processes regulated VCP 
such as ER/Golgi membrane fusion, autophagy and cell cycle regulation can also 
affect virus replication [256] (Figure). Notably, in an RNAi screen for membrane 
trafficking genes required for poliovirus replication, Arita and colleagues (2012) 
identified VCP to be required for poliovirus replication by supporting cellular 
secretion in poliovirus infected cells [264]. Thus, the requirement for VCP in the 
replication of this non-enveloped virus is distinct from that of coronavirus. 
 
One appealing speculation that could be made was that the detrimental effects on 
IBV replication associated with knocking down other UPS related genes identified 
could stem from their roles in endosomal trafficking. Several studies already 
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provided hints of ubiquitin-proteasome system involvement in membrane trafficking, 
though the identity of specific genes had emerged only recently. Shortly after VCP’s 
role in early endosomes was revealed, cullin-3 (Cul3) was also found to regulate late 
endosome maturation. Accumulation of morphologically abnormal acidic late 
endomsome/lysosomes (LE/LY) in Cul3 depleted cells caused trafficking defect of 
endolysosomal cargoes such as influenza A virus (IAV). In the absence of cullin-3, 
IAV particles were sequestered in late endosome/lysosomes and exhibit defective 
uncoating.  [265]. The fact that IBV and IAV shared a common dependence on 
cullin-3 also highlights the possibility of a common trafficking route. This is 
augmented by data showing that similar to IAV, coronavirus membrane fusion occur 
optimally at low pH of ~5 [266]. While it is apparent that endosomal acidification is 
critical for coronavirus fusion [266,267,268], an outstanding question on how virus 
particles escape from the fate of lysocytic degradation in these low pH compartments 
remains. It would be interesting to determine if any of the viral proteins are targeted 
by cullin-3, or whether its host substrates interacts with the invading viral particles  
 
In summary, our screen established conclusively, the dependence of coronavirus on 
the host ubiquitin proteasome machinery. Elucidation of specific players in this 
system allowed us to link this dependence to the requirement of an ubiquitin based 
vacuolar sorting system for viral membrane fusion. Further characterisation of these 
(and other) cellular factors and how they interact with the viral particles will thus 
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CHAPTER FOUR: HOST-VIRUS INTERACTION (II): 
CHARACTERISATION OF HOST ANTIVIRAL MECHANISMS AGAINST 
CORONAVIRUS INFECTION AND CORONAVIRAL STRATEGIES OF 
IMMUNE EVASION 
 
Apart from the conscription of cellular proteins for the purpose of viral replication, 
the interplay between the host innate immune response and coronavirus is another 
important aspect of host-virus interaction. This level of interaction between 
coronavirus and its host were explored via two approaches in this chapter: First, 
using prototypic infectious bronchitis virus (IBV) as our model, the host innate 
response elicited during coronavirus, particularly in the form of IFN signaling, was 
examined and analyzed to help shed light on the possible mechanisms of coronaviral 
strategies of immune evasion. The second part of the chapter focused on the 
identification of novel coronavirus-encoded interferon antagonist(s) through a co-




4.1 CHARACTERIZATION OF HOST ANTIVIRAL MECHANISMS 
AGAINST CORONAVIRUS INFECTION 
 
4.1.1 INTRODUCTION 
The activation of innate immune response is characterized by the production of type I 
interferons (IFN-α and IFN-β). IFN, once translated and secreted, in turn orchestrates 
the expression of hundreds of downstream IFN-stimulated genes (ISGs) 
[57,188,269,270], which collaboratively lead to the establishment of an anti-viral 
state to limit viral replication and spread.  
 
Central to the induction of type I IFN is interferon regulatory factor 3 (IRF3), a 
ubiquitously expressed transcription factor whose activation is governed by its state 
of phosphorylation [271,272]. The signaling cascade leading to IRF3 
phosphorylation is initiated by the recognition of specific viral pathogen associated 
molecular patterns (PAMPs) by host pattern recognition receptors (PPRs) in 2 major 
pathways. Cell surface toll-like receptors (TLRs), such as TLR3, TLR7, TLR8 and 
TLR9, sense viral components internalized in the endosomal compartments 
[195,196,197], while cytoplasmic viral double stranded RNAs (dsRNA) are detected 
by intracellular RNA helicases such as retinoic acid-inducible gene I (RIG-I) and/or 
melanoma differentiation-associated gene 5 (MDA-5) [200,273]. Upon binding to 
their ligands, these PPRs recruit their respective adaptor proteins to set off a series of 
signaling cascades that eventually converge to the formation of a kinase complex 
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comprising of TANK, TBK1 and non-canonical IκBkinase IKKε [204] to directly 
phosphorylate IRF3. Hyper-phosphorylation of its C terminus is a cue for IRF3 
homodimerization. Activated IRF3 homodimer then translocates to the nucleus [274] 
where it recruits CREB-binding protein (CBP/p300) [275] together with other 
transcription factors, such as nuclear factor κB (NF-κB) and ATF/C-Jun to form a 
transcriptionally active enhanceosome [276], hence switching on IFN synthesis.  
 
Given the importance of IFN in limiting viral spread, it is of no surprise that many 
viruses have evolved strategies to counteract the IFN action. These mechanisms 
include (1) evading immune detection, (2) inhibiting IFN induction by disrupting the 
signaling events in the IFN activation pathways, or (3) disrupting IFN downstream 
signal transduction [277,278,279] to block ISGs production and/or (4) antagonize the 
actions mediated by ISGs and other anti-viral molecules. In this section, the host 
innate immune response during IBV infection was characterized. 
 
Figure 4-1: Anti-innate response strategies adopted by viruses. 
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4.1.2: RESULTS  
4.1.2.1 IBV is sensitive to IFN activation 
In our first step towards the characterization of host innate response to IBV infection, 
we investigated whether IBV is sensitive to the presence of IFN-β. First, cells were 
pre-incubated overnight with DMSO or 100U/ml of IFN-β to allow for the IFN-
mediated induction of anti-viral molecules. Cells were then infected with IBV 
(MOI=0.1), and observed for cytopathic effects (CPE) (or syncytium formation) and 
expression of viral protein 16 hours post infection. The lack of syncytium formation 
and lower expression levels of viral protein (IBV-N) in IFN-β treated cells suggested 
that IBV replicate less efficiently in cells the presence of IFN-β. (Figure 4-2) 
 
 
Figure 4-2: IBV infection is sensitive to IFN activation. Cells pre-treated with IFN-β had 
(A) less pronounced synticia formation and expressed (B) lower levels of viral protein (IBV-
N) compared to mock treated controls. 
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4.1.2.2 IBV infection weakly induce IFN and IFN-stimulated genes  
The sensitivity of IBV towards IFN-β prompted us to investigate the status of 
interferon induction during IBV infection. For this purpose, RT-PCR analysis of 
IBV-infected cells was carried out to study the mRNA expression of IFN-β over a 
time course of 24 hours. Two human cell lines, H1299 (lung carcinoma) and Huh7 
(heptocarcinoma) that were previously established to be highly susceptible to IBV 
infection, were used in this study. In these cells, a modest up-regulation of IFN-β was 
only detected at the later time of IBV infection (Figure 4-3). The transcriptional 
activation of two important anti-viral ISGs – ISG56 and ISG15 was also examined. 
The low levels of IFN-β induction did not lead to significant noticeable up-regulation 
of ISG56 and ISG15, compared to mock-infected controls. These results implied a 




Figure 4-3: IBV infection failed to induce high levels of IFN and ISGs. Total RNA was 
isolated from IBV infected cells at the indicated time points. Mock infected samples were 
also  included as negative controls.  RT-PCR analysis was performed using specific primers 




4.1.2.3 IBV infection is associated with inefficient IRF3 activation. 
The activation of transcription factor, IRF3, is central to the induction of IFN in 
virus-infected cells. Hallmarks of IRF3 activation include 3 key events: (1) hyper-
phosphorylation at its C terminus by upstream kinases, (2) IRF3 dimerization and 
finally its translocation to the nucleus for the transcriptional activation of IFN-β. To 
investigate the status of these events during IBV infection, lysates from IBV infected 
cells were separated by both denaturing (SDS-PAGE) and non-denaturing (Native-
PAGE) gel electrophoresis. Hyper-phosphorylated forms of IRF3 would appear as 
lower migrating bands in SDS-PAGE. The presence of these slower migrating 
species was undetected in IBV infected H1299 and Huh7 cells. In contrast, the 
presence of these slower migrating bands that were indicative of the presence of 
hyper-phosphorylated IRF3, were readily detected in lysates obtained from dengue 
virus-infected Huh7 cells. The detection of IRF3 dimers (Figure 4-4) by Native-
PAGE further concluded the activation of IRF3 in dengue-infected cells. The 
presence of IRF3 dimers was however, not observed in either of the IBV infected 
cells. The status of IRF3 activation in H1299 cells in response to dengue infection 
was not investigated as H1299 cells cannot be infected by dengue virus (data not 
shown).  
 
The lack of IRF3 activation coupled with the inefficient induction of IFN and ISGs in 








activation that can otherwise occur readily in the presence of viral threats (in this 










Figure 4-4:  IBV infection did not lead to IRF3 activation. Lysates from IBV- or dengue-
infected cells were subjected to native PAGE or SDS-PAGE followed by immuno-blotting 
with anti-IRF3 to detect IRF3 dimers and hyper-phosphorylatied IRF3 respectively. 
Immuno-blot for IBV N protein and dengue E (DV E) demonstrate efficient viral replication 













4.1.2.4 Lack of IFN induction in IBV infected cells was not due to inherent 
defective IFN signaling in host cells 
To exclude the possibility that the weak induction of IFN-β is due to inherent 
defective IFN signaling pathways, IFN activation in response to poly (I:C) treatment 
was examined. Poly I:C is a double stranded RNA (dsRNA) mimetic that can initiate 
the onset of signaling cascades leading to IFN activation. Total RNA extracted from 
poly (I:C) treated cells were subjected to real-time PCR analysis. Real-time PCR 
analysis revealed that poly (I:C) treatment in H1299 and Huh-7 cells led to a strong 
induction of IFN-β on the transcriptional level (Figure 4-5A). 
 
Activation of IFN-β results in the subsequent induction of anti-viral effector 
molecules such such as ISG56. ISG56, alternatively known as IFITM1, is a potent 
anti-viral molecule against many viruses including SARS-CoV [280,281,282]As 
IFN-β is a secreted protein that cannot be abundantly detected in intracellular lysates, 
ISG56 is utilized as a marker for the induction of IFN (and therefore antiviral 
response). Western blot analysis of poly (I:C) treated cells revealed that poly (I:C) 
transfection strongly induced ISG56 expression, indicating that not only can these 
cells respond aptly to stimulation by viral RNA analogues, they also signal 
competently to induce ISG56 (and possibly other ISGs) expression (Figure 4-5B, 
lane 2). In contrast, IBV replication did not induce ISG56 expression in these cells 
(Figure 4-5B, lane 4). These results were congruent with the lack of ISG56 
transcriptional activation in IBV-infected cells as shown in Figure 4-3. The effect of 
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poly (I:C) treatment on IBV was also investigated. Pre-treatment of cells with poly 




(B)                    (C) 
 
Figure 4-5: IBV replication was inhibited by poly (I:C) treatment. H1299 cells were 
either mock transfected or transfected with 2μg of poly (I:C). 8 hours after transfection, cells 
were then infected with IBV (MOI=0.1) and harvested at 16 hours post infection for (A) real 
time PCR analysis of IFN-β induction or (B) probed for ISG56, IBV-S and β-tubulin 
expression in western blot analysis. Cells were also observed for the presence of syncytia 
formation under the light microscope prior to their lysis. Representative fields from each 





























To affirm that an active anti-viral state can be established in these cell types, a viral 
reduction assay was performed. Briefly, cells were first either mock transfected with 
poly (I:C) or infected with IBV at MOI=0.1. After 20 hours of infection/transfection, 
supernatant from primary infected cells (1o cells) were transferred to naive 
monolayers of H1299 or Huh-7 cells (secondary cells (2o cells)). To prevent viral 
particles from re-infecting the naive cells, supernatant collected from the primary 
infected cells (1o cells) were UV irradiated prior to their application. The naive 
monolayers were incubated with the respective supernatant(s) for 8 hours before 
secondary infection with IBV. The samples were then harvested by 3 freeze-thaw 
cycles at 16 hours post infection for standard plaque assays.  
 
As shown in Figure 4-6, poly (I:C) stimulation of H1299 and Huh-7 completely 
abolished plaque formation in their respective secondary infected cells, signifying 
that a biologically active anti-viral state could be established in these cell types. Cells 
incubated with supernatant from IBV infected cells on the other hand, were not 
‘protected’ against secondary infection. Re-infection in these cells was not due to 
insufficiently inactivated viral particles in the supernatant as the incubation of the 
secondary cells with supernatant alone did not result in infection (Figure 4-6, column 
2). These results indicated that an effective anti-viral state can be formed in these 
cells in response to appropriate stimulus (in this case, poly (I:C)). The lack of IFN 
induction in IBV-infected cells therefore provides initial evidence that IBV has 
evolved ways to either (1) evade immune detection or (2) produce viral proteins that 
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can actively suppress IFN-β production in order to ensure its efficient replication and 





Figure 4-6: H1299 and Huh-7 cells can produce biologically active IFNs in the presence 
of poly (I:C) stimulation. Supernatant from cells either mock transfected or poly (I:C) 
transfected were transferred to new monolayers of H1299 or Huh-7 cells.  After 8 hours of 
incubation, cells were infected with IBV at MOI=0.1 for 16 hours. To ensure that virus 
particles in supernatant present in the supernatant were completely inactivated by UV-
irradiation, mock infections (-) were performed in wells incubated with these supernatant. 
Cells were then harvested by 3 cycles of freeze-thaw and subjected to plaque assay analysis 
using Vero cells. Cells were fixed with paraformaldehyde 3 days after the plaque assay was 






4.1.2.5 Over-expression of cytoplasmic dsRNA receptors RIG-I, Mda5 and 
TLR3 failed to suppress viral infection 
The RLH signaling pathway leading to IFN production is a multi-step process (see 
section 1.3.1.3). To elucidate the step(s) targeted by the virus to suppress IFN-β 
induction, individual components of the RLH signaling pathway were over-
expressed, and their effects on IBV replication were studied. Transfection of poly 
(I:C) was also included as a positive control. For the ease of comparing viral 
replication, a recombinant strain of IBV expressing firefly luciferase  (IBV-Luc) was 
used. RIG-I, MDA5, VISA and IRF3 were over-expressed in H1299-RL. H1299-RL 
cells constitutively express the renilla luciferase. The firefly luciferase signal 
produced from IBV replication was thus normalized against renilla to correct for 
effects of virus–induced cell death.  
 
Expectedly, transfection of poly (I:C) completely abolished syncytium formation 
(Figure 4-6A) in IBV-infected cells. The lack of syncytium formation was 
accompanied by a strong suppression of viral protein expression (Figure 4-7B), 
coupled with low firefly activity in these cells (Figure 4-7C). IBV infection, 
however, was almost unabated in the presence of RIG-I and Mda5 over-expression. 
While RIG-I and MDA5 did not notably affect IBV replication, IBV replication was 
severely compromised in cells transfected with VISA and IRF3. VISA and IRF3 both 
function downstream of RIG-I and MDA5 in the RLH pathway. These results were 
opposed to those obtained with dengue virus as over-expression of RIG-I and MDA5 
inhibit dengue virus replication (Figure 4-8).  The suppression of dengue viral 
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replication was more efficient when both RIG-I and MDA5 were over-expressed at 
the same time. This synergistic effect of RIG-I and MDA5 on inhibiting viral 
infection appeared to be unimportant in IBV infection as IBV can replicate 
efficiently in a stable cell line that stably express high levels of RIG-I and MDA5 
(Figure 4-9).  
 
                   
 
pxj40 Poly I:C RIG-I 
IRF35D VISA MDA5 
A) 
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Figure 4-7: The effects of transient expression of RIG-I, MDA5, MAVS and IRF35D on 
IBV replication. H1299-RL cells were transfected with either control plasmid pxj40 or 
constructs encoding RIG-I, MDA5, VISA or IRF35D and either mock-infected or (-) 
infected with IBV (+) for 16 hours. Transfection with poly (I:C) was included as a positive 
control. Cells were observed for (A) syncytia formation under a phase contrast microscope 
prior to being harvested for (B) western blot analysis to probe for expression of viral antigen 
(IBV-S) or for (C) luciferase assay to quantitate viral replication. Luciferase reading obtained 
were normalized to renilla and expressed relative to the control samples transfected with the 







                              
 
Figure 4-8: Over-expression of RIG-I and MDA5 reduced dengue replication. (A) RIG-I 
and MDA5 were over-expressed in Huh-7 cells and infected with dengue virus type 1 over a 
period of 48 hours. Immuno-blotting for NS3 showed a decrease in viral antigen expression. 
The effect was more pronounced in cells where both RIG-I and MDA5 is over-expressed. 
(B) Total RNA was also extracted for real-time PCR analysis of gene expression of negative 
strand viral RNA transcripts. 
 
 
                                           
 
Figure 4-9: IBV replicates efficiently in the presence of RIG-I and MDA5 over-
expression. IBV replicate with similar efficiency in Huh-7 cells stably over-expressing RIG-
I and MDA5 were  
DV1 48h 
Huh7 RIGI/MDA5 +     Huh7 WT     
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4.1.2.6 IBV infection was not modulated by over-expression of TLR3. 
 RIG-I and MDA5 are cytosolic receptors that are responsible for the initial 
recognition of viral particles in the cell. The fact that over-expression of signaling 
molecules downstream of RIG-I and MDA5 activation (VISA and IRF3), but not 
RIG-I and MDA5, inhibited IBV replication suggested that IBV counter-strategies of 
immune evasion might involve either (I) preventing RIG-I and/or MDA5 activation 
or (2) disrupting of RIG-I and MDA5 from signaling to VISA. While RIG-I and 
Mda5 are activated by the presence of intracellular viral RNA, viral dsRNA in the 
extracellular and endoplasmic component are detected by TLR3, which is a member 
of the Toll-like receptor family. In support of the speculation that IBV is somehow 
shielded from RIG-I and MDA5 detection, exogenous expression of TLR3 also failed 
to inhibit viral replication. Expression of viral protein, IBV-S, in cells transiently 
expressing TLR3 was indistinguishable from that of those transfected with control 
plasmid (Figure 4-10A). Furthermore, over-expression of TLR3 did not elevate the 
levels of IFN-β transcripts in IBV infected cells, suggesting that the presence of 





                            
    
Figure 4-10: Effect of TLR3 over-expression on IBV replication. Cells transfected with 
empty vector (pcDNA) or pcDNA-TLR3 were mock infected or infected with IBV at 16 
hours post transfection. Cells were harvested 16 hours post-infection and (A) western blot 
analysis using the indicated anti-sera against IBV-S, TLR3 and actin was performed. (B) 
Total RNA was also harvested to detect for the mRNA expression of IFN-β and GAPDH 





4.1.2.7 IBV replication up-regulates low levels of RIG-I, MDA5 on both 
transcriptional and translational level 
The protein expression levels of RIG-I and MDA5 were also examined in IBV-
infected Huh-7 cells. Infected cells were harvested every 4 hours over a time course 
of 24 hours and the lysates obtained were subjected to immuno-blotting with 
commercially purchased RIG-I and MDA-5 antibodies. Compared to mock-infected 
controls, a slight increase in expression of both proteins was detected by the end of 
the infection. However, the levels of induction were minute, compared to the sharp 
increase in RIG-I and MDA5 protein expression in dengue-infected cells.  
 
 
       
 Figure 4-11: Comparison of RIG-I and MDA5 expression in IBV and dengue infected 
cells. IBV or dengue infected Huh-7 cells were harvested at the indicated time points and 
subjected to western blot analysis using the antibodies against RIG-I, MDA5 and the 
respective viral antigens (IBV-N and Dengue-E). Actin was included as a loading control. 
4.1.2.8  IBV replication partially inhibits IFN response at late stages of infection 
 141 
The results thus far suggested that one of IBV strategies of immune evasion is to 
elude detection by cellular receptors such as RIG-I, MDA5 and TLR3. To examine if 
IBV replication can also actively inhibit IFN activation/signaling, we determined if 
the presence of viral infection could suppress poly (I:C)-induced IFN activation. For 
this purpose, cells were either mock infected or infected with IBV for 6 hours prior to 
their stimulation with poly (I:C). In agreement with previous data, IBV infection did 
not result in ISG56 induction (Figure 4-11B, lane 2 and 6) and expression of viral 
proteins (IBV-S and IBV-N) were severely compromised in poly (I:C) treated cells 
(lane 3 and 5). However, infecting cells 6 hours prior to poly (I:C) treatment, or 
concurrently with poly (I:C) did not suppress poly (I:C) induced ISG56 expression. 
These results suggested that IFN signaling was not undermined during early stages of 
IBV infection. However, when the experiment was repeated by infecting cells at 12 
instead of 6 hours prior to poly (I:C) transfection, ISG56 expression was observed to 
be reduced in cells pre-incubated with IBV virus (Figure 4-11C, lane 3). To examine 
if IBV replication can continue in the presence of poly (I:C) transfection, a separate 
well of IBV infected cells was also harvested at the time of poly (I:C) transfection. 
Compared to these cells, cells harvested 18 hours later in the presence of poly (I:C) 
treatment expressed higher levels of viral antigen (IBV-N), suggesting that IBV 
replication and viral protein synthesis can still occur in the presence of poly (I:C) 
treatment albeit at a much compromised efficiency (Figure 4-12D, lane 7). 
Collectively, these results indicate that apart from evasion of immune detection by 
pathogen recognition receptors such as RIG-I, MDA5 and TLR3, IBV could actively 






Figure 4-12: Effect of IBV infection on IFN activation. (A) Schematic diagram of 
experiment layout. (B) Western blot analysis. Cells were first infected with IBV for 8hours 
before mock transfection (lane 2) or transfection with poly (I:C) (lane 3) Cells were then 
further incubated for another 16hours. Lysates were then probed with the indicated 
antibodies. IBV infected cells failed to induce ISG56. Compared to cells with just poly I:C 
transfection, cells with prior exposure to IBV infection had reduced poly I:C induced ISG56 
expression (lane 4). To show that virus replication has already occurred by the time poly I:C 
was introduced, (C) cells were also harvested at the time of poly (I:C) transfection to detect 




4.1.2.9 Expression of IFN and ISGs during IBV infection is cell-type dependent  
Although coronaviruses typically possess a narrow host range, the Vero-adapted 
Beaudette strain of IBV used in this study had been previously shown to infect a 
wide range of cell types derived from varying different species and tissue origins 
[283]. To investigate if the lack of interferon induction observed in Huh7 and H1299 
is a shared phenomenon in other IBV-susceptible cells, the state of interferon 
signaling in a few selected cell types were examined. 
 
We first examined the transcriptional level of interferon-stimulated genes in IBV-
infected Vero cells. Isolated from kidney epithelial cells of monkey origin, Vero cells 
are IFN deficient. In stark contrast to the results obtained with H1299 and Huh7 
(Figure 4-3), RT-PCR analysis of extracts of infected cells revealed that despite the 
lack of IFN expression, IBV infection induced high levels of ISG56 and ISG15 
transcripts during the course of infection. This was accompanied by significant up-
regulation of RIG-I and MDA5 on the transcriptional level (Figure 4-13A). Western 
blot analysis of total cell lysates demonstrated that the up-regulation of RIG-I and 
MDA5 expression was also evident on the translational level (Figure 4-13B). The 
results so far suggest that IFN-related signaling in response to IBV infection is cell-
type dependent. To further explore this hypothesis, transcriptional levels of IFN-β 
were examined in 3 other IBV-susceptible cell types [283]. 
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Figure 4-13: Up-regulation of ISGs, RIG-I and MDA5 in IBV infected Vero cells. (A) 
Total RNA extracted from IBV-infected cells and the mRNA levels of the indicated genes 
were examined by RT-PCR using specific primers. The mRNA levels of GAPDH were also 
determined for loading control. (B) The corresponding protein samples of the infected cells 







RT-PCR analyses of IFN-β and ISG56 expression were similarly performed in IBV 
infected Cos-7 cells (monkey kidney fibroblast), A549 (human lung adenocaricinoma 
epithelial cell) and 293T (transformed human embryonic kidney cells). Huh-7 cells 
were also included as controls. While IBV infection resulted in a strong up-
regulation of IFN-β and/or ISG56 mRNA expression in Cos-7 cells, no significant 
up-regulation of these genes was observed in A549, and only a weak induction was 
observed in 293T cells. Furthermore, IBV replication efficiency did not seem to 
correlate with the extent of IFN induction; IBV replication occurred efficiently in the 
presence of IFN-β and ISG56 induction in Cos-7 cells but was less efficient in A549 
and 293T cells although elevation of IFN-β or ISG56 expression was not readily 
observed. The reason as to why IBV replication is compromised in these cells is not 
entirely clear but recent studies suggest that it may be linked to the relative 
abundance of furin [283], a cellular protease that through its cleavage of the spike 
protein, has a strong bearing on the outcome of infectivity and cell-cell fusion in IBV 
infected cells. 
 
Taken together, IBV therefore appears to possess different strategies for coping with 
the host innate response in different cell types: in H1299 and Huh-7 cells, IBV 
infection adopts the strategy of dampening and delaying the induction of IFN, while 
in cells such as Vero and Cos-7, IBV may have devised ways to replicate efficiently 
amidst a background of strong induction of IFN and/or ISGs expression. 
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Figure 4-14: Up-regulation of IFN-β and ISG56 by IBV infection is cell type dependent. 
RT-PCR analysis of IFN-β and ISG56 induction in IBV infected Vero, Cos-7, A549, Huh-7 
and 293T cells. The presence of IBV positive genomic strand (+) indicated efficient viral 
replication. GADPH served as loading control. Mock infected and UV irradiated IBV 





4.1.2.10 IBV infection did not lead to establishment of an effective anti-viral 
state in infected cells where IFNs are transcriptionally activated 
Given the sensitivity of IBV to IFN signaling, the contradictory co-existence of 
strong IFN induction and efficient IBV replication in Cos-7 cells led us to investigate 
whether the up-regulation of IFN-β and ISG56 can lead to a biologically active anti-
viral state. For this purpose, a viral reduction assay similar to the one described in 
Section 4.2.4 was performed. Briefly, supernatant from either mock infected or IBV 
infected cells were collected, UV irradiated and applied to a fresh monolayer of the 
respective cells. UV irradiation prevented viral particles in the supernatant of the 
primary infected cells from re-infecting the naive H1299-RL monolayers. The 
supernatant from the respective poly (I:C)-treated cells were included as positive 
controls. A schematic diagram of the experimental design is illustrated in Figure 4-
15A. After 8 hours of incubation, the naïve cells were re-infected with IBV-Luc. 
Luciferase assay was performed after 16 hours of infection to determine the extent of 
virus replication in these cells. 
 
As expected, poly (I:C) treatment in all the cell types resulted in supernatant that can 
sufficiently inhibit IBV infection in the naïve cells they were applied to, 
demonstrating that innate immune signaling is intact in all the cell types tested. In 
contrast, despite the strong detection of IFN-β and ISG56 transcriptional activation in 
IBV infected Cos-7 and weak induction in H1299, Huh7 and 293T cells, supernatant 
from these infected cells did not confer protection against IBV re-infection, 
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suggesting that a biologically active anti-viral state had failed to be established in 
these cells during IBV infection. The results explained how efficient replication 
could occur despite strong transcriptional induction of IFN- and ISG56 in IBV-
infected Cos-7 cells. This also supports the hypothesis that apart from immune 




Figure 4-15: Reduction assay using supernatants from IBV-infected H1299, Huh-7, 
293T, and Cos-7 cells. (A) Schematic diagram of experimental setup. (B) Luciferase 
readings were normalized to renilla that is constitutively expressed in H1299-RL cells and 




































The innate immune response, embodied by the activation of IFNs, is an important 
mechanism by which host cells defend themselves against invading pathogens. 
Signaling cascade leading to IFN activation can be broadly categorized into 3 phases. 
The initial phase of IFN activation involves the detection of viral moieties by cellular 
host receptors. For RNA viruses such as coronaviruses, the presence of dsRNA is 
detected by patten recognition receptors such as TLR3 and RIG-I and MDA5. The 
second phase involves the convergence of pathways downstream of viral recognition 
to the eventual activation of transcription factors that are responsible for inducing 
IFN-β expression. Finally, the secretion of IFN into extracellular matrix, followed by 
ligand-binding to their surface receptors stimulates the expression of hundreds of 
interferon-stimulated genes (ISGs) that collectively constitute the anti-viral state. 
 
The confirmation that IBV, like many other coronaviruses, is sensitive to the 
exogenous addition of IFN-β (Figure 4-2) led to the hypothesis that IBV must have 
strategies in place to cope with IFN activation that can occur during infection. This 
hypothesis was supported by observations that IBV infection led to both delayed and 
low levels of induction of IFN-β expression and that the low induction of IFN-β 
correlated with the low levels of anti-viral ISGs such as ISG56 and ISG15 being 
induced in IBV-infected cells (Figure 4-3). The likelihood that these observations 
resulted from defective IFN signaling pathways inherent in IBV susceptible cells was 
dismissed as these cells was shown to be competent in inducing IFN-β and ISGs 
expression in the presence of dsRNA stimulus or dengue infection (Figure 4-4, 4-5). 
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Viral reduction assay using supernatant obtained from cells treated with poly (I:C) 
further augment the fact that biologically active anti-viral state can be adequately 
established in these cells (Figure 4-6).  
 
To identify the possible stages in IFN signaling was antagonized by IBV, we over-
expressed the various components of the RLH signaling pathways and found that in 
contrast to the VISA- and IRF3-mediated inhibition on IBV replication, viral 
replication efficiency was not significantly altered in cells over-expressing RIG-I and 
MDA5. In a parallel experiment, over-expression of TLR3, another receptor that is 
involved in viral sensing, viral replication was similarly unabated. While the results 
presented here are still fairly preliminary with regards to the actual recognition of 
IBV by these cellular receptors, they highlighted the possibilities that IBV may have 
evolved strategies to evade immune detection. Our findings collaborate with those 
previously described for infection with SARS-CoV and with specific strains of MHV 
infection [279]. The lack of IRF3 activation, as well as IFN and ISG induction 
therefore appears to be a consensus among many coronaviruses. dsRNA 
intermediates produced during coronavirus replication are potent activators for PRRs 
recognition. To circumvent IFN-mediated inhibition, coronaviruses must devise 
strategies to ‘shield’ the viral RNA from these immune sensors. The exact 
mechanisms by which this “shielding’ is achieved is not entirely clear but the double 
membrane vesicles had been proposed to be instrumental for this purpose 
[78,279,284]. Alternatively, the key to this immune evasion may lie with the state of 
2’-O methylation on viral RNA. Until recently, the role of 2’-O methylation in higher 
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eukaryotic and viral RMA is an unresolved mystery until recent studies have 
identified this to be an important molecular signature by which the cells distinguish 
endogenous RNA from foreign ‘non-self’ ones [285]. Coronavirus have similarly 
evolved to modify their mRNA by 2’-O methylation owing to the methyltransferase 
activity found in nsp16. By mimicking the ribose 2’-O methylation of their host 
mRNA, the “disguised’ coronavirus mRNA would then be able to curtail RLH-
dependent IFN activation and hence escape from the inhibitory effects of IFN 
activation [285,286]. Future studies focusing on the emphasis on the implication of 
coronaviral mRNA modifications by viral proteins such as nsp16 would be important 
on the study of the mechanisms supporting the evasion of IBV from MDA5 and/or 
RIG-I recognition. 
 
Apart from the passive evasion of immune detection, IBV could also actively express 
proteins that can actively antagonize IFN induction. This is supported by the findings 
that IFN expression in respond to IBV infection is cell type dependent. IBV could 
up-regulation IFN- and ISGs expression in cells such as Vero and Cos-7. The fact 
that IBV could replicate efficiently in these cell types indicates that a strategy of 
actively inhibiting the innate IFN response must also be in place. In addition, we had 
shown that poly (I:C) induced IFN activation could be compromised in the presence 
of IBV infection. 
 
In summary, our results suggested that IBV could evolve multiple strategies for 
immune evasion and the nature of strategy adopted is cell-type dependent. In fact, 
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similar multi-prong approaches of IFN antagonism have already been described for 
other members of the coronavirus family [287]. Further studies are required to 




4.2 SARS ORF8B AND ORF8AB ARE NOVEL INTERFERON 
ANTAGONISTS 
4.2.1 INTRODUCTION 
The second part of this study on host-viral interactions focused on identifying novel 
IFN antagonist expressed by the SARS-CoV. SARS-CoV is an inefficient inducer of 
IFN-β response in cell culture system [288] and was found to be sensitive to the 
antiviral state induced by IFN treatment [289,290]. Hence, to avoid IFN mediated 
growth inhibition, SARS-CoV must evolve strategies to circumvent IFN activation. 
Many of SARS-CoV encoded proteins have been reported to suppress IFN 
production by targeting different aspects of the IFN cascade. For instance, Papain-
like protease (PLpro) attenuates IFN synthesis by abrogating IRF3 phosphorylation 
and nuclear translocation by physically interacting with IRF3 [144]. Targeting 
further upstream is M protein, which prevents IRF3 phosphoactivation by preventing 
the assembly of TBK1/IKK complex [45]. Molecular moieties downstream of IFN 
synthesis can also be targets of SARS-CoV protein manipulation. Both Nsp1 and 
ORF6 inhibit signal transducer and activator of transcription (STAT) 1 activity, 
albeit by different mechanisms. Nsp1 inhibits STAT1 phosphorylation [291] and in 
addition, induce degradation of host mRNAs [292,293]. ORF6 on the other hand, 
traps nuclear import factors in the endoplasmic recticulum and Golgi apparatus, to 
prevent the nuclear translocation of STAT1, and hence STAT1 mediated 
transcription of ISGs [148]. Other IFN antagonists identified include the 
nucleocapsid protein (N) and ORF3 [63]. Over expression of protein 3a was found to 
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down-regulate type I interferon receptor by promoting its ubiquitination and 
subsequent degradation via the lysosomal pathway [206]. 
 
Interferon-regulatory factor 3 (IRF3) is a crucial regulator of IFN induction. A study 
done by Spiegel et al reported that IRF3 activation was blocked specifically during 
later stages of SARS-CoV infection [288]. Hence, in an effort to identify SARS-CoV 
proteins that may antagonize the IFN response at the level of IRF3 activation, 
structural and accessory proteins encoded by SARS-CoV were cloned, expressed and 
screened for potential interaction with IRF3. From our screen, we observed that 
accessory proteins 8b and 8ab, encoded by SARS-CoV ORF8, consistently co-
immunoprecipitated with IRF3. Using constructs expressing truncated forms of 
IRF3, the interaction domain was mapped to the dimerization domain of IRF3. 
Incidentally, the over-expression of 8b and 8ab was linked to reduced IRF3 
dimerization in poly (I:C) stimulated cells. The lack of IRF-3 dimerisation was 
accompanied by a suppressed IFN response as the over-expression of 8b and 8ab also 
led to lower levels of IFN-β and ISGs being induced. Furthermore, construction of 
recombinant IBV expressing proteins 8b and 8ab demonstrated that expression of 8b 
and 8ab enables the viruses to partially overcome the inhibitory actions of IFN 





5.2.2.1 SARS protein 8b and 8ab interacts physically with IRF3 
cDNA fragments coding for the different SARS-CoV ORFs were cloned into T7 
promoter based expression vectors with a Flag-tag at the N-termini as previously 
described [212]. These constructs were in turn co-expressed with the Myc-tagged 
IRF3 in H1299 cells using the vaccinia/T7 expression system. At 24 hours post-
transfection, total cell lysates were subjected to immunoprecipitation using agarose 
beads coated with anti-Myc antibody followed by Western blot analysis with anti-
sera against the Flag tag.   
 
During this screen, it was noted that two accessory proteins, 8b and 8ab, both 
encoded by SARS-CoV ORF8, consistently co-immunoprecipitated with IRF3. 
Representative gels from these experiments (top and second panels) were shown in 
Figure 4-16. When the immunoprecipitation experiment was repeated with agarose 
beads coated with anti-Flag antibodies, both 8b and 8ab proteins can reciprocally pull 
down the Myc-tagged IRF3 (Figure 4-16, third and bottom panels). These results 
firmly established the physical interaction between IRF3 physically and protein 8b 







Figure 4-16: SARS 8b and SARS 8ab interact physically with IRF3. Cos-7 cells were 
infected with the recombinant vaccinia virus at a multiplicity of infection (M.O.I) of 
approximately 5 per cell.  After incubation for 1 hour, the cells were transfected with pMyc-
IRF3, pFlag-8b, pMyc-IRF3, pFlag-8b, pFlag-8ab and pMyc-IRF3, pFlag-8ab, respectively. 
Cells were harvested at 18 hours post-transfection, lysates prepared, and subjected to 
immunoprecipitation (IP) with either Myc antibody-conjugated agarose beads (top two 
panels) or the Flag-antibody-conjugated beads (bottom two panels). The precipitates were 
separated on SDS-PAGE and analyzed by immunoblotted (IB) with either anti-Myc (top and 
bottom panels) or anti-Flag (2nd and 3rd panels) antibodies.  
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4.2.2.2 The DNA binding domain of IRF3 is dispensable for its interaction with 
protein 8b 
To elucidate the domain responsible for mediating IRF3 interaction with SARS 
ORF8, three deletion constructs of IRF3 were constructed (Figure 4-17). The first 
construct (IRF3 1-133) contains the first 133 amino acid and comprises of the N-
terminal DNA binding domain; the second construct (IRF3 1-193) encompasses the 
nuclear localization signal (NLS) and proline-rich (PR) domain and finally the third 
construct (IRF3 1-375) encode the C-terminal IRF association domain (IAD) 
interaction domain in addition to all the functional domains (DBD, NLS and PR) 
mentioned above. (Figure 4-17A) 
 
In view that protein 8b and 8ab exhibited comparable efficiency in terms of pulling 
down IRF3, and that the 8a domain comprises of just 39 amino acids, only the 8b 
region was then used for subsequent pull-down experiments. The IRF3 deletion 
constructs were co-transfected with Flag-tagged 8b in H1299 cells, harvested and 
prepared for immunoprecipitation using Flag- conjugated or Myc- conjugated 
agarose beads. Co-immunoprecipitation experiments showed that the N-terminal 
region covering the first 133 residue of IRF3 did not interact with protein 8b, 
suggesting that the DNA-binding domain (DBD) is dispensable for the interaction. 
Immunoprecipitation with fragments covering residues 1-193 similarly did not 
efficiently pull down protein 8b (Fig. 3d), dismissing the role of the NLS and PR 
region in this interaction. In contrast, the inclusion of the IAD domain resulted in the 
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co-immunoprecipitation of IRF3 with 8b (Figure 4- 17B). The results of this co-
immunoprecipitation study suggested that SARS ORF8 is interacting with the IAD 
domain of IRF3. 
 
Figure 4-17: Mapping the interaction domain in IRF3. H1299 cells seeded on 6 well 
plates were first infected with vaccinia virus 1 hour prior to transfection with their respective 
plasmids. 20 hours post transfection, cells were harvested with 500ul of RIPA buffer and 
200ul of lysate were co-immunoprecipitated with flag-tagged agarose beads overnight, 





4.2.2.3: Suppression of IRF3 activation by protein 8b and 8ab 
To investigate if the interaction between protein 8b/8ab and IRF3 has any 
modulatory effect on IRF3 activity, the effects of 8b and 8ab expression on IRF3 
activation were examined.  Two hallmarks of IRF3 activation - hyperphosphorylation 
status, as well as the formation of homo-dimers were tested. For that purpose, cells 
transfected with either plasmid encoding Flag-8b, Flag-8ab or a corresponding 
control vector were incubated overnight, prior to stimulation with poly (I:C). Poly 
(I:C) is a double-stranded RNA mimetic that can activate IRF3 by signaling through 
the RLH signaling pathway via Mda5 (see section 1.3.1.3). Lysates prepared from 
transfected cells at 8 hours post poly (I:C) stimulation were separated by non-
denaturing gels (native PAGE) and probed with anti-sera against IRF3.  In cells 
transfected with control plasmid, poly (I:C) treatment resulted in the detection of 
IRF3 dimers (Figure 4-18, top panel, lane 2). The levels of IRF3 dimers were 
significantly suppressed with the ectopic expression of proteins 8b and 8ab (Figure 4-
18, top panel lane 3 & 4). Analysis of the same samples resolved by SDS-PAGE 
however, showed no observable difference in the levels of hyper-phosphorylated 
IRF3 (p-IRF3) in cells over-expressing 8b and 8ab compared to the control (Figure 
4-18, middle panel), suggesting that the main effect of this interaction may be on the 





Figure 4-18: Over-expression of SARS 8b and 8ab inhibit poly (I:C)-induced IRF3 
activation. Cells transfected with empty vector, Flag-8b or Flag-8ab were subjected to 
western blot analysis following either Native-PAGE to detect IRF3 dimerization (Top panel) 
or SDS-PAGE (2nd panel) to detect IRF3 hyper-phosphorylation. Expression of tubulin was 
also probed for the purpose of loading control. 
 
 
4.2.2.4 Expression of SARS 8b and 8ab decreased IFN-β promoter activation in 
response to poly (I:C) stimulation 
To determine the effect of over-expressing protein 8b and 8ab on IFN-β induction, 
IFN-β promoter activity in response to stimulation was analyzed. For this purpose, 
cells were transfected with a reporter construct that expresses firefly luciferase under 
the control of IFN-β promoter. A constitutively active reporter expressing Renilla 
luciferase (pRLTK) was also co-transfected to be used as a normalizing control. In 
cells transfected with empty vector controls, stimulation with poly (I:C) resulted in 
an approximate 70-fold increase in IFN-β promoter activity was detected. In contrast, 
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the promoter activity was only induced 44.8 and 43.1-fold in cells that were 
transfected protein 8b or 8ab respectively (Figure 4-19). 
 
 
Figure 4.-19: Protein 8b and 8ab suppressed poly (I:C)-induced IFN-β promoter 
activation Control vector pcDNA (V), pcDNA-8b or pcDNA-8ab together with a luciferase 
reporter construct containing the IFN-β promoter were transfected into Huh7 cells. 24hours 
post-transfection, cells were then further transfected with poly (I:C) At 24 hours post 
stimulation, cells were lysed and measured for the firefly luciferase activity. Data was 





4.2.2.5 Expression of SARS8b and 8ab decreased transcriptional induction of 
IFN-β and ISGs.  
Quantitative real time RT-PCR was also carried out to investigate the levels of 
endogenous IFN-β transcripts induced. Mirroring the results obtained with the 
promoter assay earlier, the relative levels of IFN-β mRNA in poly (I:C)-treated cells 
expressing 8b and 8ab were reduced to approximately 18-20 % of control (Figure 4-
20A). Similar to the effect on IFN-β expression, the transcripts levels of other IRF3 
downstream target genes (47), such as ISG56, RANTES and ISG15, were also 
significantly lower in cells over-expressing proteins 8b and 8ab compared to control 
samples. The relative levels of ISG56 (Figure 4-20B), RANTES (Figure 4-20C) and 
ISG15 (Figure 4-20D) were reduced to approximately 41-41, 35-40 and 25-30%, 
respectively, with respect to those transfected with the empty vector. Taken together, 
these results suggested that SARS-CoV 8b and 8ab are novel antagonists of IFN 
activation and when expressed, dampen the activation of IFN signaling in response to 
dsRNA stimulation. The antagonistic activity may be partially attributed to their 





Figure 4-20: Protein 8b and 8ab suppressed transcriptional activation of IFN-β, and 
other ISGs in response to poly (I:C) stimulation. Total RNA were extracted from Huh7 
cells transfected with either 4µg of empty vector, pXJ40Flag-8b or pXJ40-Flag8ab that were 
stimulated with poly (I:C) for 20 hours. Quantitative real time PCR was carried out with 
primers for IFN-β (a), ISG56 (b), RANTES (c) and ISG15 (d). Data was represented as mean 
of replicates from 2 independent experiments. GAPDH was used as internal control. 
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4.2.2.5 Expression of 8b enable IBV to replicate more efficiently in the presence 
of poly (I:C) stimulation 
To further examine the role of 8b and 8ab in viral pathogenesis given their inhibitory 
actions on IFN signaling, we examined the relative replication efficacy of 
recombinant IBV (rIBV-) encoding SARS-8b, -8ab and -8a/b in the presence of IFN 
activation. As we had previously demonstrated that ORF 8a/b do not express 8b nor 
8ab protein [212], recombinant rIBV-8a/b in this study function as a negative control. 
The construction of these recombinant IBV strains was previously described in [212].  
 
First, the growth kinetics of the three recombinant viruses, rIBV-8b, rIBV-8ab and 
rIBV 8a/b were determined. Vero cells were infected with wild type and recombinant 
IBV (M.O.I=0.5) and harvested every 4 h over a time course of 20 h. The virus titers 
obtained at the end of each time point were then quantitated by standard plaque 
assay. At all the 6 time points tested, rIBV-8b, -8ab and -8a/b replicate with similar 
growth kinetics and replicate to similar viral titers. When compared to that of wild 
type virus however, the growth kinetics of these recombinant viruses during the first 
12 hours of infection were significantly slower (Figure 4-21A). Despite the initial 
lag, all the recombinant viruses replicate to similar levels by 16 h post-infection, and 
reached titers comparable to their wild type counterpart (Figure 4-21B). The slightly 
slower growth rates observed for the recombinant viruses at early time points of the 
infection cycle may be due to the introduction of extra sequences into the genome of 
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IBV. This is consistent with our previous observations that such manipulations may 
alter the replication of IBV in cells [93,212]. 
 
 
Figure 4-21 Growth kinetics of recombinant viruses.  
(A) Titration plaque assay. Comparable number of plaques was formed by the respective 
recombinant viruses at 16 hours post infection. Representative wells were shown. (B) 
Growth curve of wild type and recombinant viruses over a time course 20 hours. Plaque 
assays were performed with cell lysates infected with the respective recombinant viruses at 
MOI of 0.5 and harvested every 4 h post infection over a time course of 20 h. 10-fold serially 
diluted virus stock was then used for plaque assay to determine virus titer. Error bars show 




As the virus replicate with similar kinetics by 16 hours most infection, this time point 
was used for our subsequent study examining replication efficiency of recombinant 
viruses in the presence of IFN activation. For this study, H1299 cells were infected 
with wild type or recombinant IBVs for 6 h prior to mock or poly (I:C) stimulation 
for another 10 h before lysates were harvested for analysis of viral protein 
expression.  
 
In the absence of poly (I:C) treatment, all 4 viruses tested expressed similar levels of 
N protein (Figure 4-22), indicating that the viruses had replicated to  similar levels at 
this time point tested. And consistent with our previous observation that IBV is sensitive 
to interferon activation, the expression of N protein by all the 4 recombinant viruses were 
much reduced in the presence of poly (I:C) treatment compared to their respective untreated 
controls (Figure 4-22). Nonetheless, compared to the wild type recombinant, and rIBV8a/b, 
rIBV8b notably replicate significantly better and expressed higher levels of N protein in the 
presence of poly (I:C) stimulation. The relative viral titers attained in samples were then 
quantitated using standard plaque assay. As depicted by the trend observed with N protein 
expression, results from the plaque assay revealed that while poly (I:C)-treatment reduced 
the virus titers of wtIBV and rIBV8a/b by 16 and 27.5 folds respectively relative to their 
untreated controls, titers of rIBV8b and rIBV8ab were reduced by a lesser 4.03 and 6.75 
fold, respectively (Figure 4-21b). These results corroborate with the hypothesis that by 
modulating the efficacy of IFN signaling, proteins 8b and 8ab may have roles in determining 






Figure 4-22: rIBV-8b and -8ab replicated more efficiently in poly (I:C) treated cells. (A) 
Western blot analysis of rIBV infection in poly (I:C) treated cells. (B) Fold reduction in virus 
replication as a result of poly (I:C) stimulation. Data was obtained from two independent 









In this study, we reported the identification of SARS-CoV ORF8b and ORF8ab as 
novel interferon antagonist. Over-expression of protein 8b and 8ab resulted in less 
active IFN-β promoter activity, resulting in lower transcriptional activation of IFN-β, 
as well as other anti-viral molecules such as RANTES, ISG56 and ISG15. We 
hypothesized that the IFN antagonistic properties of protein 8b and 8ab is linked to 
its direct interaction with IRF3 - the core regulatory molecule for IFN induction.  
 
Activation of IRF3 is a multistep event and each of the specific steps can be the 
target of viral circumvention. SARS M protein was previously found to specifically 
target IRF3 phosphoactivation by disrupting the assembly of IRF3 upstream kinases 
[45]. In this study, we observed that while distinct modulation of poly (I:C)-induced 
IRF3 phosphorylation were not observed in cells transiently expressing 8b and 8ab, 
less IRF3 dimers were detected in cells over-expressing either of the proteins., 
suggesting that 8b and 8ab may specifically target the latter event. While we do not 
entire dimiss the possibility that these observations are consequential of the 
insensitivity of this assay as previously reported and that biological activation of 
IRF3 (dimerization and nuclear translocation) [294,295], the fact that the interaction 
between the 8b domain and IRF3 involved part the IAD domain appears to support 
the latter hypothesis. The IAD domain, known otherwise as the IRF association 
domain, mediates IRF3 homodimerization following virus-induced phosphorylation 
[272,296]. Whether the disruption to the dimerization event is a result of direct steric 
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interference or other indirect mechanisms requires further investigation. In addition, 
Spiegel and coworkers reported that SARS-CoV appears to block IRF3 activation 
specifically during later stages of virus infection [288]. This coincides with the late 
expression of 8b during SARS-CoV infection [297]. Data on the temporal and spatial 
interaction between 8b and IRF3 during natural SARS-CoV infection will perhaps 
help shed light on the exact mechanisms involved.  
 
Protein 8b and 8ab are accessory proteins exclusively expressed by the SARS-CoV. 
In spite of their similarities, 8b and 8ab were shown to possess different biochemical 
properties and cellular functions [212,298]: Protein 8ab was shown to be a 
glycosylated ER resident protein which can activate ATF6 to modulate the unfolded 
protein response [299] while 8b induces DNA synthesis and down-regulates SARS-
CoV E protein via a proteasome independent pathway. Furthermore, although 8b and 
8ab are both encoded by the ORF8 region of SARS-CoV, they are expressed under 
distinct conditions. 8ab is expressed as a single protein encoded by the single 
continuous ORF (ORF8ab) found in SARS-CoV isolated from animals and early 
stage human isolates. In contrast, as a consequence of a 29 nucleotides deletion that 
results in two separate overlapping ORFs (ORF8a ⁄ ORF8b), most human isolates 
obtained during the middle to later phases of the epidemic express 8a and 8b as two 
distinct proteins [68,300]. It is postulated that this deletion may contribute to the 
enhanced pathogenicity of SARS-CoV in humans after SARS-CoV crossed the civet 
cats-human species barrier. However, studies thus far have yet to give a clear 
indication on whether this is indeed the case. For instance, when the 29-nt sequence 
 170 
was reintroduced into human isolates to merge ORF 8a and 8b into a continuous 
ORF 8 (8ab), there was little impact on virus growth and RNA replication in cell 
culture [57]. Similarly, in our experiments, growth kinetics of rIBV-8b and 8ab were 
not noticeably different. Furthermore, experiments involving over-expression of 8b 
and 8ab showed no stark difference in their ability to bind IRF3 (Figure 4-16), 
antagonize poly (I:C) induced IRF3 dimerization (Figure 4-18) or IFN-β activation 
(Figure 4-19 and 4-20). The abilities of rIBV-8b and 8ab to replicate more efficiently 
in the presence of IFN activation were also comparable (Figure 5-7). Further studies 
are therefore required to clarify if 8b and 8ab has differential roles in promoting viral 
replication and pathogenesis in their natural hosts. 
 
One surprising observation made in our study was that although the inclusion of 
8a/8b, 8b or 8ab in recombinant IBV rendered limited effects on viral replication 
(Figure 5-7) under normal culture conditions, rIBV-8b and rIBV-8ab replicate more 
efficiently in the presence of IFN activation (Figure 5-7). This apparent discrepancy 
could perhaps be explained by the fact that IBV, like SARS-CoV and many other 
coronaviruses are weak IFN inducers and hence the replication advantage rendered 
by 8b and 8ab expression would only be obvious in the presence of IFN induction in 








CHAPTER FIVE: CONCLUSIONS AND FUTURE DIRECTIONS 
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The work presented in this dissertation focused on the investigation of host-virus 
interactions using avian coronavirus, IBV as a model. This chapter presents a 
summary of the work done thus far and suggestions for future research directions are 
also discussed. 
 
5.1 GENOME WIDE RNAI SCREEN REVEALS CELLULAR CO-FACTORS 
IN CORONAVIRUS INFECTION 
5.1.1 Main conclusions 
Conclusions derived from work described in Chapter 3 are discussed in brief below: 
• Genome wide RNAi screen identified 86 cellular cofactors involved in IBV 
replication 
• RNAi screen recovered genes associated with cellular processes/molecular 
functions that are previously implicated in coronavirus replication. Examples 
include genes associated with the hnRNP family of proteins, the 
oligoadenylate synthetase (OAS)-RNase L pathway, cell cycle and early 
secretory pathway. The recovery of these genes validated our approach. 
• RNAi screen also identified valosin-containing protein (VCP), to be 
important for supporting coronavirus replication. 
• VCP was found to be important for the early steps in coronavirus replication 
although it is not required for virus attachment to host cell surface, as well as 
for the internalization of viral particles. 
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• Subcellular fractionation of IBV infected cells demonstrated that VCP is 
required for the efficient trafficking of viral particles from the early 
endosomes to cytosol. Depletion of VCP via siRNA-mediated knock down 
resulted in an accumulation of viral particles in the early endosomal 
compartments. 
 
5.1.2 General discussions  
5.1.2.1 The use of RNAi screen to identify cellular cofactors involved in 
coronavirus replication 
Despite viral-host interactions being a theme that had been explored for a long time, 
there are still significant gaps in our knowledge of how cellular processes modulate 
viral replication. Traditionally, host factors are identified by virtue of their direct 
interaction with selected viral proteins or nucleotide sequences of interest. However, 
information derived from these methods often only allowed us to have a partial 
‘snapshot’ of the complex interplay between coronavirus and its host. Moreover, 
important cellular proteins that only interact transiently with the viral baits might also 
be overlooked. These shortcomings highlighted the importance of having alternative 
approaches that can us to study coronavirus-host interactions in a more coordinated, 
large-scale fashion. The advances made in RNAi technology, coupled with the 
advent in high-throughput handling and data analysis presented such opportunity. 
Already, RNAi screens on a genome wide level had been successfully employed to 
identify important cellular factors that affect replication of viruses such as human 
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immunodeficiency virus (HIV), influenza (IAV), hepatitis C (HCV) and West Nile 
virus (WNV). In this study, we reported the utilization of this approach for the 
identification of host genes in an unbiased fashion. Our screen identified many novel 
candidates. The identification of several known regulators of coronavirus infection 
validated our approach. Apart from identifying novel individual cofactors important 
in IBV infection, the host-gene network obtained in this study provided a strong 
platform for the derivation of a comprehensive host-viral interaction map for 
coronavirus infection. 
 
5.1.2.2 Role of VCP in virus and host endosomal trafficking 
From our screen, we identified valosin-containing protein, VCP to be required for the 
efficient transport of viral particles to the cell host cytoplasm where the translation of 
its genome can be initiated. Our findings reconciled with the newly discovered role 
of VCP as a regulator of endosomal maturation. VCP mediates diverse cellular 
functions through its associated with a plethora of adaptor proteins. In our screen we 
found that a known VCP interacting protein, Ufd1L is also a critical modulator of 
IBV infection. VCP and Ufd1L typically function in the host cell ERAD (ER 
associated degradation) pathway. Along with another protein known as Npl4, the 
three proteins form a ternary complex that is responsible for extracting ubiquitinated 
substrates from the ER membranes and transporting them to the proteasome for 
degradation. Currently, it is not certain if this degradative pathway is also implicated 
in coronavirus replication. Ufd1L is a common cofactor identified from Krishnan’s 
RNAi screen involving West Nile and dengue virus infection. Further studies to 
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search for common grounds on how VCP and/or Ufd1L can affect positive strand 
RNA viruses may yield fruitful outcomes. 
 
5.1.2.3 Involvement of ERAD and UPS players in coronavirus replication/host 
endocytic pathway 
Apart from VCP and Ufd1L, our screen also identified the involvement of several 
members of the ubiquitin-proteasome pathway (UPS) in IBV replication. These 
genes include regulators of (Nedd8) and core components of E3 ligase complexes 
(Cul3, Rbx1). Ube2m, an E2 ligase was also identified from our screen. Although 
pharmalogical studies have long established the importance of a functional UPS in 
coronavirus replication in IBV as well as in other coronaviruses, the precise 
mechanism by which the proteasomal system moderates replication, however, is still 
not entirely clear. The identification of specific UPS genes required for IBV 
replication can spearhead further studies on how UPS is particular conscripted by the 
virus during infection. 
 
5.1.2.4 Other significant findings 
The screen also uncovered the involvement of the early secretory machinery to be 
important for IBV replication. These results are in agreement with previous findings 
that depletion of GBF1 and Arf1 inhibit coronavirus replication. We also showed that 
apart for IBV replication, GBF1 and Arf1 are also important for replication of 
 176 
another RNA virus (dengue virus). Collectively the results suggest that the early 
secretory pathway is commonly exploited by a variety of RNA viruses. Hence, 
manipulation of this pathway may present a broad-based therapeutic approach. 
 
5.1.3 Future directions  
Therefore, future research endeavors resulting from this study may include: 
• In depth characterization of how each of the 87 genes or their associated 
pathways affects coronavirus replication. Defining the stage of virus 
replication they are required will help offer new insights into both 
coronavirus and host biology.  
• Examining if they are also required for other members of the coronavirus 
family, or even other RNA viruses can lead to potential therapeutic 
opportunities. 
• The screen identified genes based on mutant phenotypes associated with the 
loss of function of the specific gene mediated by RNAi. It would therefore be 
interesting to determine if any of these genes are directly interacting with 
viral antigens or are in any way modulated by viral proteins during infection.  
 
To summarize, the cofactors identified from this screen provided a useful starting 
point to study how various cellular processes identified are cooperatively modulating 
virulence. Delineation of molecular mechanisms and networks utilized by the virus 
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through further biochemical, molecular or even bioinformatics study will allow us to 
amass a more complete view on the intricate interactions between the virus and its 
host. Extension of these studies can also be potentially applied to related RNA 
viruses for the development of a common drug target. 
 
5.2 CHARACTERIZATION OF HOST INNATE RESPONSE TOWARDS IBV 
INFECTION AND CORONAVIRAL COUNTERSTRATEGIES OF IMMUNE 
EVASION 
5.2.1 Main conclusions 
Conclusions drawn from results obtained from Chapter 4 were summarized as 
follows: 
• IBV is sensitive to interferon (IFN) treatment, suggesting that the virus must 
have a counter strategy in place to antagonize IFN production and/or 
signaling. 
• IBV infection did not lead to significant up-regulation of IFN and IFN related 
genes in Huh-7 and H1299 cells. 
• Huh-7 and H1299 cells are immune competent cells that are capable of 
eliciting an innate response against viral RNA analogue and other viruses. 
• The over-expression of PRRs (PAMP recognition receptors) such as RIG-I, 
MDA5 and TLR3 did not affect IBV. This suggested that evasion of immune 
detection is one of the strategies adopted by the virus. 
• IBV infection can partially suppress poly (I:C) induced IFN activation 
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• IBV induced IFN up-regulation in Vero and Cos-7 cells. The cell type 
dependent up-regulation of IFNs, coupled with the lack of a biologically 
active anti-viral state in IBV infected cells, further implied that IBV can 
actively inhibit IFN mediated anti-viral response in cells. 
• Through a co-immunoprecipitation screen involving known encoded SARS 
ORFs, ORF8b and ORF8ab was found to interact directly with IRF3 – a key 
transcription factor mediating IFN induction. 
• The domain responsible for the homo-dimerization of IRF3 is critical for this 
interaction 
• Over-expression of ORF8b and ORF8ab inhibits IRF3 dimerization following 
poly (I:C) stimulation 
• The lack of IRF3 dimerization corresponded to suppressed IFN-β promoter 
activation, as well as decreased levels of IFN-β, ISG56, ISG15 and RANTES 
mRNA induction in response to poly (I:C). 
• Expression of 8b and 8ab by recombinant IBV viruses (rIBV-8b and rIBV-
8ab) resulted in enhanced replication in the presence of poly (I:C) induced 
IFN activation. 
 
5.2.2 General discussion 
The transcriptional activation of interferon (IFN) genes is among the best 
characterized early-onset response towards viral infections [188]. The secretion of 
interferon is pivotal to ‘turning on’ translation of interferon-stimulated genes that 
possess antiviral and immunomodulatory functions. There are mounting evidences 
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that coronavirus extensively modulate the host IFN response. In this study, we 
presented several lines of evidences indicating the multi-dimensional IFN-
antagonistic activities associated with IBV infection.  
 
5.2.2.1 Coronavirus passive evasion of immune detection during IBV infection.  
The initiation of IFN induction is mediated by the detection of foreign viral 
molecular patterns. In particular, intracellular dsRNAs produced during virus 
replication are ligands for cytoplasmic RLH family of receptors such as RIG-I and 
MDA5. At present, the receptor(s) responsible for coronavirus detection remains 
largely controversial. For instance, while earlier studies had proposed that 
recognition of MHV is mediated solely via MDA5 [301], subsequent studies 
alternatively suggest that MHV-induced IFN signaling is channeled through a 
collaborative involvement of both RIG-I and MDA5 [302] For other coronaviruses 
which have been documented as poor interferon inducers, the involvement of these 
receptors remained elusive. 
 
Here, we demonstrate that like SARS-CoV, IBV is a weak inducer of IFN signaling 
and its detection cannot be enhanced by the augmentation of known pathogen 
receptors like TLR3, RIG-I and MDA5. By evading immune detection mediated by 
RIG-I, MDA5 and TLR3 and therefore impeding the initiation of signaling events 
leading to IFN production, IBV thwarts the host innate defense at the very forefront. 
While the exact mechanism by which this is achieved cannot be really detailed in this 
 180 
study, shielding by double membrane vesicles [279] and ‘disguising’ viral RNA by 
O-methylation by virally encoded O-methyl-transferases [285,286] are likely to be 
instrumental to this process.  
 
5.2.2.2 Coronavirus active inhibition of host innate response 
Observations that IBV infection can induce transcriptional activation of IFN-β and/or 
ISGs in some cell types, and that IBV infection can inhibit poly (I:C) induced ISG56 
protein translation, provided compelling evidences that apart from ‘passive’ immune 
evasion, IBV also activity antagonizes the host IFN response via other mechanisms. 
This feature is possibly shared among coronaviruses as the ‘sabotage’ of IFN 
signaling in at multiple levels has been well-documented for several coronavirus 
[63,287]. Furthermore, the divergent IFN responses in different cell type suggest that 
future studies on coronavirus-host interactions must involve multiple cell types. The 
cell type dependent variation of IFN response may hence determine the predominant 
strategy. It is not known however, if this could also be a factor for cell tropism for 
IBV infection. 
 
5.2.2.3 SARS ORF8 as a novel IFN antagonist 
In parallel, we adopted a different approach to identify novel IFN antagonists 
encoded by SARS-CoV. Through an interaction screen, we identified SARS ORF8b 
and 8ab to be novel SARS encoded IFN antagonists. The ability of recombinant IBV 
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expressing 8b and 8ab to replicate better in the presence of poly (I:C) treatment 
suggested that 8b and 8ab can similarly modulate SARS-CoV virulence in infected 
cells. Exactly how this level of antagonism is attained is yet to be elucidated, but the 
fact that 8b interacts with the dimerization domain of IRF3, along with the lack of 
change in IRF3 phosphorylation status provided hints that 8b and 8ab may inhibit 
IRF3 self association. This process may be reminiscent of that of M protein role in 
disrupting the assembly of IRF3 upstream kinase complex [45]. Future work may 
involve investigations into how 8b’s interaction with this domain impedes the 
various aspects of IRF3 activation. 
 
6.2.3 Future directions 
Future work would therefore involve investigating how IFN antagonism is achieved. 
While the hypothesis that evasion of RIG-I, MDA5 and TLR3 detection is due to 
passive ‘shielding’ conferred by the double membrane vesicles formed during 
replication would be difficult to test, work can be carried out to determine if 2’-O-
methylation of viral encoded RNA contribute to this mechanism. Recombinant virus 
expressing an inactive/mutant form of Nsp16 would provide an effective mean of 
unraveling this mystery.  In addition, future efforts can be placed on identifying viral 
protein(s) that is responsible for the active inhibition of IFN signaling observed. 
There are several methodologies that can be employed to for this purpose. Apart 
from using co-immunoprecipitation screens such as the one performed during our 
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study of SARS ORFs and IRF3, large-scale studies such as yeast-2-hybrid studies 
can also be considered. 
 
5.3 FINAL REMARKS 
The interplay between a virus and its host is a highly complex affair, often engaging 
multiple players derived from both the virus and the host. While the host is equipped 
with several lines of defense mechanisms to ward off viral infection or to contain its 
spread, viruses have also co-evolved mechanisms to thwart these efforts. In addition, 
viruses also co-opt cellular factors for replication or manipulate host cellular 
processes to yield to its advantage. Although substantial headway had been made in 
the elucidation of these pathways, many of these processes are still poorly 
understood. Therefore, the findings reported in this dissertation had contributed to 
advancing the understanding of this intricate field of host-viral interactions. 
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